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1. Tissue Engineering 
At the end of the year 2002, 82,749 patients were registered on the OPTN (Organ 
Procurement and Transplantation Network) waiting list for organ transplantation (from the 
OPTN / SRTR Annual report on www.optn.org) with kidney (68%) and liver (22%) being the 
most required organs followed by lung (5%) and heart (5%). In contrast, a total of only 
24,544 organs could be transplanted. Further data provided by the OPTN indicates a death 
rate of approximately 10% on the waiting list. The active waiting list of Eurotransplant states 
the need for 12,157 kidneys and 1,841 livers as of July 1, 2004 (from www.eurotransplant.nl). 
Not only is the need for organs constantly rising, less complex tissues, such as skin, are also 
required to more efficiently cure the 4.5 million severe burn injuries that are reported each 
year (from www.medindic.net). Due to the constantly rising life expectancy, the discrepancy 
between organ donations and patients on the waiting list will become even worse. In the 
United States, for example, an estimated one person in five reaching 65 years of age will 
receive temporary or permanent organ-replacement therapy during their remaining life span 
[1].  
These few examples drastically indicate why the replacement of organ functions and living 
tissue with synthetic substitutes represents one of the most important contributions of 20th 
century science to clinical medicine [1]. Organ failure and tissue defects resulting from 
traumatic injury, tumor resection, degenerative deceases, and congenital deformities are the 
specific problem surgeons have to face with [2-4]. Current strategies to deal with complex 
tissue defects and organ failure involve surgical reconstruction and organ transplantation. 
Besides the organ shortage, the risk associated with long-term treatments with 
immunosuppressive medication is a critical shortcoming in transplantation medicine. Existing 
methods of tissue replacement therapy rely upon a variety of permanent implants made of 
metals, ceramics, non-degradable polymers, or composite materials [5-7]. Most of these 
devices were developed in the 1960s and gradually optimized throughout the following 
decades. However, such implant devices can only restore tissue form and mechanical 
function, while their application is limited by finite durability and non-physiological 
performance as well as a considerable risk of infection or thromboembolism [8]. Surgical 
tissue reconstruction by the transplantation of autografts, however, is still the ‘gold standard’ 
in the management of several tissue defects, especially osseous defects. Nevertheless, this 
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treatment is often constrained by anatomical limitations and associated with donor-site pain 
and morbidity, extra blood loss and risk of infection [9]. 
To overcome these limitations, tissue engineering emerged as discovery research in the 1970s 
[10]. The National Science Foundation (NSF) defined tissue engineering as an 
interdisciplinary field that applies the principles of engineering and the life sciences to the 
development of biological substitutes that restore, maintain, or improve tissue function [2]. 
Work in the field is focused towards replacing tissue defects with living tissue that is ideally 
generated from autologous cells and designed to meet the specific needs of each individual 
patient [8]. Generally, two different strategies have been adopted for the de novo generation 
of living tissue from isolated cells. One involves the in vitro cultivation of the harvested cells 
on three-dimensional cell carriers under tailored conditions and biological stimuli. Following 
this strategy, the cell carrier, which is fabricated from a biomaterial, provides the 
macroporous architecture on which cells can attach, proliferate and develop into the desired 
tissue, thus assuming the function of the natural extracellular matrix [11]. The other strategy 
favors the direct in vivo implantation of isolated cells with and without an artificial matrix [2]. 
Ideally, both strategies lead to a tissue construct that is ultimately indistinguishable from the 
surrounding or host tissue by histology and radiography. Over the last two decades, promising 
advances have been made towards the engineering of various types of tissues and organs 
(Fig. 1) [12]. 
Cells Matrix In vitro
cultivation
Implantation
 
Fig. 1: The Tissue Engineering process (adapted from Vacanti et al. [12]). 
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By the end of 2002, twenty tissue-engineered products had entered Food and Drug 
Administration clinical trials, while four were already approved: Apligraf® (Organogenesis; 
living skin), Carticel® (Genzyme Biosurgery; autologous chondrocytes), Dermagraft® (ATS; 
living skin), and OrCel® (Ortec; living skin) [13]. Germany's BioTissue Technologies AG 
has five products in clinical use since the end of 2001 (www.biotissue-tec.com). BioTissue 
follows the principle of autologous (patient's own) tissue replacement to treat skin 
(BioSeed®-S), oral mucosa (BioSeed®-M), oral bone (BioSeed®-Oral Bone) and cartilage 
(BioSeed®-C) defects. The specific cells are taken from the patient as a tissue specimen 
(biopsy) and then cultured in a GMP-certified laboratory. Once the required quantity of newly 
cultured cells is reached, combining the cells with a specific, resorbable biomatrix enables the 
cells to be transplanted into the existing defect.  
Generally, the total U.S. health care costs for patients suffering from tissue loss or organ 
failure exceed $400 billion per year and approximately 8 million surgical procedures are 
performed annually to treat these disorders. It has been estimated that the total market for 
tissue-engineered products is $80 billion annually in the United States alone [10]. Despite this 
tremendous economic potential, the field has yet to produce a profitable product [13]. 
However, the transition from a development state to a successful product has been constrained 
both by regulatory issues [14-16] and the complexity of tissue biology [17] . Critical issues in 
creating an entire organ or even a complex functional tissue include enhancing cell survival, 
maintaining the differentiated function, developing a significant cell mass embedded in its 
extracellular matrix, and achieving vascularization [10]. Future research has especially to 
overcome the problems arising from insufficient nutrient supply and the lack of 
vascularization [18,19]. Furthermore, cell carriers and scaffolding materials have to be 
designed to mimic natural extracellular matrix design and cell-matrix-interactions, and to 
support the structural orientation of the developing tissue with regard to the engineering of 
entire organs [20-23]. 
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2. The cell carrier-based Tissue Engineering concept 
The most common approach to tissue regeneration is based on cell-matrix constructs (Fig. 1) 
[4,24]. This concept is derived from the natural tissue assembly, where cells are embedded in 
a tissue-specific extracellular matrix that is composed of structural proteins (collagen and 
elastin), specialized proteins supporting cell matrix-interactions (e.g. fibrillin, fibronectin, and 
laminin) and hydrophilic proteoglycans (e.g. hyaluronic acis or glycosaminoglycans) [25]. 
This matrix supports cell proliferation, migration and tissue development [26]. 
The cell-matrix strategy of tissue engineering generally involves the following components 
and steps [27-29]: (i) An appropriate cell source, either allogeneic or autologous, must be 
identified, the cells need to be isolated and produced in sufficient numbers. (ii) A suitable 
biocompatible material that can be used as a cell substrate (open system) or cell-encapsulation 
material (closed system) must be isolated or synthesized and manufactured into the desired 
shape and dimensions, forming an artificial extracellular matrix. (iii) The cells must be 
uniformly seeded onto or into the material and grown in a bioreactor. (iv) The appropriate 
biochemical and/or mechanical stimulus must be identified and administered or applied in a 
controlled manner (amount and time) to improve cell differentiation, extracellular matrix 
production and tissue formation. (v) Finally, the engineered structure is placed into the in vivo 
site, where, depending on the site and the structure, vascularization may be necessary.  
2.1. Cell types and sources 
Suitable cells for tissue engineering applications generally include autologous cells from the 
patient, allogeneic cells from a human donor who is not immunologically identical to the 
patient, and xenogeneic cells from a different species [17]. The ideal way to obtain cells is to 
harvest autologous cells directly from the patient, followed by controlled expansion in vitro 
[30]. Although this option is preferred because the cells are acceptable to the recipient’s 
immune system without the need for immunosuppressive therapy, it is limited by the scarcity 
of available donor tissue and donor site morbidity. Each category, autologous, allogeneic, or 
xenogeneic, may be further delineated in terms of whether the cells are differentiated (mature 
cells) or undifferentiated (progenitor or stem cells). In most cases, differentiated cells isolated 
from adult tissues exhibit a very limited proliferative capacity and tend to lose differentiation 
within the first passages. Culturing progenitor or stem cells that, by definition, have a higher 
proliferative capacity is more promising.The differentiation of such cells, however, has to be 
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obtained in vitro by changing the culture conditions after cell expansion or in vivo as a 
consequence of the new microenvironment in the transplant area [31]. The use of stem cells 
that can be expanded for long periods and finally differentiated into a variety of cell lineages 
is particularly of interest [31-34]. Despite evidence suggesting that embryonic stem cells 
might represent a more potent regenerative reservoir than stem cells collected from adult 
tissues [35,36], ethical considerations have redirected attention to undifferentiated pluripotent 
cells derived from the bone marrow [37-43], the umbilical cord [44] and cord blood [45,46]. 
2.2. Biological stimuli 
The controlled supplementation of biological stimuli, e.g. growth factors, is required to 
promote cell proliferation, differentiation and tissue maturation in the cell-carrier constructs 
[28,47]. 
Various growth factors that induce cell differentiation and tissue maturation have been 
identified [28]. Cell-matrix constructs that are cultured in vitro can be easily supplemented 
with growth factors, e.g. with every medium exchange. In vivo, growth factors are preferably 
supplemented via drug delivery systems, such as microparticles, implants or even factor-
loaded cell carriers to avoid repeated injections. Epidermal growth factor (EGF) was 
successfully used to improve dermal regeneration [48]. Basic fibroblast growth factor (bFGF) 
is known to support adipogenesis [49,50] and osteogenesis [51,52], as well as cartilage [53] 
and nerve regeneration [54,55].  Nerve growth factor (NGF) has also been delivered and 
demonstrated to improve nerve regeneration. A plethora of studies have been conducted 
focusing on suitable growth factors for bone [56] and cartilage [57,58] tissue engineering. 
Transforming growth factor β1 (TGF-β1) [59-62] and members of the bone morphogenetic 
proteins (BMPs) [63-65] proved to be especially potent differentiation factors for orthopedic 
tissue engineering when applied in the appropriate regimen. BMP-2 turned out as a highly 
effective factor for bone regeneration, capable of de novo bone formation [66,67].  
In regard to the engineering of large tissue constructs and organs, angiogenesis and 
neovascularization, the formation of new blood vessels from existing ones, are key 
prerequisites to overcome limitations in nutrient and oxygen supply. Acid and basic fibroblast 
growth factor (aFGF and bFGF), platelet-derived growth factor (PDGF) and vascular 
endothelial growth factor (VEGF) are the most important factors that have been identified to 
influence and regulate endothelial cell differentiation and blood vessel formation [19]. 
Consequently, these proteins have been released from a variety of delivery devices to induce 
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angiogenesis in engineered tissue constructs [19,68-70]. It was demonstrated that the dual 
delivery of VEGF-165 and PDGF, each with distinct kinetics, from a single, structural 
polymer scaffold results in the rapid formation of a mature vascular network [71]. Another 
study demonstrated that VEGF-121 remained an active and very efficient mitogen for human 
endothelial cells after immobilization to fibrin. The fibrin-VEGF hydrogels are proposed as a 
growth matrix for ischemic regions that require an angiogenic response [72]. Recently, a 
hydrogel system was designed that is capable for the on-demand release of matrix-conjugated 
VEGF [73]. 
2.3. Cell carrier (scaffold) 
In cell carrier-based tissue engineering attempts, the macroporous three-dimensional cell 
carriers (scaffolds) play a pivotal role in cell seeding, proliferation, and new tissue formation 
in three dimensions [74]. Figure 2 summarizes the scaffold characteristics that influence the 
tissue engineered construct. 
Bulk properties
Crystallinity
Degradation kinetics
Mechanical stability
Biocompatibility
Surface properties
Hydrophilicity / lipophilicity
Biomimetic design
Architectural properties
Construct size and shape
Pore size and shape
Pore morphology
Pore interconnectivity
Construct porosity
Others
Use as delivery system
 
Fig. 2: Critical characteristics of a biodegradable polymer scaffold.  
The development of a functional cell carrier that is tailored to the intended application and/or 
type of engineered tissue involves careful consideration and adaptation of bulk, surface and 
architectural properties. This is realized by choosing an appropriate scaffold material that 
mainly determines the bulk and surface characteristics (section 3.1). Control over the 
architectural properties has to be provided by the scaffold fabrication technique (section 3.2). 
Ideally, the technique allows for the incorporation of the necessary biological stimuli in a 
further step. 
A functional tissue engineering concept, especially when focused on the engineering of 
tissues that are naturally vascularized, has to involve an angiogenic strategy.    
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3. Scaffold materials and fabrication techniques 
3.1. Biomaterials for Tissue Engineering 
A large variety of biomaterials, namely natural and synthetic polymers, ceramics and metals 
have been employed as scaffold materials [40,75-82]. On the basis of the materials 
hydrophilicity and mechanical properties, the scaffolding materials can be divided into 
materials that swell significantly in water forming a hydrogel and materials that only dissolve 
in organic solvents and are used for the fabrication of macroporous solids. Due to the 
mechanical properties, hydrogels are the preferred materials for the engineering of soft 
tissues, nerve fibers and blood vessels [73,83-86]. For the engineering of skeletal tissue, 
especially bone, the appropriate scaffolds should maintain a rigid structure under 
physiological conditions. 
Hydrogel forming materials 
Hydrogels have been increasingly studied as matrices for tissue engineering due to their 
mechanical similarity to the natural extracellular matrix [75]. Hydrogels are characterized by 
a high water content and pores that can accommodate living cells. Table 1 gives a survey of 
the wide and diverse range of hydrogel-forming polymers that are used in biomedical 
applications. The substances can be categorized into natural polymer hydrogels, synthetic 
polymer hydrogels and combinations of the two classes. Natural materials, such as collagen, 
which is a key component of the extracellular matrix, and gelatin, which is denatured 
collagen, are of special interest as these polymers interact with cells and induce tissue 
formation [11,87]. While collagen forms gels in physiological environments (pH and 
temperature), gelatin dissolves in water at body temperature. Therefore, chemical crosslinking 
with glutaraldehyde, genipin or other crosslinkers is often used to render gelatin insoluble 
[88-90]. Hydrogel matrices, prepared from crosslinked gelatin, have been comprehensively 
investigated by Tabata and co-workers in a variety of tissue engineering studies [50,52,61,91]. 
In these studies, the hydrogel serves not only as cell carrier but also as a growth factor 
delivery system. Combinations of gelatin with other natural materials, such as alginate or 
hyaluronic acid, are accepted materials for skin reconstruction [92,93]. Mooney and 
coworkers have intensively investigated the feasibility of ionically crosslinked alginate 
hydrogels as cell carriers for tissue engineering experiments [84,94,95].  
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Table 1: Hydrophilic polymers used to synthesize hydrogel matrices (adapted from [75]) 
Natural polymers and their derivatives (± crosslinkers) 
Anionic polymers: hyaluronic acid, alginate, pectin, carrageenan, chondroitin sulfate, dextran sulfate 
Cationic polymers: chitosan, polylysine 
Amphipathic polymers: collagen, gelatin, carboxymethyl chitin, fibrin 
Neutral polymers: dextran, agarose, pullulan 
Synthetic polymers (± crosslinkers) 
Polyesters:  PEG-PLA-PEG, PEG-PLGA-PEG, PEG-PCL-PEG, PLA-PEG-PLA, PHB, 
 poly(PF-co-EG) ± acrylate end groups 
Other polymers 
PEG-bis-(PLA-acrylate), PEG-CDs, PEG-g-poly(AAm-co-vinyl amine), poly(AAm), poly(NiPAAm-co-
AAc), poly(NiPAAm-co-EMA), PVAc/PVA, PNVP, poly(MMA-co-HEMA), poly(AN-co-allyl sulfonate), 
poly(biscarboxy-phenoxy-phosphazene), poly(GEMA-sulfate) 
Combinations of natural and synthetic polymers 
P(PEG-co-peptides), alginate-g-(PEO-PPO-PEO), P(PLGA-co-serine), collagen-acrylate, alginate-
acrylate, poly(HPMA-g-peptide), poly(HEMA/ Matrigel®), hyaluronic acid-g-NiPAAm 
 
Abbreviations: CD, cyclodextrin; EG, ethylene glycol; HEMA, hydroxyethyl methacrylate; AAc, acrylic acid; AAm, acrylamide; 
AN, acrylonitrile; EMA, ethyl methacrylate; GEMA, glucosylethyl methacrylate; HEMA, hydroxyethyl methacrylate; HPMA, 
hydroxypropyl methacrylamide; MMA, methyl methacrylate; NiPAAm, N-isopropyl acrylamide; PCL, poly(caprolactone); PEG, 
poly(ethylene glycol); PEO, poly(ethylene oxide); PF, propylene fumarate; PHB, poly(hydroxy butyrate); PLA, poly(lactic acid); 
PLGA, poly(lactic-co-glycolic acid); PNVP, poly(N-vinyl pyrrolidone); PPO, poly(propylene oxide); PVA, poly(vinyl alcohol); 
PVAc, poly(vinyl acetate) 
 
Many different routes have been used to form hydrogels from the polymers listed in Table 1. 
Gelation is induced either physically or chemically [75]. Physical gels are formed by a change 
of temperature (e.g. poly(NiPAAm), PEO-PPO-PEO)) or pH (e.g. polyAAc, collagen), by 
mixing polyanions and polycations (e.g. alginate-chitosan), or by crosslinking a 
polyelectrolyte with multivalent ions (e.g. calcium-alginate). Chemical gels are synthesized 
by a crosslinking reaction between electron-poor olefins, such as acrylate, vinyl or fumarate 
groups. In this way a plethora of PEG- or PEO-based hydrogels has been synthesized [96-98]. 
Recent research has particularly been focused on injectable hydrogel systems, which are 
liquid at room temperature to enable a comfortable mixing with cells and/or growth factors 
and form a gel when heated up to body temperature. Promising examples are poly(NiPAAm)-
based copolymers exhibiting thermoreversible gelation properties [99-101] and in situ 
polymerizable PEG-based macromers [96,98,102,103]. For instance, injectable PEG-fumarate 
based hydrogels, like oligo(poly(ethylene glycol)-fumarate) (OPF) and poly(PF-co-EG), have 
been demonstrated to be biocompatible, biodegradable and suitable biomaterials for the 
engineering of bone-like tissue [104-109].  
Different strategies have been applied to further improve these hydrophilic hydrogels with 
regard to tissue engineering applications. By covalently attaching adhesion peptides 
containing the tripeptide Arg-Gly-Asp (RGD), artificial extracellular matrix substitutes have 
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been developed [22,110-112]. Hubbel and coworkers introduced a fully-synthetic substitute of 
alginate for cell encapsulation [113] and developed an injectable PEG-based hydrogel for 
bone regeneration that is proteolytically remodeled by ingrown cells and delivers BMP-2 
[114]. 
The ease with which one may covalently incorporate cell adhesion peptides and the potential 
to design injectable systems are two significant advantages of using hydrogels as tissue 
engineering matrices vs. more hydrophobic alternatives. However, a major disadvantage of 
hydrogels is their low mechanical strength, which poses a significant challenge in their 
handling. Sterilization issues are also very challenging [75]. A further parameter to consider is 
the biodegradability of the material. Polyacrylate hydrogels, many polysaccharides, alginates, 
and polyethers (PEG, PEO, PPO), for example, do not degrade in a physiological 
environment, but can be excreted if the molecular weight is below the renal threshold barrier 
[115,116].    
Generally, hydrogels containing cell adhesive components are biodegradable and can be 
remodeled by encapsulated or invading cells, forming a practical and useful material for 
biomedical applications that do not require a mechanical stable carrier. We intend to employ a 
functional hydrogel that delivers angiogenetic growth factors and can be injected into rigid 
scaffolds as an ingrowth matrix for blood vessels.    
Materials for the fabrication of rigid scaffolds 
Tissue engineering scaffolds have been fabricated from natural and synthetic polymers, 
ceramics and metals [40,79,117,118]. Biodegradable polymers are the most attractive and 
widely applied scaffolding materials, often considered superior to ceramics and metals 
because they degrade as the new tissues are formed [79,119]. In contrast to natural scaffolding 
materials, such as collagen, chitosan or chitin, these synthetic polymers can be supplied in 
reproducible quality and free of pathogenic or immunogenic organic residues. 
Poly(α-hydroxy acids), namely poly(D,L-lactic acid) (PLA) and copolymers (PLGA) with 
poly(glycolic acid) (PGA), a polymer that has already been approved by the FDA as a suture 
material, are probably the most common class of synthetic, biodegradable polymers. Further 
materials that are under investigation are polyanhydrides [120], polycaprolactones [121] and 
copolymers with PLA [122], polycarbonates [123], polyurethans [124] and polyfumarates 
[125]. The polymer structures are summarized in Table 2. 
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Table 2: Structures of synthetic, biodegradable polymers. 
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Besides the FDA approval as suture materials, poly(α-hydroxy acids) have other advantages 
that make them interesting for biomedical applications. By varying the polymer composition, 
crystallinity and molecular weight, the degradation kinetics and mechanical stability of the 
polymer can be adapted to the tissue that is to be engineered [79,126-128]. In addition, the 
polymers are soluble in numerous solvents allowing for lab scale scaffold fabrication.  
In tissue engineering approaches with the currently available biodegradable polymers, 
however, many difficulties arise from the poor control of cell function on the lipophilic 
polymer surfaces. In a biological environment, proteins non-selectively attach to the polymer 
surface, which may in turn trigger a number of non-specific cellular responses and lead to 
uncontrollable tissue development and growth [129]. Strategies to overcome these limitations 
and to control cell-material-interactions include the covalent grafting of cell type specific 
adhesion peptides (RGD peptides) to the polymer surfaces [130,131]. The RGD-sequence is 
the cell attachment site of a large number of adhesive ECM, blood, and cell surface proteins 
[132,133]. Because cells contain cell adhesion receptors (integrins) that recognize only certain 
ECM molecules, the use of an appropriate cell-binding sequence leads to cell-selective 
surfaces [134]. The modification of a lipophilic polymer, however, is often accompanied with 
laborious chemistry due to the lack of functional groups on the polymer [131]. In addition, 
surface modification is significantly more efficient when unspecific protein adsorption is 
suppressed. In this way, recent studies on poly(D,L-lactic acid)-poly(ethylene glycol)-
monomethyl ether diblock copolymers (MeO-PEG-PLA) (Table 2) demonstrated the effect of 
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reduced protein adsorption, caused by the presence of the hydrophilic poly(ethylene glycol) 
(PEG) [135,136]. The altered surface chemistry also had a significant effect on cell adhesion 
and cell differentiation compared to unmodified PLA [137]. With the objective of enabling a 
convenient surface modification with adhesion peptides or growth factors to create a 
biomimetic surface design, a new class of amine- and thiol-reactive polymers was developed 
on basis of the PEG-PLA diblock copolymers [138,139]. These reactive copolymers are 
designed to covalently bind peptides or proteins from aqueous solutions to preformed polymer 
surfaces during a simple incubation step. As the positive effects of surface-attached adhesion 
peptides on cell adhesion are thoroughly described [131], the first studies indicate that 
covalently attached growth factors retained their activity and activated their receptors and 
downstream signaling proteins [140-142]. Non-diffusional growth factors may allow for 
localized cell stimulation, surface patterning and a prolonged half-life of the protein. A 
surface modification concept based on reactive diblock copolymers would allow for an “off 
the shelf” scaffold or implant coating fabrication, which could be covalently modified with 
peptides in response to individual needs by incubation with a sterile solution of the required 
peptide. The general feasibility of this concept has been previously shown in a study on the 
immobilization of fluorescent dyes or model proteins to preformed films [139]. These 
polymers are therefore promising scaffold materials for the fabrication of functional or even 
biomimetic scaffolds. 
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4. Scaffold fabrication techniques 
Several requirements have to be considered in the design of macroporous, polymeric scaffolds 
for tissue engineering [74,143,144]. First, the scaffold material should be biocompatible and 
biodegradable. Second, an ideal scaffold is highly porous with an interconnected pore 
network to accommodate cells, to support cell proliferation and differentiation, and to 
enhance tissue formation. A high porosity (> 90%) is also important for sufficient oxygen 
supply and to guarantee unimpaired flow transport of nutrients and metabolic wastes. Third, a 
suitable surface chemistry is necessary to optimize cell attachment, proliferation, and 
differentiation. Fourth, the scaffold should have adequate mechanical properties to match 
those of the tissues at the site of implantation.  
A variety of processing technologies have been developed to fabricate polymeric scaffolds. 
These techniques mainly include textile technologies, solvent casting and particulate leaching, 
gas foaming, emulsion freeze drying, thermally induced phase separation, electrospinning, 
and rapid prototyping.  
Fiber meshes / fiber bonding 
Fibers, produced by textile technology, have been used to fabricate non-woven meshes from 
PGA and PLLA [24] (Fig. 3a). Fiber meshes represent the ‘gold standard’ in permeability and 
are still the standard scaffolds for many applications, but lack the necessary structural 
stability. To improve the mechanical properties of the meshes, the PGA fibers were bound 
together with solutions of other polymers [145]. In detail, PLLA is dissolved in methylene 
chloride, which is not a solvent for PLA, and cast over the PGA mesh. After solvent 
evaporation, the construct is heated above the melting point of PGA. Finally, the PLLA is 
removed by dissolving in methylene chloride again. This treatment results in a mesh of PGA 
fibers joined at the cross-points. 
Electrospinning  
Electrospinning is a fabrication process that uses an electric field to control the formation and 
deposition of polymer fibers onto a target substrate [146-149]. The electrospinning technique 
can fabricate fibrous scaffolds from polymer solutions or melts with fiber diameters ranging 
from several microns down to several hundred nanometers [146] (Fig. 3b). 
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Fig. 3: Scaffold microstructures. Scale bars represent 200µm; except in image b and c: 100 µm. 
a) Non-woven fiber mesh prepared from crystalline PLLA. b) Electrospun PCL scaffold 
[148]. c) PLLA fibrous matrix prepared by phase separation [150] d) PLGA scaffold 
fabricated by salt leaching [151]. e) Scaffold prepared by salt leaching from injectable PPF 
[152]. f) PLGA scaffold as obtained from gas foaming / salt leaching [153]. g) PLLA 
scaffold prepared by phase separation [154]. h) PLLA scaffolds prepared with a 
hydrocarbon porogen [155]. i) PCL scaffold fabricated by fused deposition modeling [156].    
Solvent-casting and particulate-leaching 
Solvent casting and particulate leaching is a simple and the most commonly used method for 
the lab-scale fabrication of scaffolds [157]. This method involves mixing water-soluble salt 
particles into a solution of a biodegradable polymer. After solvent evaporation, the salt 
particles are leached out with large amounts of water to obtain a porous structure (Fig. 3d,e). 
The advantages of this method include adequate control of pore size and porosity by the size 
of the pore-forming salt particles and the salt to polymer ratio, respectively. However, most of 
the porous materials prepared by solvent casting are characterized by a low pore 
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interconnectivity that is disadvantageous for uniform cell seeding, tissue growth and fluid 
flow. Furthermore, the difficulty of removing soluble particles from the interior of a polymer 
matrix limits the scaffold thickness to 2 mm. Larger constructs were built from thin porous 
discs by compression molding or lamination techniques.  
Strategies to improve the pore interconnectivity of scaffolds prepared by salt leaching involve 
the use of salt particles in combination with gas foaming agents, e.g. ammonium carbonate 
[158] or sodium bicarbonate / ascorbic acid [159]. In another attempt, the salt particles were 
partially fused via treatment in 95% humidity to create a continuous polymer matrix [160]. 
Despite these improvements, scaffolds prepared by a solvent-casting salt-leaching technique 
still lack sufficient permeability for homogeneous cell distribution, nutrient and oxygen 
supply, and tissue development [161]. 
Recently, water insoluble paraffin microparticles were used as pore forming devices. To 
generate interconnected scaffolds, the paraffin spheres were bonded together through a heat 
treatment to form a three-dimensional assembly in a mold. Biodegradable polymers such as 
PLLA and PLGA were dissolved in a solvent and cast onto the paraffin sphere assembly. 
After dissolving the paraffin in a non-solvent for the polymer, a porous polymer scaffold was 
formed (Fig. 3h) [155].       
Gas foaming 
The gas foaming process can be used to fabricate highly porous polymer foams without the 
use of organic solvents [162]. In this approach, solid polymer discs are saturated with carbon 
dioxide (CO2) at high pressures. The solubility of the gas in the polymer is then rapidly 
decreased by releasing the excess CO2 and bringing the pressure back to atmospheric level. 
This results in thermodynamic instability followed by the nucleation and growth of gas 
bubbles in the material with sizes ranging between 100 - 500 µm. The disadvantage of this 
method is that it mostly yields a nonporous surface and closed-pore structure, with only 10 - 
30% of interconnected pores. The porosity and pore interconnectivity can be significantly 
improved by combining the gas-foaming process with the salt leaching technique [163] 
(Fig. 3f). Nonetheless, completely eliminating closed pores remains challenging. 
Melt molding 
Melt molding, another process free of organic solvents, involves filling a mold with polymer 
powder and gelatin microspheres of specific diameter [164]. By heating the mold above the 
glass transition temperature of the polymer while applying pressure to the mixture, the 
Chapter 1  Introduction and Goals of the Thesis  
- 23 - 
polymer particles are bound together. Once the mould is removed, the gelatin component is 
leached out in water and porous scaffolds are produced in the shape of the mold. Again, this 
technique is commonly combined with the salt-leaching technique. Like other particulate-
leaching techniques, scaffolds fabricated by melt molding often lack sufficient pore 
interconnectivity and porosity.  
Freeze drying 
Low-density polymer foams have been produced from several polymers including PLGA and 
PLGA/PPF using a freeze-drying technique [165,166]. The polymers are first dissolved in a 
solvent such as glacial acetic acid or benzene. The solution is then frozen and the solvent is 
removed by lyophilization. The foams have either leaflet or capillary structures depending on 
the polymer and solvent used in fabrication. These foams are generally not suitable as 
scaffolds for cell transplantation. 
Scaffolds from natural polymers, such as collagen and gelatin, were similarly prepared 
[82,91,167,168]. Freezing a swollen hydrogel from crosslinked gelatin or collagen results in 
the formation of ice crystals that cause the collagen molecules to aggregate in the interstitial 
spaces. The ice crystals are then removed by freeze-drying. The pore size can be controlled by 
the freezing rate and pH [169-171]. With regard to the mechanical stability, it was shown that 
the incorporation of PGA fiber is a promising way to reinforce collagen sponge without 
impairing biocompatibility [172]. 
Phase separation / emulsification 
Instead of the incorporation of a porogen, additional techniques proposed for the fabrication 
of porous polymer scaffolds are based on the concepts of phase separation. They include 
emulsion freeze-drying and thermally induced phase separation.  
Emulsion freeze-drying 
Emulsion freeze-drying creates porous scaffolds by adding water to an organic polymer 
solution [173]. The two immiscible layers are then homogenized to form a water-in-oil 
emulsion, which is then quenched in liquid nitrogen and freeze-dried to produce the porous 
structure. Scaffolds with porosity greater than 90% and low pore sizes (typically below 50 
µm) can be fabricated with this method. Again, the major disadvantage of this technique is the 
closed pore structure in the resulting matrix [174]. 
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Thermally Induced Phase Separation 
The controlled thermally induced phase separation (TIPS) process, developed for the 
preparation of porous membranes, was recently utilized to fabricate biodegradable polymer 
scaffolds from PLLA and PLGA [122,174-180]. In this approach, the polymer is first 
dissolved in a solvent with a low melting point and that is easy to sublime, such as 
naphthalene, phenol, 1,4-dioxane or tetrahydrofurane. In some cases, small amounts of water 
are added as a non-solvent to induce phase separation [174,178,181]. Liquid–liquid or solid–
liquid phase separation is induced by lowering the solution temperature below the melting 
point of the solvent (polymer poor phase). Subsequent removal of the solidified solvent-poor 
phase by sublimation leaves a porous polymer scaffold. The pore morphology of the scaffolds 
varies depending on the polymer, solvent, concentration of the polymer solution and phase 
separation temperature [174] (Fig. 3c,g). Scaffolds fabricated by TIPS often have good 
mechanical properties and interconnected pore structures but control of architectural 
properties and the generation of non-oriented pore structures are difficult.  
Rapid-Prototyping Techniques 
Rapid prototyping is a technology that has developed from advances in computer science and 
manufacturing industry [182]. The main advantage of these techniques is their ability to 
produce complex products for the individual patient from a computer-aided design (CAD) 
model. The reader is referred to literature reviews on the advantages and benefits, and 
limitations and shortcomings of current RP techniques [182,183]. Common techniques use 
established lipophilic polymers for scaffold fabrication. Recently, a technique was developed 
that allows for the fabrication of hydrogel scaffolds [184,185]. However, all rapid prototyping 
techniques require a complex instrumental setup and resulting scaffolds often suffer from 
insufficient resolution and high fiber thickness. 
  
In conclusion, each of the described techniques exhibits several limitations. Fiber meshes lack 
mechanical stability and salt leached scaffolds are short of interconnected pores and exposed 
to aqueous media over several days, which constrains the processing of water soluble proteins 
and polymers containing water-sensitive functions. Phase separation or freeze drying 
techniques are often anhydrous and generate interconnected pores, but the control of pore size 
and shape is considerably limited. Several techniques, such as rapid prototyping or fiber 
fabrication, are limited to polymers that offer distinct physicochemical properties and are not 
suitable for the processing of small batches of new, functional polymers. 
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5. Goals of the Thesis 
A functional cell carrier design concept involves a biodegradable material that allows for a 
tailored interaction with cells in terms of adhesion and differentiation. Furthermore, a suitable 
scaffold fabrication technique is required to process lab-scale amounts of the polymer into 
macroporous, biocompatible and biodegradable cell carriers with controlled architectural 
properties. Last but not least, a concept to induce neovascularization of the tissue engineered 
construct has to be established. 
The work presented in this thesis aims at the fabrication of cell carriers following the 
functional design concept described above. The intention was to model the microstructure of 
the cell carriers on the load-bearing structure of spongy bone that is shown in Figure 4. The 
spongy structure is characterized by a high permeability and a pore diameter of approximately 
400 µm. 
 
Lamellae
Osteon
Trabecular (spongy) bone
Compact bone
Periosteal blood vessel
Periosteum
 
 
 
Fig. 4: Structure of bone. a) Compact and trabecular (spongy) bone (from Sobotta/Welsch, textbook 
of histology) b) Structure of trabecular bone as determined by micro-computed tomographic 
imaging (adapted from [186]).  
We started this work by investigating the ability of a recently developed class of reactive and 
low adhesive diblock copolymers [138,139] to bind RGD peptides. To this end, reactive 
polymer films were incubated with a RGD peptide solution in order to create a cell adhesive 
polymer film surface (Chapter 2). These polymers hold great potential for the fabrication of 
biomimetic surfaces and represent a promising material for the fabrication of functional cell 
carriers. 
 
400 µm b) a) 
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Chapter 3 aims at the processing of amine-reactive diblock copolymers into macroporous 
cell carriers with a spongy microstructure. To this end, a technique was developed (solid lipid 
templating) on the basis of an anhydrous processing concept [187] that employs triglycerides 
as biocompatible porogen materials and a non-halogenated solvent mixture to process the 
block copolymers into appropriate cell carriers. The technique combines the advantages of a 
particulate leaching technique, namely control of pore size, pore shape, and scaffold porosity, 
with a phase separation concept to obtain a highly interconnected pore structure. Insulin was 
used as a model protein that was bound to the surface of a prefabricated surface to 
demonstrate the preservation of polymer reactivity during processing. 
Typical solvents for the processing of biodegradable polymers are chloroform and methylene 
chloride. In the development stages of the solid lipid templating technique, an azeotropic 
mixture from acetone and chloroform was employed and suitable processing parameters that 
result in the desired scaffold microstructure were established. In order to replace the 
halogenated solvent mixture with a less toxic (according to the ICH guideline on residual 
solvents [188]) solvent or solvent mixture without the need for the laborious adaptation of 
processing parameters, we followed a thermodynamic approach. The Hansen solubility 
parameters (HSPs) of the established solvent mixture were determined and a 
thermodynamically similar solvent or solvent mixture was systematically searched by 
solubility parameter comparison (Chapter 4). 
Based on the promising results of the solvent replacement study, which indicated the 
usefulness of the HSPs as predictive parameters in polymer processing, we aimed at the 
determination of the HSPs of poly(lactic acid), poly(lactic-co-glycolic acid) and monomethyl 
ether-poly(ethylene glycol)-block-poly(lactic acid) using theoretical and experimental 
methods (Chapter 5). 
Since the architectural properties of a scaffold influence fluid flow and tissue development 
within the scaffold, the processing parameters to vary these architectural parameters are 
determined in a further study (Chapter 6). To this end, rheological measurements are 
conducted to access the required adaptation of polymer concentration to varied porogen 
particle properties. In addition, several polymers characterized by different molecular weights 
and compositions are processed using the solid lipid templating technique to demonstrate the 
versatility of this lab-scale process. 
Finally, an injectable hydrogel matrix was developed from gelatin and PNiPAAm (Chapter 
7). The conjugate contains gelatin, which is denatured collagen, a key component of the 
natural ECM, to attract blood vessel ingrowth. Due to the gelatin backbone, the hydrogel can 
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be proteolytically remodeled by ingrown cells, because the peptide is a substrate for matrix 
metalloproteinases. Since gelatin dissolves in aqueous media under physiological conditions, 
PNiPAAm chains are grafted to the peptide to trigger gelation at body temperature. 
Rheological measurements are performed to demonstrate and characterize the thermogelling 
of the conjugate. Cell culture experiments are performed to access cell viability in the gels. 
This hydrogel is the first step towards an ingrowth matrix to support neovascularization of 
tissue engineered constructs. To this end, angiogenetic growth factors will be incorporated in 
the hydrogel in future studies.      
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Abstract 
One promising strategy to control the interactions between biomaterial surfaces and attaching 
cells involves the covalent grafting of adhesion peptides to polymers on which protein 
adsorption, which mediates unspecific cell adhesion, is essentially suppressed. This study 
demonstrates a surface modification concept for the covalent anchoring of RGD peptides to 
reactive diblock copolymers based on monoamine poly(ethylene glycol)-block-poly(D,L-lactic 
acid) (H2N-PEG-PLA). Films of both the amine-reactive (ST-NH-PEG2PLA20) and the thiol-
reactive derivative (MP-NH-PEG2PLA40) were modified with cyclic αvβ3/αvβ5 integrin 
subtype specific RGD peptides simply by incubation of the films with buffered solutions of 
the peptides. Human osteoblasts known to express these integrins were used to determine cell-
polymer interactions. The adhesion experiments revealed significantly increased cell numbers 
and cell spreading on the RGD-modified surfaces mediated by RGD-integrin-interactions. 
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1. Introduction 
The surface design of biomaterials applied in implant technology and tissue engineering is a 
key element in controlling the interaction with attaching cells and the surrounding tissue [1-
4]. Cell adhesion to a material is primarily mediated by integrins, with a plethora of integrin 
subtypes providing selective interactions with different proteins of the extracellular matrix 
[5,6]. A number of integrin subtypes recognize the simple tripeptide sequence Arg-Gly-Asp 
(RGD) as their ligand, but show specific interactions depending on the amino acids flanking 
the RGD motif as well as on the conformation of the peptide [7-9]. The covalent linking of 
these adhesion peptides to biomaterials is a widely accepted approach to improve a material’s 
biocompatibility, biological activity and its interactions with cells [9-15]. Biomaterials used in 
such attempts preferably suppress protein adsorption and the accompanying unspecific cell 
adhesion on their surfaces in order to provide undisturbed peptide dependent cell-biomaterial 
interactions [16]. Additionally, these materials need to provide a functional group to allow for 
the attachment of RGD peptides. Some hydrogels have been shown to be capable of fulfilling 
both specifications [12,17-19], but lack the mechanical strength and macroporous structure 
necessary for many tissue engineering applications. Alternatively, non-swelling, lipophilic 
polymers have been investigated as materials for the fabrication of implants or scaffolds in the 
engineering of hard tissue. They provide higher mechanical strength and insolubility in water, 
allowing for defined geometries, macroporosity and permeability [20,21]. However, the 
covalent modification with RGD peptides is often a laborious procedure since most of these 
lipophilic polymers lack the required functional groups for surface modification [9]. To 
address the problem of unspecific protein adsorption and cell adhesion to lipophilic polymer 
surfaces, diblock copolymers, such as poly(D,L-lactic acid)-poly(ethylene glycol)-
monomethyl ether (MeO-PEG-PLA), were developed. These polymers consist of both a 
hydrophilic and lipophilic chain and therefore combine mechanical stability and water 
insolubility with low adhesive properties. MeO-PEG-PLAs that contain high ratios of PEG, 
making them non-conductive for protein and peptide adsorption, have been particularly 
effective as ‘stealth’ biomaterials in numerous applications [22,23]. We have recently shown 
that protein adsorption and cell adhesion can be controlled via the length and content of the 
MeO-PEG block in these diblock copolymers [23,24]. To enable the convenient modification 
of these materials with adhesion peptides, mono amine derivatives (H2N-PEG-PLA) of the 
MeO-PEG-PLA diblock copolymers have been synthesized and subsequently functionalized 
by the covalent attachment of disuccinimidyl tartrate or N-succinimidyl-3-maleimido 
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propionate, resulting in amine- (ST-NH-PEG-PLA) and thiol-reactive polymers (MP-NH-
PEG-PLA), respectively [25,26]. These reactive copolymers (Fig. 1) are designed to 
covalently bind peptides or proteins from aqueous solutions to preformed polymer surfaces 
during a simple incubation step. This concept would allow for an “of the shelf” scaffold or 
implant coating fabrication, which could be covalently modified with peptides in response to 
the individual needs by incubation with a sterile solution of the required peptide. The general 
feasibility of this concept has been shown in previous studies on the immobilization of 
fluorescent dyes or model proteins to preformed films and scaffolds [26,27]. In the present 
study, we aimed at surface modification of reactive polymer films with αvβ5/αvβ3 integrin 
subtype specific cyclic RGD peptides via a free amine or thiol group (Fig. 2) [14,28]. The 
success of the procedure was demonstrated in a cell adhesion study, since cell adhesion to and 
spreading on the modified low-adhesive surfaces requires a high density of integrin-binding 
sites [1,29]. 
Two polymers were investigated in this study, ST-NH-PEG2PLA20, an amine-reactive 
copolymer composed of a 20 kDa PLA chain and a 2 kDa PEG chain, and MP-NH-
PEG2PLA40, a thiol-reactive copolymers with a 40 kDa PLA chain. Polymer films were cast 
on glass object slides and subsequently modified with cyclic RGD peptides [14]. According to 
the polymer design concept, the RGD peptide was attached to the polymer surface by an 
instant procedure. This means that the prefabricated polymer films were simply incubated 
with a buffered solution of the peptide in a procedure adjusted to the chemistry of the 
polymers functional groups and to solid phase modification. The adhesion of human 
osteoblasts on the modified films was investigated, since this cell type is known to strongly 
express the corresponding αvβ5/αvβ3 integrin [5,15]. This study demonstrates a surface 
modification concept based on low-adhesive, amine- and thiol-reactive copolymers, to which 
cell adhesion is mediated by covalently attached integrin subtype specific RGD peptides. 
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2. Materials and Methods 
2.1. Polymer synthesis and characterization  
The amine-reactive polymer ST-NH-PEG2PLA20 (Mw: 22 kDa) (α-Hydro-ω-[3-succinmidyl-
oxycarbonyl-2,3-hydroxy-propyl-amido]-poly(oxy-1-oxopropane-2,1-diyl-block-
oxyethylene)) (Fig. 1a) was synthesized from H2N-PEG2PLA20 and disuccinimidyl tartrate. 
Synthesis and analytical characterization were performed as described in the literature [25]. 
The synthesis and characterization of the thiol-reactive diblock copolymer MP-NH-
PEG2PLA40 (Mw: 42 kDa) (α-Hydro-ω-[3-maleimido-propylamido]-poly(oxy-1-oxopropane-
2,1-diyl-block-oxy-ethylene)) (Fig. 1b) have been recently presented in [26]. 
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Fig. 1:  Polymer structures. a, Amine-reactive ST-NH-PEG-PLA. b, Thiol-reactive MP-NH-PEG-
PLA. Circles mark the amine-reactive functionality of the N-hydroxysuccinimide ester and 
the thiol-reactive double bond of the maleimide. 
2.2. RGD peptides and RAD analoges 
The αvβ5/αvβ3-integrin subtype specific cyclic RGD peptide cyclo(-Arg-Gly-Asp-D-Phe-
Lys-) (cyclo(-RGDfK-)) (Fig. 2a) and its non-binding analogue cyclo(-Arg-Ala-Asp-D-Phe-
Lys-) (cyclo(-RADfK-)) were synthesized as described by Haubner et al. [28,30]. These 
peptides were used to modify the amine-reactive copolymer surfaces. The thiol-reactive 
copolymer was modified with cyclo(-RGDfE-)-spacerAA-C-OH (Fig. 2b), another 
αvβ5/αvβ3-integrin subtype specific cyclic RGD peptide, which contains a spacer amino acid 
(spacerAA: 20-amino-3,6,9,12,15,18-hexaoxaeicosanoic acid) and a free thiol group on the 
amino acid cysteine [30]. A non-binding RAD-derivative was used as a control. 
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Fig. 2: Chemical structures of the cyclic RGD peptides. a, cyclo(-RGDfK-) and b, cyclo(-RGDfE-)-
spacerAA-C-OH (spacerAA: 20-amino-3,6,9,12,15,18-hexaoxaeicosanoic acid). The boxed 
functional groups were used for a chemoselective ligation of the peptides to the reactive 
polymer surfaces. 
2.3. Human osteoblasts 
Osteoblasts were harvested from cancellous human bone fragments derived from routine 
surgical procedures (during total hip or knee replacement) with informed consent and in 
accordance with the terms of the ethics committee of the University of Ulm. Cell isolation 
was done following the published standard protocol [31,32]. Further cultivation was 
performed in DMEM with 10% fetal bovine serum (FBS, Gemini Bio-Products Inc., 
Calabasas, California, USA), 1% penicillin/streptomycin (Sigma, Taufkirchen, Germany) and 
ascorbic acid 50 mg/l (Sigma). For cell adhesion experiments, cells were used following the 
third passage. 
2.4. Experimental setup 
An experimental setup (Fig. 3), which allows for easy handling, for direct observation of 
attaching cells and which requires only low amounts of RGD peptides, has been developed. 
Glass object slides (Super-Frost Plus, Menzel-Gläser, Braunschweig, Germany) were used as 
carriers for the cell adhesion experiments. To create a defined area, two rings (diameter: 1.5 
cm each) were engraved on the glass object slides using a diamond drill. Before polymer film 
casting, the glass object slides were aminated to improve polymer adhesion. For this process, 
the glass object slides were carefully washed using a detergent followed by intensive rinsing 
with water and finally acetone to remove any lipids. All slides were autoclaved. For 
amination, the slides were submerged in a stirred solution of 2% (v/v) 
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3-aminopropyltriethoxysilane (ABCR GmbH & Co. KG, Karlsruhe, Germany) in absolute 
ethanol for 30 min. After careful rinsing with absolute ethanol, the slides were annealed in an 
oven for another 30 min at 90°C. After amination the enclosed areas were coated with 
polymer films. For film casting, solutions of 50 mg diblock copolymer in 1 mL acetone 
(Merck, Darmstadt, Germany) were prepared and subsequently 20 µL of the polymer 
solution, corresponding to a mass of 1 mg polymer, were distributed on each marked area of 
1.77 cm2. Polymer films were fabricated from ST-NH-PEG2PLA20 and MP-NH-PEG2PLA40. 
The slides were dried under a petri-dish for the first 5 min. Covering the slides decelerated the 
solvent evaporation and ensured the formation of a smooth polymer film surface. Afterwards, 
the surrounding groove on the slides was covered with a lipophilic barrier (Dako-Pen, Dako, 
Glostrup, Denmark) so that fluids remained in the engraved area during the incubation and 
cell adhesion study. Finally, the polymer films were vacuum-dried for 12 hours. 
 
Fig. 3: Illustration of the experimental set-up.  
2.5. Surface modification with RGD peptides 
Different incubation protocols were used to modify the reactive copolymer surfaces. Details 
on these protocols are summarized in Table 1. In order to achieve a covalent anchoring of the 
RGD peptides to the reactive copolymers, the polymer films (1.77 cm²) were incubated with 
250 µL of a buffered solution of 2 mg/mL RGD peptide. Control surfaces were obtained by 
incubating polymer films with the non integrin-binding RAD peptides or the reaction buffer. 
During the incubation step with the bicarbonate reaction buffer, the amine-reactive 
N-hydroxysuccinimide ester of ST-NH-PEG2PLA20 was hydrolyzed, forming a negatively 
charged carboxylate residue. To obtain non-charged surfaces, other films were aminolyzed by 
incubation with ethanolamine (stop buffer). In a further control group, the effect of non-
covalently attached RGD peptide was investigated. To this end, ST-NH-PEG2PLA20 surfaces 
were hydrolyzed by incubation with bicarbonate
 
buffer before cyclo(-RGDfK-) was brought 
in contact with the polymer film. 
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Table 1: Description of diverse surface treatment protocols applied to prepare diblock copolymer 
surfaces for the cell adhesion studies. 
Abbreviation Incubation reagent Incubation conditions 
ST-NH-PEG2PLA20 surfaces 
RGD 2 mg/mL cyclo(-RGDfK-) in 0.15 M NaHCO3, pH: 8,0  11h at 4°C + 3h at 18°C 
RAD 2 mg/mL cyclo(-RADfK-) in 0.15 M NaHCO3, pH: 8,0 11h at 4°C + 3h at 18°C 
hydrolysis 0.15 M NaHCO3, pH: 8,0 11h at 4°C + 3h at 18°C 
stop 0.1 M  ethanolamine in 0.15 M NaHCO3, pH: 8,0 11h at 4°C + 3h at 18°C 
hydrolysis 
RGD 
1.) 0.15 M NaHCO3, pH: 8,0 
2.) 2 mg/mL cyclo(-RGDfK-) 
 in 0.15 M NaHCO3, pH: 8,0 
1.) 11h at 4°C 
2.) 3h at 18°C 
MP-NH-PEG2PLA40 surfaces 
RGD 2 mg/mL cyclo(-RGDfE-)-spacerAA-C-OH in PBS, pH: 7,4  11h at 4°C + 3h at 18°C 
RAD 2 mg/mL cyclo(-RADfE-)-spacerAA-C-OH in PBS, pH: 7,4 11h at 4°C + 3h at 18°C 
buffer PBS, pH: 7,4 11h at 4°C + 3h at 18°C 
 
2.6. Cell adhesion study 
In order to investigate cell adhesion on the modified polymer surfaces, 200 µL of a cell 
suspension containing human osteoblasts at a concentration of 44,250 cells/mL, as determined 
with a hemacytometer, was seeded onto each marked area (5000 cells/cm2, i.e., 8850 
cells/marked area). Cells were allowed to attach for 7 hours [23,33]. The low seeding density 
of 5000 cells/cm2 was chosen to avoid artifacts from cell aggregation. Non-attached cells 
were then removed by rinsing twice with PBS. The attached cells were fixed with 10 % 
formalin in PBS and cells were stained with an aqueous solution of safranin O (0.5%) (Sigma) 
before counting using light microscopy. A representative section of each seeded surface was 
counted and the cell count was extrapolated to the total surface area. All cell adhesion studies 
were performed under serum-free conditions. 
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With the objective to demonstrate that osteoblast adhesion to RGD-grafted surfaces was 
integrin-mediated, some cells were incubated with medium containing dissolved cyclo(-
RGDfK-) peptide (0.2 mg/mL) to block the corresponding cell surface receptor, the 
αvβ3/αvβ5 integrin, prior to seeding on RGD-modified films [12]. The pretreated cells were 
also seeded onto TCPS (tissue culture polystyrene) in order to ensure that these cells were still 
able to undergo non-integrin mediated cell attachment. 
2.7. Study on cell shape 
The shape of the attached cells was evaluated under a light microscope (Leica DM IRB, Leica 
Microsystems Wetzlar, Wetzlar, Germany) and documented photographically (Panasonic 
System Camera, Japan; DYNAX, 600si Classic, Minolta, Ahrensburg, Germany) after 
staining with safranin O (0,5%). 
To assess the shape of the attached cells by scanning electron microscopy (SEM), a further 
cell adhesion experiment was performed. For this study, 5,000 cells/cm2 (8850 cells/film) 
were seeded on RGD- and RAD-modified ST-NH-PEG2PLA20 and MP-NH-PEG2PLA40 
films. After 7 hours adhesion-time, the cells were rinsed with PBS and fixed with 
glutaraldehyde (2.5 % in PBS) for 15 min. Following repeated rinsing steps, cells were further 
fixed with an aqueous solution of OsO4 (1 %) (Roth, Karlsruhe, Germany) for 30 min under 
ice-cooling. Excess OsO4 was removed by washing with water. The object-slides were then 
frozen at -80°C and lyophilized (Christ Beta 2-16, Martin Christ Gefriertrocknungsanlagen; 
Osterode am Harz, Germany). For SEM, samples were mounted on aluminium stubs using 
conductive carbon tape and coated with gold - palladium (Polaron SC515, Fisons Surface 
Systems; Grinstead, UK). Photomicrographs were acquired at 10 kV on a DSM 950 (Carl 
Zeiss, Oberkochen, Germany). 
2.8. Statistical Analysis 
Cell numbers were determined (n = 4) and expressed as means ± standard deviation (SD). 
Single factor analysis of variance (ANOVA) was used in conjunction with a multiple 
comparison test (Tukey test) to assess the statistical significance. 
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3. Results and Discussion 
3.1. Modification of the amine-reactive ST-NH-PEG2PLA20 films 
Since we intended to covalently bind the RGD peptides from low-concentrated aqueous 
solutions, reaction conditions had to favor aminolysis of the polymer’s N-hydroxysuccinimide 
ester rather than hydrolysis. Therefore, the peptide sequences were dissolved in a sodium 
bicarbonate buffer at pH 8 to ensure the presence of a neutral ε-amino-group on the lysine 
side chain for coupling with the N-hydroxysuccinimide ester, while the nucleophilicity of the 
arginine side chain in the cyclic RGD peptide was nearly abolished due to protonation at pH 8 
[11,29]. Typical reaction protocols of peptides or proteins with N-hydroxysuccinimide esters 
propose reaction times up to a few hours and a, at least initially, low reaction temperature to 
favor the formation of an amide bond. Therefore, the films were refrigerated (4°C) during the 
incubation step. Concurrently, an extended coupling time of 11 h was chosen to allow for 
passive diffusion of the RGD peptide to the reaction sites on the films (Fig. 3). From the 
plethora of characterized adhesion peptides, we chose a potent cyclic RGD peptide 
[cyclo(-RGDfK-)] (Fig. 2a) with αvβ3/αvβ5 integrin subtype selectivity to detect even low 
peptide grafting densities in cell adhesion experiments. The high affinity of this peptide to the 
αv subunit is associated with the insertion of D-phenylalanin (=f) in the cycle [14,28]. To 
confirm that the surface modification was successful, the number and shape of the attaching 
human osteoblasts, which are known to express the corresponding αvβ5/αvβ3 integrin [5,15], 
were examined. 
3.2. Cell adhesion study on modified ST-HN-PEG2PLA20 films 
The adhesion studies showed that osteoblast adhesion (Fig. 4) and spreading (Fig. 5a and 6) 
on cyclo(-RGDfK-)-modified ST-NH-PEG2PLA20 surfaces was significantly increased 
compared to the control surfaces 7 hours after seeding. 70% (68.9% ± 8.8) of the seeded 
human osteoblasts had attached to RGD-modified ST-NH-PEG2PLA20 polymer films, while 
only 30% (31.8% ± 5.0) adhered to films modified with the non integrin-binding 
cyclo(-RADfK-). Approximately 10% of the seeded cells attached to the polymer films 
incubated with reaction buffer (10.7% ± 1.6) and the stop reagent ethanolamine 
(11.8% ± 1.3). These results demonstrated that an effective covalent surface modification has 
been achieved during the incubation step. More specifically, on polymer films incubated with 
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buffer, which led to hydrolysis of the amine-reactive N-hydroxysuccinimide group and the 
formation of negatively charged surfaces, the cell adhesion was indistinguishable from the 
cell adhesion on non-charged surfaces, as generated by aminolysis with ethanolamine. Even 
on surfaces modified with the non integrin-binding cyclo(-RADfK-) peptide, which presents 
the positively charged arginine side chain and the negatively charged aspartate side chain in a 
similar configuration as in the cyclo(-RGDfK-) peptide, comparatively few cells were found 
attached. Hence, under serum-free conditions, the surface charge had no considerable 
influence on cell adhesion. 
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Fig. 4: Percentage of cell attachment normalized to the initial cell seeding density on modified ST-
NH-PEG2PLA20 (9% PEG) surfaces 7 hours after cell seeding. Columns and error bars 
represent means ± SD for n = 4. Statistical significance is indicated by a  (p < 0.01). 
The specificity of the observed cell interaction with the RGD-modified surface was 
demonstrated in an integrin receptor blocking experiment. Therein, cells were incubated with 
dissolved cyclo(-RGDfK-) before they were seeded on RGD-grafted surfaces. Integrin 
blocking caused almost a complete loss of cell attachment to the RGD-modified surfaces 
(5.6% ± 3.5) (Fig. 4), demonstrating that the cell-biomaterial interactions are indeed integrin-
specific. In order to test for the impact of any non-covalently attached, adsorbed 
cyclo(-RGDfK-) on cell adhesion and spreading on the polymer films, we treated 
ST-NH-PEG2PLA20 surfaces with buffer to hydrolyze the N-hydroxysuccinimide ester. 
Thereafter, these polymer films were incubated with the RGD peptide. In the cell adhesion 
test we found about 15% of the seeded cells attached to the film (13.9% ± 7.5), indicating a 
very low interaction with this control surface (Fig. 4).  
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a, ST-NH-PEG2PLA20 / RGD ST-NH-PEG2PLA20 / RAD ST-NH-PEG2PLA20 / RGD / 
blocking 
   
b, MP-NH-PEG2PLA40 / RGD MP-NH-PEG2PLA40 / RAD MP-NH-PEG2PLA40 / buffer 
Fig. 5: Representative images depicting shape of human osteoblasts attached to peptide-modified 
polymer surfaces. a) Modified ST-NH-PEG2PLA20 surfaces. b) Modified MP-NH-PEG2PLA40 
surfaces. Cells were stained with safranin O (0.5%) and appear in black. Scale bars 
represent 50 µm. 
In good accordance with the determined cell numbers in the cell adhesion study, we observed 
well-spread osteoblasts on the RGD-modified polymer surfaces, indicating a strong cell-
biomaterial interaction (Fig. 5a and 6). Osteoblasts seeded on surfaces incubated with 
cyclo(-RADfK-) (Fig. 5a and 6), with the reaction buffer, with ethanolamine or with 
cyclo(-RGDfK-) after hydrolysis of the reactive N-hydroxysuccinimide ester (data not 
shown), however, remained rounded, indicating low cell-biomaterial interactions. Integrin 
blocking also resulted in round cells on cyclo(-RGDfK-) modified surfaces (Fig. 5), whereas 
50 µm 50 µm 50 µm 
50 µm 50 µm 50 µm 
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the blocked cells spread well when seeded on TCPS, which was used to control for any toxic 
effects of the dissolved peptide.  
  
 
ST-NH-PEG2PLA20 / RGD ST-NH-PEG2PLA20 / RAD MP-NH-PEG2PLA40 / RGD 
Fig. 6: Cell shape of human osteoblasts on RGD- and RAD-modified ST-NH-PEG2PLA20 polymer 
films and on RGD-modified modified MP-NH-PEG2PLA40 surfaces depicted by SEM. Scale 
bars represent 20 µm. 
To summarize, the number of cells attached to ST-NH-PEG2PLA20 surfaces grafted with 
cyclo(-RGDfK-) was significantly increased compared to all control groups (p < 0.01). 
Although we currently have no instrumental means to identify this covalent attachment of the 
peptide, the adhesion study discussed above proves that a covalent surface modification was 
achieved and that human osteoblast adhesion is mediated by specific interactions between 
cells and the attached RGD peptides. 
3.3. Modification of the thiol-reactive MP-HN-PEG2PLA40 films 
To broaden the applicability of PEG-PLA based-reactive diblock copolymers to the 
attachment of other proteins and peptides via simple surface chemistry, a group of thiol-
reactive copolymers (MP-NH-PEG-PLA) was recently developed [26]. Targeting the thiol 
groups of proteins allows for a more selective surface modification, as free thiol groups are 
less frequent compared to free amine groups. Additionally, the thiol-reactive maleic acid 
imides are stable in aqueous media and not prone to hydrolysis like amine-reactive 
N-hydroxysuccinimide esters. MP-NH-PEG2PLA40 and a cyclic RGD peptide carrying a free 
cysteine thiol group (Fig. 2b) were employed to test our surface modification strategy for a 
thiol-reactive diblock copolymer. We tested a copolymer composition (PEG2PLA40, 42kDa) 
with only 5% PEG that provides a lower surface density of reactive functionalities. However, 
this composition with a PLA block of 40 kDa offers a higher molecular weight, a glass 
transition temperature clearly above body temperature and therefore improved processing 
properties compared to the 22 kDa PEG2PLA20 copolymer [24,27]. 
20 µm 20 µm 20 µm 
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3.4. Cell adhesion study on MP-HN-PEG2PLA40 films 
As a result of the lower PEG content (5% PEG), a higher percentage of the seeded osteoblasts 
adhered to the buffer treated MP-NH-PEG2PLA40 films (Fig. 7), 55.0% ± 7.3 compared to 
10.7% ± 1.6 cells on ST-NH-PEG2PLA20 films (9% PEG). This is in agreement with a 
previous study on rat marrow stromal cell adhesion to different MeO-PEG-PLAs [23,34]. 
However, after solid-state surface modification with RGD peptides, all (114% ± 21.1; values 
exceeding 100% originate from the extrapolation of the counted areas to the total surface) 
seeded osteoblast adhered on the polymer film (Fig. 7). Moreover, they spread well on these 
surfaces (Fig. 5b and 6), indicating strong interactions between the cells and the tethered RGD 
peptides. Thus, both cell count and spreading demonstrate the efficacy of the chemical 
ligation. In contrast, no increase in cell count was found on RAD-modified films compared to 
the buffer treated surface (Fig. 7). Furthermore, cells on the control surfaces retained their 
round shape (Fig. 5). This means that despite the fact that unspecific cell adhesion was 
increased on the MP-NH-PEG2PLA40 compared to the ST-NH-PEG2PLA20 films, interactions 
between the control surfaces and the cells remained limited. Therefore, the widely spread cells 
on the RGD-modified MP-NH-PEG2PLA40 films indicate that a sufficient number of adhesion 
peptides are present even on this 42 kDa copolymer surface with only 5% PEG. 
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Fig. 7: Percentage of cell attachment normalized to the initial cell seeding density on modified MP-
NH-PEG2PLA40 films (PEG content: 5%) 7 hours after cell seeding. Columns and error bars 
represent means ± SD for n = 3. Statistical significance is indicated by a  (p < 0.01). 
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4. Conclusions 
In conclusion, we showed the instant surface modification of preformed polymer films with 
high affinity adhesion peptides via two different linkers. The modification of low adhesive 
polymer films was performed by the simple incubation of amine- and thiol-reactive diblock 
copolymers, consisting of a reactive PEG and a PLA block. Although unspecific cell adhesion 
was shown to depend on the PEG content of the diblock copolymers, even MP-NH-
PEG2PLA40 (5% PEG) displayed a sufficient density of reactive groups to provide for specific 
interactions with the αvβ5/αvβ3 integrin on human osteoblasts. As these reactive copolymers 
offer several modification options as well as variable mechanical properties and rates of 
biodegradation, these materials appear to be well suited to various customized applications in 
the field of tissue engineering and implant technology. 
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Abstract 
The development of biomimetic materials and their processing into three-dimensional cell 
carrying scaffolds is one promising tissue engineering strategy to improve cell adhesion, 
growth and differentiation on polymeric constructs developing mature and viable tissue. This 
study was concerned with the fabrication of scaffolds made from amine-reactive diblock 
copolymers, N-succinimidyl tartrate monoamine poly(ethylene glycol)-block-poly(D,L-lactic 
acid), which are able to suppress unspecific protein adsorption and to covalently bind proteins 
or peptides. An appropriate technique for their processing had to be both anhydrous, to avoid 
hydrolysis of the active ester, and suitable for the generation of interconnected porous 
structures. Attempts to fabricate scaffolds utilizing hard paraffin microparticles as hexane-
extractable porogens failed. Consequently, a technique was developed involving lipid 
microparticles, which served as biocompatible porogens on which the scaffold forming 
polymer was precipitated in the porogen extraction media (n-hexane). Porogen melting during 
the extraction and polymer precipitation step led to an interconnected network of pores. 
Suitable lipid mixtures and their melting points, extraction conditions (temperature and time) 
and a low-toxic polymer solvent system were determined for their use in processing diblock 
copolymers of different molecular weights (22 and 42 kDa) into highly porous off-the-shelf 
cell carriers ready for easy surface modification towards biomimetic scaffolds. Insulin was 
employed to demonstrate the principal of instant protein coupling to a prefabricated scaffold. 
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1. Introduction 
One major aim in tissue engineering is the development of transplantable tissue by seeding, 
proliferation and differentiation of isolated cells on biodegradable polymeric carriers [1]. 
Modifying the surface of such carriers in order to control the response of attached cells has 
proven to be a valuable tool for improving the development of mature and viable tissue [2,3]. 
For this purpose, adhesion proteins, their peptide motives [4-7] and growth factors [8-10] 
have been covalently bound to biomaterial surfaces. However, only few studies, primarily on 
hydrogels [11,12], transferred this concept beyond two-dimensions to three-dimensional 
applications, such as cell carrying scaffolds.  
Control of surface composition and cell behavior through bound bioactive substances requires 
consideration of dynamic surface changes caused by the adsorption of serum proteins when 
the modified materials come into contact with body fluids. To this end, we have utilized 
diblock copolymers, consisting of a biodegradable lipophilic polymer block and a hydrophilic 
block to limit or suppress the non-specific adsorption process and concomitant 
disadvantageous side effects [13-15]. A biocompatible organic link, e.g. tartaric acid 
N-hydroxysuccinimide ester, which is capable of covalently binding biologically active 
molecules bearing free amine groups, was attached to the hydrophilic block in order to create 
a new class of non-adsorbing, amine-reactive polymers [16]. N-hydroxysuccinimide esters are 
among the most frequently used agents for protein crosslinking, labeling [17] and conjugation 
with PEG [18,19] under formation of stable amide linkages. Furthermore, they can be stored 
under moisture exclusive conditions for extended periods of time. Therefore, these amine-
reactive diblock copolymers, carrying N-hydroxysuccinimide esters, are designed to be 
processed in their active state making amine-reactive off-the-shelf scaffolds available [16]. 
Finally, the surface of such pre-fabricated scaffolds can be modified just before use, by 
covalently binding proteins or peptides in an instantaneous manner, i.e. by simply incubating 
the polymeric construct with an aqueous solution containing the selected biomolecules. Such 
amine-reactive diblock copolymers, N-succinimidyl tartrate monoamine poly(ethylene 
glycol)-block-poly(D,L-lactic acid), with different block ratios, were recently synthesized in 
our group [16].  
The study presented here aimed at the development of a technique for processing these 
polymers into scaffolds, which play a prominent role in tissue engineering since they provide 
a three-dimensional framework for cells to attach, proliferate and lay down extracellular 
matrix. This concept demands a highly porous and interconnected scaffold structure to ensure 
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sufficient space for tissue development and unimpaired diffusion of nutrients, oxygen and 
waste [20,21]. Processing amine-reactive polymers into scaffolds required consideration of 
two essential points: firstly, in order to preserve the active group from hydrolysis, aqueous 
media had to be avoided, and secondly, a sufficient surface density of reactive PEG-chains 
demands a low molecular weight PLA-block (20 to 40 kDa) [15]. Thus, we required an 
anhydrous, lab-scale scaffold fabrication technique, which would be suitable for processing 
low molecular weight polymers into highly porous scaffolds and would provide an 
interconnected pore structure.  
Numerous methods for polymer processing into three-dimensional scaffolds have been 
described, according to the literature, such as polymer casting-salt leaching with or without 
subsequent compression molding [22-24], phase separation and gas foaming [25,26]. None of 
these methods, however, met all the demands listed above. Recently, two anhydrous 
processing techniques based on particulate leaching were published. Both involved hard 
paraffin microparticles prepared as pore forming devices [27,28]. One method started from a 
dispersion of such paraffin microparticles in a polymer solution and finally led to scaffolds 
with an interconnected pore structure by concomitant porogen extraction and polymer 
precipitation in warm n-hexane [29]. This hydrocarbon templating technique has been applied 
to a range of amorphous and semicrystalline high molecular weight polymers (> 70 kDa) with 
glass transition temperatures (Tg) exceeding 50 °C. This is well beyond the Tg of the polymers 
investigated in this study (31 – 43 °C). Moreover, this technique had been assumed to work 
only with polymers of more than 40 kDa [29]. Therefore, this study aimed at achieving the 
following three goals: 
1. Employing the hydrocarbon templating technique to identify process parameters critical 
for the processing of low molecular weight polymers. 
2. Developing an anhydrous polymer processing technique which is suitable for low 
molecular weight polymers and avoids non-physiological porogen materials. 
3. Finally, proving the principle of the instant protein coupling to a preformed scaffold with 
insulin as model substance.  
Chapter 3 Towards biomimetic scaffolds 
- 63 - 
2. Materials and Methods 
2.1. Materials  
Both the biodegradable poly(D,L-lactic acid)-poly-(ethylene glycol)-monomethyl ether 
diblock copolymers (MeO-PEGxPLAy) as well as their amine-reactive derivatives ST-NH- 
PEGxPLAy (monoamine poly(ethylene glycol)-block-poly(D,L-lactic acid) activated with 
disuccinimidyl tartrate) were synthesized as previously described [14,16] (Fig. 1). x and y in 
PEGxPLAy represent the molecular weight of the PEG and the PLA block, respectively, in 
kDa. Table 1 gives a survey on molecular weight and polydispersity index (PI) of the 
investigated copolymers. 
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Fig. 1. Structures of the processed polymers. (a) poly(lactic acid)-block-poly(ethylene glycol)-
monomethyl ether (MeO-PEGxPLAy); (b) poly(ethylene glycol)-block-poly(lactic acid)-
monoamine activated with disuccinimidyl tartrate (ST-NH-PEGxPLAy). m and n represent 
the number of ethylene glycol and lactic acid units in the polymer. x and y represent the 
molecular weight (kDa) of the poly(ethylene glycol) and poly(lactic acid) chain. 
Hard paraffin types with a melting temperature of 42 – 44 °C (P 42) and 46 – 48 °C (P 46) 
according to product specification were purchased from Merck (Darmstadt, Germany). Hard 
paraffin with a declared melting temperature of between 50 and 52 °C (P 50) was purchased 
from Fluka Chemicals (Buchs, Switzerland). All lipids (Dynasan® 114, Dynasan® 116, 
Softisan® 154 and Witepsol® H42) were kindly provided by SASOL Germany GmbH 
(Witten, Germany). Relevant properties of the bulk materials used for porogen microparticle 
preparation are summarized in Table 2. 
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Table 1: Physical properties of the processed polymers. Glass transition temperature as obtained 
with MDSC (2nd heating). Weight average molecular weight (Mw), number average 
molecular weight (Mn) and polydispersity indices (PI = Mw/Mn) of the polymers as 
determined from GPC. 
Polymers MDSC Molecular weight                
  Declared GPC analysis             1H-NMR 
 Tg [°C]  Mn Mw PI Mn 
MeO-PEG2PLA20 33.7 22 kDa 23,000 47,600 2.1 22,900 
ST-NH-PEG2PLA20 31.1 22 kDa 22,800 39,200 1.7 --- 
MeO-PEG2PLA40 42.3 42 kDa 42,000 64,500 1.5 42,900 
ST-NH-PEG2PLA40 38.1 42 kDa 43,200 65,200 1.5 --- 
Table 2: Physical properties and composition of materials used for porogen microparticle 
preparation.  
Hard paraffin type Density [g⋅cm-3] 
Tm [°C] of bulk material 
(specification)        (DSC) 
Tm [°C] of side fractions 
(DSC) 
P 42 42 – 44 38.4 13.2 26.8 
P 46 46 – 48 38.9 13.6 27.7 
P 50 
approx. 
0.90 
50 – 52 47.2 27.4 34.4 
Lipid   composition 
Witepsol® H 42 0.97 41 – 43 35.8 1.6 % di-  /   98.2 % tri-glycerides  
Softisan® 154 0.95 53 – 58 54.2 3.5 % di-  /  96.4 % tri-gylcerides 
Dynasan® 114 55 – 58 54.6 glyceryltrimyristat 
Dynasan® 116 
0.96 
61 – 65 59.2 glyceryltripalmitat 
  
Acetone, chloroform, ethyl methyl ketone (EMK), tetrahydrofurane (THF), which were used 
as polymer solvents, and n-hexane, utilized as a porogen extraction medium were purchased 
in analytical grade from Merck (Darmstadt, Germany). Solvents were dried over 4 Å 
molecular sieves (Carl Roth GmbH, Karlsruhe, Germany) prior to the processing of amine-
reactive polymers.  
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2.2. GPC and 1H-NMR analysis  
The molecular weights of the diblock MeO-PEG-PLA copolymers were measured according 
to Lucke et al. [14]. The results indicated that both polymers were synthesized in the declared 
composition and molecular weight. With regard to the amine-reactive ST-NH-PEG-PLA 
copolymers, the composition and molecular weight of the H2N-PEG-PLA precursor were 
confirmed with 1H-NMR analysis during synthesis [16]. The declared number average 
molecular weights (Mn) of all diblock copolymers correlated well with the values for Mn 
obtained by GPC analysis. Furthermore, the polydispersity indices of the polymers indicated 
their appropriate molecular weight distribution. 
2.3. DSC and MDSC analysis 
The glass transition temperatures (Tg) of the polymers were measured utilizing modulated 
differential scanning calorimetry (MDSC). This method, which is characteristic for a heating 
rate associated with a sinusoidal temperature oscillation, was applied to detect the faint glass 
transition step with high resolution and to separate this thermal event from overlapping 
relaxation or melting phenomena typical for these diblock copolymers [14]. Generally, Tg of 
the diblock copolymers decreased with molecular weight. Tg of the reactive ST-NH- 
PEGxPLAy was slightly lower compared with the analog MeO- PEGxPLAy derivative in both 
cases. 
Differential scanning calorimetry (DSC) was used to determine the melting points of different 
hard paraffin types and lipid bulk materials as well as the fabricated porogen microparticles. 
Paraffin residuals inside fabricated scaffolds were detected and quantified with DSC analysis, 
too. The detection of triglyceride residuals inside the scaffolds, however, was realized through 
MDSC.  
For calorimetric analysis, all samples were precisely weighed in non-hermetic AutoDSC 
aluminum sample pans (TA Instruments, Alzenau, Germany). The sample pans were sealed 
using the sample encapsulating press (TA Instruments, Alzenau, Germany) and analyzed on a 
DSC 2920 equipped with a refrigerated cooling system and an autosampler (TA Instruments, 
Alzenau, Germany). An empty, sealed pan served as reference. 
All measurements were carried out between –20 °C and 120 °C. Typically, samples were 
equilibrated at –20 °C for 15 min and heated to 120 °C at a heating rate of 2 °C/min (analysis 
of porogen materials (DSC) and determination of polymer’s Tg (MDSC)) or 5 °C/min 
(determination of residual paraffin (DSC) and triglyceride (MDSC) content). After an 
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isothermal phase of 15 min, samples were cooled down to –20 °C at the same heating rate. 
Finally, after another isothermal phase of 15 min, samples were again heated to 120 °C at the 
described heating rate. In case of MDSC measurements, a sinusoidal temperature modulation 
with a period of 60 s and a temperature amplitude of 1 °C (determination of polymer’s Tg) or 
0.8 °C (determination of residual lipids), was applied to both heating cycles. 
The obtained thermograms were analyzed for melting temperature (onset point detection) and 
melting enthalpy (peak area) as well as glass transition temperature (obtained as half height of 
the transition step) with the Universal Analysis for NT® software provided with the DSC 
system. 
2.4. Preparation of porogen microparticles 
Microparticles were prepared using a melt dispersion technique. The hard paraffin types were 
processed by heating a mixture of 10 g hard paraffin with 12.5 ml of a 1.5% (m/v) aqueous 
solution of poly(vinyl alcohol) (PVA, 98% hydrolyzed, Aldrich Chemical Company, 
Milwaukee, USA) up to 65 °C. The mixture was emulsified by vortex mixing and 
subsequently casted into a larger volume (500 ml) of an ice-cooled (5 °C) 0.1% (m/v) aqueous 
PVA solution stirred with a propeller stirrer. After 10 min the hardened particles were 
collected by filtration, intensively rinsed with water and vacuum dried at room temperature 
for 24 hours. Particles or aggregates larger than 710 µm were removed by sieving. 
Lipid microparticles were fabricated as described above but without any polymeric surfactant. 
The size distribution of the prepared lipid microparticles was investigated using laser 
diffraction (Mastersizer 2000 Hydro 2000S, Malvern Instruments, Herrenberg, Germany) as 
follows: 100 mg lipid microparticles were suspended in 100 µl 3% (m/v) aqueous HPMC 
(Metolose 90 SH 100, Shin-Etsu Co. Ltd., Tokyo, Japan) solution using a vortex mixer.  This 
suspension was diluted in the dispersion unit (water as dispersant) in accordance with the 
obscurity indicator on the instrument and stirred at 3000 µm under sonification (30% 
intensity) during the measurement. The volume based particle size distribution was calculated 
choosing the Fraunhofer approximation (Malvern Software V5.1).   
2.5. Solubility of porogen microparticles 
In order to quantify the solubility of the porogen microparticles in the polymer solvent under 
processing conditions, 100 mg particles were precisely weighed in glass vials. The vials were 
placed in a shaking water bath (frequency: 150 min-1) at a temperature of 0 °C. 5 ml of cold 
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solvent mixture were added. After exactly 10 min of shaking the dispersion was filtered 
through a 0.2 µm solvent resistant regenerated nitrocellulose membrane filter (Spartan 30/A 
from Schleicher & Schuell, Dassel, Germany). The filtrate was collected in glass vials of 
known weight. Following solvent evaporation under a fume hood the vials were dried at 
60 °C to constant weight. The amount of dissolved porogen material was measured as the 
weight increase of the vials.  
This screening method was specifically adapted to the polymer processing conditions, 
concerning temperature and contact time (preparation of porogen particle dispersion and 
transfer into molds). To improve the resolution of this test, a low material to solvent ratio 
(100 mg per 5 ml) was chosen. 
2.6. Scaffold fabrication 
Describing the general procedure (Fig. 2), polymer was weighed in a glass vial and dissolved 
in the appropriate amount of solvent. Porogen microparticles were weighed into a separate 
vial. The amounts of polymer, porogen microparticles and solvent used per batch varied with 
respect to the polymer to porogen ratio and the concentration of the polymer solution, as 
described in the results section. After 1 h storage at – 20 °C the porogen particles were 
transferred into the polymer solution and mixed for 5 min on ice. The resulting highly viscous 
dispersion was then transferred into a 5 ml polypropylene syringe and injected into cubic 
Teflon® molds (1 cm x 1 cm x 1cm with a cylindrical cavity of 0.8 cm in diameter. After a 
pre-extraction treatment step in n-hexane at 0 °C (Fig. 2 (∗)), which was only applied when 
lipid microparticles served as porogens, the filled molds were submerged in warm n-hexane to 
precipitate the polymer and extract the porogen particles concurrently. This procedure was 
carried out in two separate n-hexane baths of different temperatures T1 and T2 for t1 and t2 
with t1 + t2 = 30 min. Subsequently, the molds were transferred into an n-hexane bath of 0 °C 
for 5 min to solidify the generated structures. Finally, the porous cylindrical polymer 
constructs were removed from the molds and vacuum dried for 48 h. For further 
investigations the constructs were cut into 2 mm slices which were then addressed as 
scaffolds.  
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Fig. 2: Schematic illustration of the polymer processing procedure. (∗) Pre-extraction treatment of 
molds in n-hexane at 0°C applied when lipids were used as porogen material. 
2.7. Scaffold characterization 
The overall structure of the fabricated porous constructs was visualized using a zoom stereo 
microscope (Wild M7A, Wild Heerbrugg Ltd., Heerbrugg, Switzerland). For examination of 
scaffold microstructure using scanning electron microscopy (SEM), samples were mounted on 
aluminum stubs with conductive carbon tape and coated with gold (Fig. 4) or gold –
 palladium (Fig. 9). All micrographs were obtained at 10 kV on a JEOL JSM-840 (Jeol Ltd., 
Tokyo, Japan) (Fig. 4) or a DSM 950 (Zeiss, Oberkochen, Germany) (Fig. 9). 
Pore size distribution was determined by mercury intrusion porosimetry (AutoPore IV 9500, 
Micromeritics, Mönchengladbach, Germany). Scaffolds weighing approximately 25 mg were 
sealed in a penetrometer (3 bulb, 0.412 stem, powder; Micromeritics, Mönchengladbach, 
Germany) and subjected to analysis. The measurements were performed between 0.0007 and 
100 MPa to determine pore-size distributions and porosities. A 30 s equilibration time was set 
for each intermediate data point. For data interpretation, a contact angle of 140° and a surface 
tension of 0.48 Nm-1 were assumed. These measurements were kindly provided by 
Micromeritics.  
Chapter 3 Towards biomimetic scaffolds 
- 69 - 
2.8. Attachment of human insulin to scaffold surfaces 
To evaluate the amine reactivity of the scaffold surface, human insulin served as model 
protein. In order to provide optimal conditions for the reaction of insulin’s free amine groups 
and the activated esters of the polymer, the protein was dissolved (6 mg/ml) in a 0.1M 
NaHCO3 buffer at pH = 8.0 with an urea content of 75 mg/ml. Scaffolds were incubated with 
2 ml of this insulin solution for 2.5 hours at room temperature on a shaker in a micro test tube 
(Eppendorf, Hamburg, Germany). After rinsing with pure buffer and water, the scaffolds were 
freeze dried and prepared for GPC analysis: 50 mg of scaffold were dissolved in 400 µl 
DMSO. DMSO is a solvent not only for the polymers and the insulin-polymer conjugates, but 
also for any free insulin that remained adsorbed to the scaffold even after rinsing. 1600 µl of 
chloroform were then added to precipitate free insulin, thus separating adsorbed and 
covalently linked insulin. After filtration, 50 µl of the solution were analyzed using GPC 
analysis equipped with a RF-551 fluorescence detector (Shimadzu, Duisburg, Germany). The 
resulting chromatograms were obtained at λex = 274 nm and λem = 308 nm for the detection of 
insulin’s amino acid tyrosine. 
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3. Results and Discussion 
This study was concerned with processing low molecular weight amine-reactive ST-NH-
PEG-PLA and the corresponding non-reactive MeO-PEG-PLA diblock copolymers (42 and 
22 kDa (Table 1)) into highly porous and interconnected cell carriers. MeO-PEGxPLAy 
diblock copolymers were used to identify the decisive parameters for the processing of PEG-
PLA diblock copolymers, which were then correlated to polymer’s molecular weight and 
glass transition temperature (Tg) and finally adapted to the special properties of the amine-
reactive derivatives. 
 A recently published hydrocarbon templating method [27,29] met our demands for 
anhydrous processing, for an interconnected pore structure, and for pore size control. This 
method involved preparation of a dispersion of paraffin microparticles in a polymer solution. 
This dispersion was transferred into a Teflon® mold and placed into warm n-hexane, a solvent 
for the porogen to achieve particulate leaching while being a poor solvent for the polymer. 
Thus, on contact with this solvent, the polymer precipitated on the extracted porogen particles 
leading to an interconnected scaffold architecture [27]. However, up to now only 
biodegradable polymers with a molecular weight of above 70 kDa had been processed and a 
limit of 40 kDa had been assumed by the authors. In order to develop a new processing 
method for low molecular weight diblock copolymers based on the hydrocarbon templating 
technique, it was necessary to investigate the limitations of this technique.  
Three problems soon became obvious in preliminary investigations; firstly, the published 
extraction temperature of 45 - 50 °C over 20 min [29] or even 50 °C over 40 min [30] were 
incompatible with the low glass transition temperature (Tg) of the diblock copolymer 
investigated in this study and led a  collapse of the constructs during processing. A survey of 
these polymers including their determined Tg and molecular weights, is given in Table 1. 
Secondly, lowering the extraction temperature made the commonly used high melting paraffin 
(Tm = 53 – 57 °C) [28] unsuitable as a porogen material due to insufficient extraction. 
Thirdly, lower melting hard paraffin was soluble in the published polymer solvent 
chloroform. Consequently, we varied each of the three parameters: the porogen material, the 
polymer solvent and the extraction conditions. 
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3.1. Scaffold fabrication using paraffin microparticles as porogens 
3.1.1. Porogen material: Characterization of paraffin microparticles 
Microparticles were prepared from three low melting hard paraffin types with declared 
melting points of 42 – 44 °C (P 42), 46 – 48 °C (P 46) and 50 – 52 °C (P 50), respectively. 
Although these paraffin types apparently offered a considerable range of melting points, the 
fabricated particles formed cohesive powders not allowing for the preparation of a 
homogeneous dispersion of these particles in a polymer solution, especially in case of the hard 
paraffin types P 42 and P 46. DSC analysis of bulk and processed hard paraffin clarified this 
behavior: instead of one endothermic melting peak, the thermograms revealed three peaks 
representing different hydrocarbon fractions (Table 2). Moreover, the predominant side 
fraction in each of the three investigated hard paraffin types melted at least 20 °C below the 
main hydrocarbon fraction. These low melting fractions were probably responsible for 
microparticle agglomeration. In consequence, only P 50 particles were suitable as porogen 
material for further experiments.  
3.1.2. Polymer solvent 
Methylene chloride or chloroform have been described as suitable polymer solvents [29]. 
Preliminary tests revealed that all three described hard paraffin types were soluble in these 
solvents to a considerable extent. Acetone, a non-solvent for the hard paraffin, would have 
been a suitable polymer solvent, but was excluded in early experiments due to its low boiling 
point, which disturbed the scaffold formation by forming gas bubbles during porogen 
extraction. To overcome these problems, we chose an azeotropic mixture of 65% (v/v) 
acetone and 35% (v/v) chloroform with a boiling point of 65°C as polymer solvent [31]. Since 
the azeotrope’s boiling point was well above the ones of both single components, the addition 
of acetone did not limit the applicable extraction conditions.  
Solubility tests of the porogen microparticles made of the three investigated hard paraffin 
types revealed that microparticle solubility increased with decreasing melting temperature 
(Fig. 3). The solubility of P 50 and P 46 microparticles was below 10 mg in 5 ml of the 
acetone - chloroform mixture. Less than 15 mg of P 42 were dissolved in 5 ml solvent 
mixture. Thus, the solubility of all three paraffin types was considered as being sufficiently 
low, however, due to the thermal characteristics described above, only P 50 was suitable as 
porogen material.  
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Fig. 3: Relative amount of dissolved porogen material in 5 ml of two different polymer solvent 
mixtures after 10 min (left axis). (n.d.): Value of porogen particle solubility in the EMK - 
THF mixture not determined. Columns and error bars represent means ± SD for n = 3. 
Melting points of the porogen microparticles as obtained with DSC analysis (right axis). 
Table 3: Determined processing conditions for the investigated polymers with different porogen 
materials.  
Polymer Porogen 
material 
Polymer /  
porogen 
Conc. 
(polymer 
solution) 
Extraction conditions  
   (w/w)  (w/v) step 1        (T1 ; t1) 
step 2 
(T2 ; t2) 
 
Hard paraffin    
MeO-PEG2PLA20 P 50 17.6 % 33  % 40°C ; 10 min 30°C ; 20 min 
MeO-PEG2PLA40 P 50 17.6 % 30 % 52°C ; 2 min 35°C ; 28 min 
 
Witepsol : Softisan 
  
2 : 1 40°C ; 5 min 30°C ; 25 min 
MeO-PEG2PLA20 
1 : 1 
33 % 55.5 % 
45°C ; 5 min 33°C ; 25 min 
MeO-PEG2PLA40 1 : 1 25 % 42 % 45°C ; 10 min 35°C ; 20 min 
ST-NH-PEG2PLA20 1 : 1 33 % 55.5 % 40°C ; 5 min 33°C ; 25 min 
ST-NH-PEG2PLA40 1 : 1 33 % 55.5 % 40°C ; 10 min 35°C ; 20 min 
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3.1.3. Extraction conditions: Influence of processing parameters on the scaffold 
microstructure  
Both MeO-PEG-PLA copolymers were processed with P 50 porogen microparticles (Table 3). 
Through choosing a fixed polymer to porogen ratio of 17.6 %, the amount of polymer solvent 
was the variable parameter, which was minimized to obtain a highly viscous, and therefore 
stable, dispersion of porogen particles in the polymer solution. Concentrations of the 
processed polymer solutions were 30 % (m/v) for MeO-PEG2PLA40 and 33 % (m/v) for MeO-
PEG2PLA20 in the acetone – chloroform mixture. 
By applying P 50 microparticles with a melting point clearly above the Tg of the copolymers, 
we investigated the influence of extraction conditions on pore structure. In order to avoid 
deformation of the polymer constructs, we set up a two-step extraction method applied for 30 
min, involving two extraction temperatures: a high one, T1, near or exceeding the polymer’s 
Tg for a certain time t1 and a lower one, T2, clearly below Tg for a longer period t2 = 30 min – 
t1. Three extraction schemes, one with T1 = 47 °C close to Tm of the porogen microparticles 
determined by DSC analysis, one with T1 = 52 °C at the upper limit of the declared melting 
range and the third with T1 = 42 °C at the Tg (42.3 °C) of the polymer were applied for the 
processing of MeO-PEG2PLA40. Figure 4a shows the SEM pictures of scaffolds processed 
according to that scheme. These investigations revealed that an extraction temperature 
approaching the polymer’s Tg led to stable constructs, but that they lacked the necessary 
interconnected microstructure (Fig. 4 a/1). A T1 of 47 °C (t1 = 5 min) or 52 °C (t1 = 2 or 
5 min) followed by further extraction at T2 = 35 °C for t2 = 30 min – t1, however, generated an 
interconnected pore structure (Fig. 4 a/2-4), indicating that an initial extraction temperature 
near the porogen’s Tm is required for pore interconnectivity. Furthermore, the melting 
temperature determined by DSC proved to be representative as a benchmark for the 
determination of T1. 
An increase of T1 to 52°C with t1 = 2 min led to a very regular pore size formation 
(Fig. 4 a/3). These extraction conditions were therefore recommended in table 3 for the 
processing of MeO-PEG2PLA40. Nevertheless, exposure time to an extraction medium with a 
temperature well beyond the Tg had to be chosen with care. Extraction for t1 = 5 min resulted 
in increasing pore sizes and a coarsening of the polymer structures (Fig. 4 a/4). A further 
increase in t1 to up to more than 6 min caused scaffold deformation during processing. 
However, in the case of MeO-PEG2PLA40 the developed two step extraction technique 
allowed for the fabrication of scaffolds with the desired pore structure, despite the high 
melting point of the P 50 microparticles. In case of MeO-PEG2PLA20, T1 was limited to 
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40 °C. Higher extraction temperatures resulted in the collapse of the polymer constructs. As 
expected from the investigation of MeO-PEG2PLA40, these conditions resulted in a 
honeycomb-like architecture of low interconnectivity, reflecting the size and shape of the 
porogen microparticles (Fig. 4 b). To sum up these results, extraction temperatures close to 
the melting point of the porogen during the first extraction step were a prerequisite for an 
interconnected pore structure. The process responsible for the formation of an interconnected 
structure appeared to be the melting of the porogen particles, which led to coalescing oil 
droplets on which the polymer precipitated. 
(a) MeO-PEG2PLA40: different extraction conditions 
  
(1) T1 = 42 °C ; t1 = 10 min (2) T1 = 47 °C ; t1 = 5 min 
  
(3) T1 = 52 °C ; t1 = 2 min (4) T1 = 52 °C ; t1 = 5 min 
(b) MeO-PEG2PLA20 (c) MeO-PEG2PLA40 
  
T1 = 40 °C ; t1 = 10 min additional purification 
Fig. 4: SEM pictures (original magnification x100) of polymeric scaffolds prepared with P 50 
microparticles as porogen: (a) The influence of extraction temperature (1-3) and extraction 
time (3+4) is shown for MeO-PEG2PLA40 scaffolds; (b) MeO-PEG2PLA20 scaffold; 
(c) MeO-PEG2PLA40 scaffold after 2h extraction in n-hexane (52°C).  
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3.1.4. Determination of residual paraffin 
Complete paraffin extraction is crucial since this non-physiological material is non- 
biodegradable and is known to cause mineral oil granuloma (paraffinoma) [32,33] after 
parenteral application. To find out how complete the paraffin extraction had been, DSC 
analysis was employed to detect melting peaks of potential paraffin remnants inside fabricated 
scaffolds. To distinguish between paraffin melting and polymer relaxation, which both 
appeared as endothermic signals at about the same temperature during the first heating cycle, 
we analyzed the second heating cycle of every DSC run. In that cycle, relaxation phenomena 
were minimized due to controlled cooling after the first set of heating cycles. Since we aimed 
for quantification of porogen residuals, different mixtures of MeO-PEG2PLA40 and P 50 
particles were prepared and analyzed in order to correlate the paraffin content with its melting 
enthalpy (the area under the melting peak). A linear correlation was found for the investigated 
area of 0.2 – 13.5 % paraffin (Fig. 5). 
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Fig. 5: DSC analysis of pure polymer and different MeO-PEG2PLA40 – P 50 microparticle mixtures 
(P 50 content: 0.2 – 4 %) used for calibration. Inserted figure shows the correlation between 
paraffin content of the mixtures and area under the melting peak. 
In a typical thermogram of fabricated MeO-PEG2PLA40 scaffolds, the endothermic melting 
peaks (main + side fraction) of paraffin were detected surrounding the glass transition step of 
the diblock copolymer, indicating the presence of paraffin remnants (Fig. 6). As expected, 
these melting peaks were shifted towards lower temperatures relative to the pure particles. 
When no further purification steps were applied, paraffin remnants ranging from 2.5 % to 8 % 
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were found in the scaffolds. Even the application of thorough washing procedures such as 2h 
extraction in n-hexane at 52 °C, did not reduce the residual paraffin to below 1.8 – 2 %. These 
washing techniques, however, did cause strong alterations in the scaffold’s microstructure 
(Fig. 4 c).  
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Fig.6: DSC thermograms obtained from (b) MeO-PEG2PLA40 scaffold after standard processing, 
(a) MeO-PEG2PLA40 scaffold after 2h extraction in n-hexane (52°C) and (c) pure MeO-
PEG2PLA40 polymer (left axis). (d) Thermogram of P 50 microparticles (right axis). 
To summarize the results concerning the suitability of hard paraffin as a porogen material for 
the processing of low molecular weight polymers, one can ascertain that besides the low 
biocompatibility of paraffin, it also lacked the flexibility in melting points necessary for the 
investigated polymers. Although we achieved well interconnected scaffolds with MeO-
PEG2PLA40, considerable amounts of paraffin remained in the scaffolds even after extensive 
washing steps. Due to the large difference between the Tg of the polymer and the melting 
point of the porogen, we did not manage to obtain interconnected scaffolds with polymers of 
lower molecular weight, such as MeO-PEG2PLA20.  
Chapter 3 Towards biomimetic scaffolds 
- 77 - 
3.2. Scaffold fabrication using triglyceride mixtures as porogen material 
The second aim of this study was the development of a new processing method in order to 
overcome the problems limiting the hydrocarbon templating technique. Paraffin was 
exchanged for physiologically tolerated triglycerides, which are known to serve as parenteral 
drug carriers in the form of solid lipid nanoparticles [34,35]. To further improve the 
physiological tolerance of scaffolds fabricated using this method, we also replaced the 
acetone – chloroform mixture used as polymer solvent with an ethyl methyl ketone (EMK) - 
tetrahydrofurane (THF) mixture (59:41) (v/v). In contrast to chloroform or methylene 
chloride, both solvents - EMK and THF - are classified as low toxic according to the ICH 
guideline Q3C [36]. 
3.2.1. Preparation and characterization of lipid microparticles 
The first task was to identify triglycerides providing both a modest solubility in the polymer 
solvent and suitable melting properties. Particles from pure triglycerides (Dynasan®) and lipid 
mixtures (Witepsol®, Softisan®) were prepared and analyzed with regard to their solubility in 
the polymer solvent mixtures and melting point according to DSC analysis. By blending 
different lipids, melting points were easily made variable within a certain range. As a measure 
for the solubility of the porogen microparticles in the polymer solvent, the screening method 
described in the paraffin section was applied. All lipid microparticles were obtained as a free 
flowing powder in contrast to the hard paraffin particles. No significant differences between 
bulk and particle melting points were observed with DSC analysis (data not shown). 
Two general trends became obvious from these investigations. Firstly, following comparisons 
made within one class of lipids, such as the Dynasan® types or the mixed lipids, we found that 
the solubility generally increased with decreasing melting temperature, as was previously 
observed for the hard paraffin types (Fig. 3). The solubility of all particles tested in the EMK -
 THF mixture was slightly increased relative to the acetone - chloroform system. Secondly, 
pure triglycerides composed of only one type of fatty acid, therefore representing the better 
specified class of triglycerides, such as Dynasan® 114 and 116, appeared to have a higher 
degree of solubility than mixed triglycerides with a comparable melting point. More 
specifically, the solubility of Dynasan 114 particles was remarkably high, especially in the 
EMK - THF mixture, in spite of its relatively high melting temperature of above 50 °C. 
Dynasan 116 particles were only sparingly soluble in the tested solvent mixture, which was, 
however, irrelevant because its melting temperature was unacceptably high. Thus, Dynasan® 
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114 and 116 were classified as non-suitable porogen materials. Among the commercially 
available lipid mixtures which were tested alternatively, we chose Softisan® 154 and 
Witepsol® H 42, both of which had a triglyceride content of more than 95% and contained no 
monoglycerides or additional emulsifying agents (Table 2). Despite the high solubility of 
Witepsol® H 42, it was mixed with Softisan® 154 to prepare microparticles with a melting 
point of below 50°C. DSC analysis of microparticles prepared from such Witepsol® - 
Softisan® mixtures revealed a linear correlation between particle composition and melting 
point (Fig. 7). However, the solubility of these particles increased nonlinearly and only slowly 
with increasing Witepsol® content up to 50% (Fig. 7) under the applied conditions. The 
solubility of particles from a 1:1 mixture was below 15 mg in 5 ml of the EMK - THF solvent 
mixture. These particles were used for further experiments. 
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Figure 7: Determined solubility in two different solvent mixtures (left axis) and melting points (DSC) 
(right axis) of microparticles prepared from different mixtures of Witepsol® H42 and 
Softisan® 154. Symbols (? and ?) and error bars represent means ± SD for n = 3. 
3.2.2. Determination of processing parameters and scaffold microstructure  
The determined processing parameters are summarized in Table 3. Generally, the use of the 
described 1:1 triglyceride mixture (Witepsol®: Softisan®) as porogen material allowed for the 
desired reduction of extraction temperature approaching the glass transition temperatures of 
the investigated polymers. 
Due to the increased density of the used lipids relative to paraffin (Table 2), sedimentation of 
molten porogen material in the polymer constructs was observed during scaffold processing 
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with the consequence of large cavity formation at the bottom of the constructs (Fig. 8 a). Two 
alterations of the processing method were necessary to suppress this phenomenon, both 
resulting in a viscosity increase of the dispersion of porogen microparticles in polymer 
solution. Firstly, the polymer to porogen ratio was increased from 17.6 % to 25 % in the case 
of MeO-PEG2PLA40 and to 33 % to process MeO-PEG2PLA20. Secondly, the filled molds 
were pre-treated in ice-cooled n-hexane (0 °C) for 90 minutes prior to porogen extraction 
(Fig. 2 (∗)). Under these conditions the polymer solvent was partly extracted, causing the 
polymer concentration to further increase, while the porogen microparticles appeared to 
remain unchanged. Only the combination of these steps was successful in preventing lipid 
droplet sedimentation (Fig. 8 b). 
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Fig. 8: Light micrographs (original magnification x6) of MeO-PEG2PLA40 scaffolds fabricated with 
particles from a 1:1 mixture (Witepsol : Softisan) as porogens: (a) no pre-extraction 
treatment; (b) 90 min in n-hexane (0 °C) before porogen extraction. 
Processing of MeO-PEG2PLA40 with lipid microparticles was now possible at an extraction 
temperature T1 = 40 °C close to the Tg (42.3 °C) of the polymer. Under these conditions, we 
obtained stable scaffolds providing an interconnected pore structure (Fig. 9 a/2). In 
accordance with the trend observed during polymer processing with paraffin microparticles 
scaffold permeability was compromised when the extraction temperature had been lowered to 
35 °C (Fig. 9 a/3), which was nevertheless sufficient to completely extract the porogen. On 
the other hand, an increase of extraction temperature T1 up to 45 °C, which could only be 
applied for a maximum of 10 min, led to an increase in pore interconnectivity (Fig. 9 a/1). 
This extraction temperature, optimized with regard to Tm (DSC) of the porogen microparticles 
(44.1 °C; Fig. 7), probably caused coalescence and growth of lipid droplets before their 
extraction, providing an explanation for the observed changes in scaffold structure. 
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(a) MeO-PEG2PLA40 - [1:1]: different extraction conditions 
 
 
 
(1) T1 = 45 °C ; t1 = 10 min (2) T1 = 40 °C ; t1 = 10 min (3) T1 = T2 = 35 °C (30 min) 
(b) MeO-PEG2PLA20 - [1:1]: different extraction conditions MeO-PEG2PLA20 - [2:1] 
 
 
 
(1) T1 = 45 °C ; t1 = 5 min (2) T1 = 40 °C ; t1 = 5 min (3) T1 = 40 °C ; t1 = 5 min 
(c) ST-NH-PEG2PLA40 - [1:1] (d) ST-NH-PEG2PLA20 -[1:1]  
 
 
 
T1 = 40 °C ; t1 = 10 min T1 = 40 °C ; t1 = 5 min  
Fig. 9: SEM images (original magnification x100 – bars represent 100 µm) of scaffolds prepared 
from different polymers with lipid microparticles as porogens: (a) MeO-PEG2PLA40 with the 
1:1 mixture (Witepsol : Softisan) as porogen material; (b) MeO-PEG2PLA20 with 1:1 mixture 
and MeO-PEG2PLA20 with 2:1 mixture; (c) ST-NH-PEG2PLA40 with 1:1 mixture and (d) ST-
NH-PEG2PLA20 / MeO-PEG2PLA20 (75:25) with particles from the 1:1 lipid mixture. 
As a consequence of the favorable solubility properties of the 1:1 triglyceride mixture, MeO-
PEG2PLA20 was also processed with these porogen microparticles. Consequently, an 
extraction temperature of 40 °C or even 45 °C was necessary to obtain an interconnected pore 
Chapter 3 Towards biomimetic scaffolds 
- 81 - 
structure. Combined with a reduction of t1 to 5 min, these conditions were applicable without 
compromising the scaffold structure and interconnected pores were generated (Fig. 9 b/1,2). 
As observed with MeO-PEG2PLA40, an extraction temperature above the Tm (DSC) of the 
porogen material provided optimum pore microstructure. 
Processing of MeO-PEG2PLA20 with different porogen materials further confirmed that even 
after pre-extraction incubation in n-hexane at 0 °C for 90 min, the velocity of porogen melting 
still had an effect on pore structure. After processing with the 1:1 mixture at 40 °C, the 
polymer precipitated in between the porogen particles forming wall like structures with some 
large interconnections and many small perforations (Fig. 9 b/2). On the other hand, condensed 
polymer structures were found after processing with the 2:1 mixture (Witepsol®: Softisan®) as 
porogen material (Fig. 9 b/3), most likely as a result of the accelerated porogen melting 
forming a continuous phase. Although a closer match of the porogen’s melting point and the 
polymer’s Tg was achieved with this 2:1 mixture, the scaffold structure was not much 
improved since irregular pores had been formed in the scaffold, possibly because of the 
relatively high degree of solubility of the porogen mixture in the polymer solvent (Fig. 7). 
Generally, it may be difficult to find triglyceride mixtures fulfilling both the requirement of an 
even lower melting point than the 1:1 mixture and a comparably low solubility in a polymer 
solvent. However, polymers with a lower Tg than those used in our study are not common as 
scaffold materials since they are prone to distortion processes due to a stability loss in vitro 
and in vivo at 37 °C. The particular structure of the diblock copolymers containing a 
hydrophilic swelling PEG chain used in this study may be the reason why scaffolds made 
from these polymers remained stable after loading with adhesive cells at 37 °C despite a low 
Tg of approximately 33 °C.  
In summary, the MeO-PEGxPLAy copolymers of both molecular weights were successfully 
processed with particles prepared from lipid mixtures. The best results were obtained with the 
1:1 mixture of Witepsol® H42 and Softisan® 154. Even though the DSC determined melting 
point of these microparticles was only 3 °C below the Tm (DSC) of the initially used P 50 
microparticles (Fig. 10), the minimum extraction temperature creating an interconnected pore 
structure was decreased from 47 °C to 40 °C. Assuming that the formation of a continuous 
liquid porogen phase during extraction is required for pore interconnectivity, these findings 
could be explained by differences in these materials’ melting behavior. Investigation of the 
different porogen microparticles revealed a broad melting signal of the triglyceride mixture 
and three narrow peaks of the hard paraffin (Fig. 10).  
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Fig. 10: Thermograms and melting points (bold: main fraction) of porogen microparticles prepared 
from (a) P 50 (left axis) and (b) the 1:1 mixture (Witepsol : Softisan) (right axis) as obtained 
from DSC analysis.  
In the case of the triglyceride microparticles, a significant fraction of short chain triglycerides 
were already melted at 40 °C, consequently leading to pore interconnectivity (Fig. 9), while 
the narrow melting peak of the main fraction of P 50 microparticles explains why 
interconnected pore structures did not form below 47 °C (Fig. 4).  
Although some additional changes were necessary to suppress sedimentation of the porogen 
particles in the mold, such as the increase of polymer content and pretreatment in cold 
n-hexane, which were expected to impede the scaffold structure, the desired highly porous 
and interconnected scaffold microstructure has been achieved. The polymers still remained 
moldable, possibly due to an extraction temperature T1 close to or above the Tg, and were thus 
able to adapt to the variable form of the melting and coalescing lipid droplets. 
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Fig. 11: Temperature course during the two-step extraction procedure. Schematic snapshots of the 
mold filling at three time points: 0, t1 and 30 min. 
We developed a general two step extraction procedure as shown in figure 11. Ideally, a lipid 
mixture with a melting point (Tm) close to the glass transition temperature (Tg), is used to 
prepare porogen microparticles. Extraction conditions should then be chosen in a way, such 
that extraction starts at T1 above Tm for a short time t1 (up to 10 min) and continues at T2 
below Tg for t2 = 30 min – t1. Nevertheless, T2 must be sufficiently high to allow for complete 
porogen extraction. 
3.2.3. Determination of triglyceride residuals (MDSC) 
To detect and quantify triglyceride residuals inside MeO-PEG2PLA40 scaffolds, MDSC 
analysis was applied for the following reason: due to the proximity of polymer’s Tg to the 
porogen’s Tm (Fig. 12), the endothermic signals of the glass transition step and porogen 
melting overlap. The amount of residual porogen material could only be calculated from the 
area under the melting peak appearing in the 2nd heating cycle if it was ensured that every 
deviation from a linear baseline after the transition step was a result of residual porogen 
melting and not of relaxation phenomena. In MDSC measurements, such phenomena appear 
in the total and the non-reversing heat flow, but are eliminated from the reversing heat flow. 
Consequently, the reversing heat flow of the 2nd heating cycle was analyzed. 
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Fig. 12: MDSC thermograms obtained from MeO-PEG2PLA40 scaffolds (b: T1 = T2 = 35 °C ; t = 30 
min) (c: T1 = 45 °C ; t1 = 10 min), MeO-PEG2PLA40 mixed with (a) 1.8 % and (d) 0.3 % of 
microparticles (1:1 mixture) as well as (e) pure MeO-PEG2PLA40 (left axis). (f) MDSC 
thermogram of lipid microparticles (1:1 mixture) (right axis). The inserted figure shows the 
correlation between lipid microparticle content and area under the melting peak. 
For calibration, different mixtures of MeO-PEG2PLA40 and porogen microparticles prepared 
from the 1:1 lipid mixture (Witepsol®: Softisan®) were investigated in this way. A linear 
correlation between area under the melting peak and lipid microparticle content was found 
between 0.1 - 5.4 % (Fig. 12). In thermograms resulting from such calibration mixtures 
(Fig. 12 a, d) a concentration dependant melting peak was visible, overlapping the glass 
transition step of the pure polymer (Fig. 12 e). Hardly any melting peak caused by lipid 
residuals was found in the analysis of the MeO-PEG2PLA40 scaffolds, regardless of the 
extraction conditions (Fig. 12 b, c). Calculations revealed a residual lipid content of 
0.7 ± 0.1 %. Interestingly, the initial extraction temperature T1 had no effect on residual 
porogen content as long as T2 was sufficient to dissolve the porogen microparticles in 
n-hexane. 
Likewise, in MeO-PEG2PLA20 scaffolds, which were prepared with the same porogen 
microparticles, less than 1 % of residual porogen material was found (data not shown). 
Thus, hardly any remnants of triglycerides, particularly less than found after polymer 
processing with paraffin microparticles, were detectable in the fabricated scaffolds. Moreover, 
in contrast to hard paraffin, the residual triglycerides finally undergo metabolism in a 
biological system. In combination with the low toxic EMK – THF mixture as polymer 
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solvent, we consider the developed method to be suitable for the fabrication of biocompatible 
scaffolds. In contrast to the paraffin system, triglyceride mixtures offer sufficient flexibility of 
melting points and solubility to meet the requirements of different low molecular polymers. 
Finally, the small-scale processing method presented here is expected to be adaptable to a 
broad range of established and newly developed polymers of various molecular weights. 
3.2.4. Processing of amine-reactive polymers and scaffold microstructure  
Since the best results in processing MeO-PEG-PLA diblock copolymers were obtained with 
the 1:1 mixture (Witepsol®: Softisan®), this porogen material was also used for the processing 
of the amine-reactive ST-NH-PEG-PLA derivatives (Table 3). Porogen microparticles were 
extracted at T1 = 40 °C for t1 = 10 min when ST-NH-PEG2PLA40 was processed and at T1 = 
40 °C for t1 = 5 min to fabricate scaffolds from ST-NH-PEG2PLA20. These mild extraction 
conditions, shown to be sufficient in generating permeable pore structures inside MeO-
PEGxPLAy scaffolds (Fig. 9 b, e), were chosen with regard to the lower Tg of both ST-NH-
PEGxPLAy copolymers compared with their MeO-PEGxPLAy derivatives (Table 1). 
Furthermore, the polymer to porogen ratio was increased in order to suppress sedimentation 
and to ensure scaffold stability. Applying these modified conditions, scaffolds from pure ST-
NH-PEG2PLA40 were successfully prepared. In the case of ST-NH-PEG2PLA20, however, a 
blend containing 25 % of MeO-PEG2PLA20 was necessary to obtain stable scaffolds.  
Scanning electron microscopy showed a permeable pore microstructure inside ST-NH-
PEG2PLA40 (Fig. 9 g) and ST-NH-PEG2PLA20 (Fig. 9 h) scaffolds. The pore structure of the 
ST-NH-PEG2PLA40 scaffolds in particular was comparable to the microstructures inside 
scaffolds prepared from MeO-PEG2PLA40 under the same extraction conditions. 
3.2.5. Pore size distribution and porosity  
Mercury intrusion porosimetry displayed a close correspondence between pore size 
distribution and porogen particle size in all investigated scaffolds. Scaffolds from MeO-
PEG2PLA40 and ST-NH-PEG2PLA40 as well as MeO-PEG2PLA20 scaffolds showed a nearly 
identical pore size distribution, corresponding well with the size distribution (determined by 
laser diffraction) of the porogen microparticles used for their fabrication (Fig. 13). 
Additionally, a porosity of between 85 and 90 % was calculated for the investigated scaffolds. 
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Fig. 13: Pore size distribution inside different scaffolds as obtained by mercury intrusion 
porosimetry. Porogen microparticle (1:1 mixture) size distribution as measured by laser 
diffraction. 
3.3. Instant surface modification 
Finally, our study aimed at proving the principle of instant protein attachment from an 
aqueous solution to the surface of a preformed scaffold with insulin as model protein. 
Therefore, scaffolds were submerged in a buffered (pH = 8) solution of insulin. After washing 
and freeze drying, GPC analysis was applied to detect covalently bound insulin. Adsorbed 
insulin was precipitated during sample preparation. In chromatograms of incubated ST-NH-
PEG2PLA20 scaffolds, a strong fluorescence signal at the elution volume of the polymers 
(13 – 14 min) was detected (Fig. 14).  
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Fig. 14: Chromatograms of human insulin covalently attached to amine reactive scaffolds 
(fluorescence detection). (a) ST-NH-PEG2PLA20 + insulin; (b) ST-NH-PEG2PLA20 + buffer; 
(c) MeO-PEG2PLA20 + insulin. 
 
Analysis of ST-NH-PEG2PLA40 scaffolds revealed similar results (data not shown) but signal 
intensity normalized to scaffold weight was lower. This decrease is most likely a result of the 
lower density of active groups on the scaffold surface when ST-NH-PEG2PLA40 with a 
molecular weight of 42 kDa is used instead of ST-NH-PEG2PLA20 (22 kDa). Thus, polymer 
reactivity was maintained during processing. Furthermore, the concept of instant protein 
binding from buffered solutions to a prefabricated scaffold was demonstrated. 
Insulin was chosen as model substance because an insulin sensitive three-dimensional 
cartilage engineering model system has been developed [37], in which the biological activity 
of such surface modified scaffolds should be tested in future experiments. 
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4. Conclusions 
We were able to process amine-reactive ST-NH-PEG-PLA diblock copolymers and their non-
reactive MeO-PEG-PLA derivatives into stable and highly porous scaffolds using an 
anhydrous porogen leaching technique. ST-NH-PEG-PLA scaffolds were proven to be amine-
reactive after scaffold fabrication. This enables us to fabricate scaffolds for future applications 
which can be easily conjugated with molecules containing free amine groups immediately 
preceding implantation or use in cell culture experiments.  
We demonstrated the superiority of triglyceride mixtures relative to paraffin as porogen 
materials for scaffold fabrication especially with low molecular weight biodegradable 
polymers. Their physiological tolerance and applicability in fabricating free flowing 
microparticles of matching solubility and various melting points are outstanding 
characteristics of such triglyceride blends. We showed that initial porogen melting at 
extraction temperature was important in obtaining interconnected pore structures. However, 
working with low molecular weight polymers requires careful consideration of the extraction 
conditions. By combining high and low extraction temperatures with varying durations, as 
well as using porogen materials with melting points near the glass transition temperature of 
the polymer, the processing parameters were adapted to polymer properties. 
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Abstract 
Hansen solubility parameters (HSPs) are accepted tools to describe the thermodynamic 
interactions between solvent molecules and polymers. In this study, these parameters were 
employed to systematically replace halogens and other toxic solvents used in an established 
scaffold fabrication technique with solvents with a low toxicity rating (ICH guideline Q3C) 
without any changes to the other processing parameters. To systematically search for solvent 
alternatives, the HSPs of the original solvent mixture were calculated and compared to the 
parameters of 26 class 3 solvents and binary mixtures thereof. The HSPs of a mixture 
containing methyl ethyl ketone 59% (v/v) and tetrahydrofurane 41% (v/v) were found to most 
closely fit the parameters calculated for the original acetone-chloroform-mixture. Using the 
alternative solvent mixture, poly(lactic-co-glycolic acid) and monomethyl ether-poly(ethylene 
glycol)-co-poly(lactic acid) could be processed into tissue engineering scaffolds without 
further changes to the procedure. Importantly, the solvent exchange only minimally affected 
the macro- and microstructure of the resulting scaffolds.    
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1. Introduction 
Since 1970, when poly(glycolic acid) (PGA) was approved by the FDA for the use as a 
degradable suture material, the application of biodegradable polymers, especially  poly(α-
hydroxy acids), has proliferated throughout the biomaterial and medical sciences [1,2]. A 
plethora of drug release devices, orthopedic implants and fixation devices as well as cell 
carriers for tissue engineering applications have been fabricated from these materials [3-7]. 
Since lipophilic materials are not water-soluble, they must be processed either in their molten 
state or dissolved in organic solvents. In particular, the fabrication of microparticles and tissue 
engineering scaffolds from biodegradable polymers often employs halogenated solvents, such 
as methylene chloride and chloroform [8,9]. The elimination of these toxic solvents from such 
fabrication procedures, however, is necessary to avoid risks to human health and minimize 
any influence on the physicochemical properties of the product, such as microstructure, 
storage stability or the stability of encapsulated substances [10]. In tissue engineering 
applications, residual solvents may compromise cell development on the polymeric carriers. 
Due to their toxicity, regulatory authorities strictly limit halogenated solvent residuals. The 
International Conference on Harmonization (ICH), a project that brought together the 
regulatory authorities of Europe, Japan and the United States, published a guideline for 
residual solvents [11] that classifies the chemicals on the basis of their toxicity and gives 
exposure limits for each solvent. Halogenated solvents, such as methylene chloride and 
chloroform, are categorized as ‘solvents to be limited’ (class 2 solvents). Less toxic chemicals 
are labeled as class 3 solvents by this guideline (Table 1). Therefore, class 3 solvents should 
be used to replace halogenated solvents in biomaterial processing wherever possible. 
This study particularly aimed at eliminating chloroform from a recently developed scaffold 
fabrication procedure [12]. This anhydrous porogen leaching technique allows for the 
processing of poly(lactic-co-glycolic acid) (PLGA) and diblock copolymers consisting of 
poly(ethylene glycol) (PEG) and poly(lactic acid) (PLA) into macroporous cell carriers 
(scaffolds) with an interconnected pore structure. In the first step of the process, an azeotropic 
mixture containing 65% (v/v) acetone and 35% (v/v) chloroform is used to dissolve the 
polymers. Solid lipid microparticles, the pore forming templates, are dispersed in the polymer 
solution and the dispersion is transferred into molds. Polymer precipitation and microparticle 
extraction are simultaneously initiated by submerging the molds in warm n-hexane [12]. To 
obtain macroporous, form-filling scaffolds, processes like solvent extraction, phase separation 
and porogen extraction have been carefully examined and related to each other during this 
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processing step. The process temperature and solvent composition are the key parameters in 
controlling these processes. With regard to the ICH guideline, we aimed at replacing 
chloroform by exclusively using class 3 solvents or mixtures thereof. However, the previously 
determined parameters for polymer processing should remain applicable. We hypothesized 
that by employing a solvent or a solvent mixture with solubility and miscibility properties 
comparable to the established acetone-chloroform-mixture, the substitution could successfully 
be accomplished. To avoid laborious empirical screenings, Hansen solubility parameters 
(HSPs) were used for a systematical search. We calculated the HSPs of the original acetone-
chloroform-mixture and compared them to the parameters of 26 class 3 solvents and binary 
mixtures thereof. The solvent mixture, which most closely fit the acetone-chloroform-mixture, 
was used for PLGA and MeO-PEG-PLA processing without additional parameter changes. 
The macro- and microstructure of the resulting scaffolds was examined to determine the effect 
of the solvent exchange. Several class 3 solvents, which have similar HSPs to the acetone-
chloroform-mixture, were also tested as polymer solvents. 
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2. Theory 
The solubility parameter theory was originally established to describe the enthalpy of mixing 
of nonpolar, nonassociated solvents, but has been extended to apply to polar solvents and 
polymers. In coatings and paint technology, the solubility parameter is important for the 
selection of solvents and polymer plasticizers as well as to predict polymer and solvent 
compatibility with dyes, nonionic emulsifiers and pigments.  
Hildebrand defined the total solubility parameter (δ) as the square root of the cohesive energy 
density (CED) [13], which is equal to the energy of vaporization (∆Ev) per molar volume 
(Vm): 
 
m
v
V
ECED ∆==δ  (1) 
The solubility parameter is a measure of all the intermolecular forces responsible for the 
material cohesion.  
To predict interactions between two solvents or a solvent and a polymer, the difference 
between the solubility parameters of the molecules is determined. Similar solubility parameter 
values, resulting in a small difference, indicate strong interactions, meaning that two solvents 
are miscible or that the polymer will dissolve in the solvent.  
With the objective of describing the quality of the interaction between two molecules more 
precisely, the total solubility parameter was decomposed into several terms representing 
different contributions to the free energy of mixing [14]. In the three-parameter (three-
dimensional) Hansen approach, the interaction capacity of a compound arises from three 
partial solubility parameters that quantitatively describe the non-polar, dispersive interactions 
(δd), permanent dipole-dipole interactions (δp), and the hydrogen bonding forces (δh) [15-18]. 
The total solubility parameter is related to the partial ones by the following equation: 
 
2222
hpdtotal δδδδ ++=  (2) 
The values of the HSPs for many solvents were calculated from a large number of solubility 
data sets and are tabulated in literature [19]. In Table 1, the HSPs for the ICH class 3 solvents 
are listed based on published data [19]. Polymer solubility parameters can also be 
decomposed to a three-term set. Determination of this data, however, is a difficult and 
laborious undertaking. Nevertheless, the published total solubility parameter value of PLA is 
9.8 – 10.2 cal1/2cm-3/2 [20], which is equal to 20.1 – 20.9 MPa1/2.  
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Hansen found that the complete miscibility of a polymer (subscript p) and a solvent 
(subscript s) is obtained when the difference in solubility parameters (∆δ) is lower than the 
solubility radius Rp, which is characteristic for each polymer.  
 phphspppsdpds R<−+−+−=∆
222 )()()(4 δδδδδδδ  (3) 
So far, neither the solubility radius nor experimental HSPs have been determined for 
poly(α-hydroxy acids). The solubility radii described for other polymers range between 2 and 
12 MPa1/2 [21-23].  
Due to the incomplete data on biodegradable polymers, attempts to explain or predict the 
encapsulation efficacies and release data of proteins from biodegradable polymer 
microspheres in a thermodynamic approach that was exclusively based on HSPs proved to be 
insufficient [24,25]. The established scaffold fabrication technique [12], however, is even 
more complex in terms of the underlying thermodynamics. Different processes, namely 
solvent extraction, polymer precipitation and porogen material dissolution, have to be 
kinetically adapted to each other to fabricate interconnected pore structures [12]. Changes in 
the polymer or the extraction solvent will affect all three processes in different ways. 
Therefore, our intention was not to describe the entire fabrication procedure by means of 
HSPs, but rather to replace the halogenated polymer solvent mixture with a 
thermodynamically equivalent solvent or solvent mixture with a lower toxicity rating 
(class 3). Since the three-dimensional HSPs are quantities that exactly describe the 
thermodynamic properties of a solvent or a solvent mixture, they are the appropriate tools to 
accomplish this aim. 
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3. Materials and Methods 
3.1. Materials 
Poly(D,L-lactic-co-glycolic acid) (PLGA) (75:25), Resomer® RG756, was provided by 
Boehringer Ingelheim (Ingelheim, Germany). Poly(D,L-lactic acid)-block-poly(ethylene 
glycol)-monomethyl ether diblock copolymers (MeO-PEG2PLA40, MeO-240) (Mn = 42kDa) 
were synthesized in our laboratory [26]. The solid lipids that were used as porogen materials, 
namely Softisan® 154 and Witepsol® H42 were kindly provided by SASOL Germany GmbH 
(Witten, Germany). Acetone, chloroform, methyl ethyl ketone (MEK), tetrahydrofurane 
(THF) and ethyl acetate, which were used as polymer solvents, and n-hexane, n-pentane and 
n-heptane, which were utilized as porogen extraction media, were purchased in analytical 
grade from Merck (Darmstadt, Germany). The solubility parameters of these solvents are 
listed in Table 1. 
Table 1: Hildebrand (δtotal) and three-dimensional Hansen solubility parameters of solvents listed in 
class 3 of the ICH guideline. The parameters of n-hexane and chloroform (ICH class 2) are 
included. 
 
Solvent 
Solubility Parameters 
[MPa1/2]  Solvent 
Solubility Parameters 
[MPa1/2] 
 δd δp δh δtotal   δd δp δh δtotal 
ICH class 3 
    
 
 
    
Hydrocarbons      Ethers     
n-Pentane 14.5 0.0 0.0 14.5  Ethyl ether 14.5 2.9 5.1 15.8 
n-Heptane 15.3 0.0 0.0 15.3  Tetrahydrofurane 16.8 5.7 8.0 19.4 
Alcohols      Esters     
1-Butanol 16.0 5.7 15.8 23.1  Butyl acetate 15.8 3.7 6.3 17.4 
2-Butanol 15.8 5.7 14.5 22.1  Ethyl acetate 15.8 5.3 7.2 18.2 
Ethanol 15.8 8.8 19.4 26.6  Ethyl formate 15.5 8.4 8.4 19.6 
2-Methyl-1-propanol 15.1 5.7 16.0 22.7  Isobutyl acetate 15.1 3.7 6.3 16.8 
1-Pentanol 16.0 4.5 13.9 21.7  Isopropyl acetate 14.3 8.4 5.7 17.6 
1-Propanol 16.0 6.8 17.4 24.6  Methyl acetate 15.5 7.2 7.6 18.8 
2-Propanol 15.8 6.1 16.4 23.5  Propyl acetate 14.1 8.1 7.8 18.0 
Ketones      Acids     
Acetone 15.5 10.4 7.0 20.1  Acetic acid 14.5 8.0 13.5 21.3 
Methyl ethyl ketone  16.0 9.0 5.1 19.0  Formic acid 14.3 11.9 16.6 25.0 
Methyl isobutyl 
ketone 15.3 6.1 4.1 17.0 
 
Others     
     
 Dimethylsulfoxide 18.4 16.4 10.2 26.6 
ICH class 2 
    
 
     
n-Hexane 14.9 0.0 0.0 14.9  Chloroform 17.8 3.1 5.7 18.9 
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3.2. Hansen solubility parameter calculation of binary solvent mixtures  
Based on the HSPs listed in Table 1, the three-dimensional HSPs of the established acetone-
chloroform-mixture (65:35 (v/v)) were estimated according to the following equations 
(acetone: subscript a; chloroform: subscript c): 
 dccdaadmix δδδ Φ+Φ=  δdmix: dispersive HSP of the mix, (4) 
 pccpaapmix δδδ Φ+Φ=  δpmix: polar HSP of the mix, (5) 
 hcchaahmix δδδ Φ+Φ=  δhmix: hydrogen bonding HSP of the mix, (6) 
where Φa and Φc are the mole fractions for the two components of the mixture, namely 
acetone (a) and chloroform (c). Technically, the solubility parameter of a mixture of liquids is 
determined by calculating the volume-wise contributions of the solubility parameters of the 
individual components of the mixture. 
3.3. Determination of the alternative solvent or solvent mixture 
To systematically search for a thermodynamically equal, low-toxic solvent or solvent mixture, 
the following strategy was applied: Generally, every substance can be represented by a point 
in a three-dimensional coordinate system with its HSPs as coordinates (δd, δp, δh). By mixing 
two solvents, any HSP along a line in between the two points representing the mixture 
components can be attained (defined by equations (4)-(6)). From a pool of 26 ICH class 3 
solvents, 325 binary solvent combinations are possible. Using an algorithm to plot the 
trajectory that is perpendicular to the line describing the solubility parameters for each of the 
325 solvent mixtures and intersects the coordinates of the acetone-chloroform mixture 
(target), the coordinates (HSPs) that are closest to the target were determined for each mixture 
(Fig. 1). This operation determined the ‘best mix’ for each possible solvent combination. 
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Fig. 1: Schematic illustration of the geometric algorithm used to determine alternative solvent 
mixtures thermodynamically comparable to the acetone-chloroform-mixture (target). For 
every binary solvent combination, the respective ‘best mix’ is determined by calculating the 
coordinates perpendicular to the target. Two values (∆geo and ∆poly) expressing the distance 
between the best mix and the target parameter are calculated according to the depicted 
equations. 
Concomitantly, the distance of the 325 ‘best mixes’ from the target was calculated. For each 
mix, we calculated the geometric distance ∆geo and a further distance value ∆poly, which was 
derived from the Hansen plot (2δd, δp, δh) and calculated according to formula (3). ∆poly 
emphasizes the significance of the dispersive solubility parameter, which Hansen identified 
for interactions involving polymers. Finally, the mixtures were ranked according to their 
geometric distance to the target point. 
3.4. Scaffold fabrication procedure  
To fabricate macroporous scaffolds from biodegradable polymers, we recently developed an 
anhydrous technique employing solid lipid microparticles as porogens [12] (Fig. 2). The solid 
lipid microparticles were prepared from either a 1:1 mixture of Softisan® 154 and Witepsol® 
H 42 (SH 1:1) or a 2:1 mixture (SH 2:1) using a melt dispersion technique. The resulting 
SH 1:1 microspheres with an average size distribution of [d10; d90] = [68µm; 347µm] were 
used to process MeO-PEG2PLA40. SH 2:1 microparticles, average size distribution [d10; d90] = 
[105µm; 319µm], served as the porogen material when PLGA was processed. 
Briefly, the scaffold fabrication started with a polymer solution. PLGA was dissolved in the 
polymer solvent to obtain a final concentration of 308 mg/mL. In the case of  
MeO-PEG2PLA40, the concentration was 420 mg/mL. Under ice cooling, the polymer solution 
was mixed with the porogen particles. A polymer to porogen ratio of 1:4 (w/w) was chosen. 
The homogeneous dispersion was transferred into Teflon® molds (1.9 cm x 1.9 cm x 1.2 cm) 
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with a cylindrical cavity 0.8 cm in diameter. After a pre-extraction treatment step in n-hexane 
at 0°C (PLGA: 15 min, MeO-240: 90min), the molds were submerged in warm n-hexane to 
induce solvent extraction followed by the precipitation of the polymer and extraction of the 
lipid porogen. This procedure was carried out in two separate n-hexane baths with different 
temperatures T1 (PLGA: 52°C, MeO-240: 40°C) and T2 (PLGA: 40°C, MeO-240: 35°C) for  
t1 = 10min and t2 = 20min. The resulting porous, cylindrical polymer constructs were allowed 
to cool in cold (0°C) n-hexane and were finally removed from the molds, vacuum dried for  
48 h and cut into 2mm slices which were then described as scaffolds. 
polymer
solution
porogen
microparticles
polymer precipitation 
& porogen extraction
in n-hexane (T1,T2) 
porous polymer
cylinder 
dispersion transfer
into mold
 
Fig. 2: Schematic illustration of the scaffold fabrication procedure. Molds are filled with a 
dispersion prepared from a polymer solution and triglyceride microparticles and submerged 
in warm n-hexane. In a two step extraction (T1, T2), the porogen microparticles are extracted 
at two different temperatures, while the polymer is concomitantly precipitated forming 
macroporous polymer scaffolds. 
3.5. Microscopic assessment of scaffold macro- and microstructure 
The macrostructure of the porous polymer cylinders and scaffolds was examined using a 
zoom stereo microscope (Wild M7A, Wild Heerbrugg Ltd., Heerbrugg, Switzerland). The 
scaffold microstructure was visualized by scanning electron microscopy (SEM). For this 
procedure, samples were mounted on aluminum stubs with conductive carbon tape and coated 
with gold-palladium. All micrographs were obtained at 10 kV on a DSM 950  
(Zeiss, Oberkochen, Germany). 
3.6. Determination of solvent viscosity and polymer solution viscosity 
The kinematic viscosity of the polymer solvents and solvent mixtures was determined at 25°C 
using a calibrated Ubbelohde capillary viscometer (size: 0c, Schott AG, Mainz, Germany) 
with a Lauda S5 detector (Lauda, Lauda-Königshofen, Germany), which was connected to a 
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Lauda PVS1 Processor Viscosity System with a PVS 2.28a analysis program  
(Lauda, Germany) (n = 8). 
In order to determine the reduced viscosity of different polymer solutions (c = 0.01 gcm-3), we 
measured the kinematic viscosity of the polymer solutions at 25°C. All of the solutions were 
prepared in triplicate and each solution was measured 2-3 times. The relative viscosity was 
calculated from the average kinematic viscosity of each solution: 
 
solvent
solution
rel η
ηη =  . (7) 
The reduced viscosity was defined as: 
 
c
rel
red
)1( −
=
ηη . (8) 
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4. Results 
4.1. Determination of low-toxic solvent alternatives 
A total of 28 solvents are classified as ‘solvents with low toxic potential’ in class 3 of the ICH 
guideline ‘Impurities: Guideline for residual solvents’ [11]. Table 1 lists 26 class 3 solvents 
and the corresponding HSPs. Anisole and cumene, which also are class 3 solvents, were not 
considered in this study. Generally, the solvents listed in this class belong to several chemical 
substance classes ranging from non-polar hydrocarbons to alcohols and acids that show strong 
hydrogen bonding. This way, the class 3 solvents offer a broad spectrum of solubility 
parameters to choose from. 
The solvents used in the original scaffold fabrication procedure are n-hexane, acetone and 
chloroform, with acetone and chloroform being used as a mixture to dissolve the polymer and 
n-hexane serving as extraction solvent. According to the ICH guideline, chloroform and n-
hexane are classified as ‘solvents to be limited’ (class 2). The HSPs of these two solvents are 
listed in Table 2. 
The main goal of this study was to find an alternative to the established acetone-chloroform-
mixture (65:35 (v/v)) used as the polymer solvent. To define a measure for the 
thermodynamic interaction forces of this mixture, its HSPs were calculated according to 
equations (4)-(6). The parameters of the acetone-chloroform-mixture, representing the target 
coordinates for the systematic search, are listed in Table 2. An algorithm, described in the 
methods section, was used to compare the HSPs of 26 class 3 solvents and their binary 
mixtures with the target mixture in order to screen for a thermodynamically equal or at least 
similar solvent alternative. The ten best mixtures are listed in Table 2. All of them exhibited a 
geometric distance (∆geo) from the target below 1 MPa1/2. A mixture of methyl ethyl ketone 
and tetrahydrofurane (59:41 (v/v)) fit best in terms of both ∆geo and ∆poly. In contrast to ∆geo, 
which represents the spatial distance of the mixture HSPs to the target in a 3-D coordinate 
system (δd, δp, δh), ∆poly is based on the Hansen plot (2δd, δp, δh) that emphasizes the disperse 
interactions between polymer and solvent. Like four other mixtures, all indicated with a star 
(*) in Table 2, this mixture is free of nucleophilic solvents and therefore suitable for the 
processing of functional, electrophilic, reactive polymers [27].  
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Table 2: Solubility parameters (Hansen and Hildebrand) of the original solvent mixture and 
parameters calculated for the 10 best alternative class 3 solvent mixtures. ∆geo and ∆poly are 
measures for the distance of the calculated alternative mixtures to the target parameters. 
Solvent mixtures that are free of a nucleophilic component are indicated by a *. 
Solvent Mixture ratio (v/v) Solubility Parameters [MPa1/2] Distance  
   δd δp δh δtotal  ∆geo ∆poly  
Target 
          
Acetone : Chloroform 65 : 35  16.3 7.8 6.5 19.2  0.0 0.0  
Alternatives 
          
MEK : THF 59 : 41  16.3 7.6 6.3 19.1  0.3 0.1 * 
MEK : 1-Pentanol 81 : 19  16.0 8.1 6.8 19.2  0.5 0.5  
Ethyl ether : DMSO 63 : 37  15.9 7.9 7.0 19.1  0.6 0.7 * 
Methylacetat : MEK 46 : 54  15.8 8.2 6.3 18.7  0.7 1.3 * 
2-Butanol : MEK 19 : 81  16.0 8.4 6.9 19.3  0.7 0.9  
1-Butanol : MEK 17 : 83  16.0 8.4 6.9 19.4  0.8 0.9  
Aceton : Butylacetat 57 : 43  15.6 7.5 6.7 18.6  0.8 2.0 * 
Ethylacetat : MEK 43 : 57  15.9 7.4 6.0 18.6  0.8 1.1 * 
MEK : 2-Propanol 84 : 16  16.0 8.5 6.9 19.4  0.9 1.1  
MEK : 2-Methyl-1-propanol 83 : 17  15.8 8.4 7.0 19.3  0.9 1.4  
 
Suitable alternatives for n-hexane, which was used in the fabrication process to induce phase 
separation and to extract the porogen material, can be found among the hydrocarbons listed in 
class 3 of the ICH guideline, namely n-pentane and n-heptane (Table 1). According to the 
solubility parameter theory, a 50:50 (v/v) mixture of both solvents would exactly meet the 
HSPs of n-hexane. From another point of view, the HSPs of all three hydrocarbons are 
considerably different from the other class 3 solvents since only disperse interactions 
contribute to the cohesive forces of a hydrocarbon. Therefore, any hydrocarbon that is a liquid 
under the applied extraction conditions should be suitable to induce polymer precipitation and 
to extract the porogen microparticles. Additionally, the number of organic solvents involved 
in the fabrication procedure should be kept to a minimum due to regulatory demands. 
Consequently, pure n-heptane was used to replace n-hexane, as the boiling point of n-pentane 
(36°C) is far below the extraction temperatures. 
4.2. HSP-based illustration of solvents and solvent mixtures  
(Two-dimensional solvent map)  
Figure 3 illustrates the thermodynamic solvent characteristics in a two-dimensional map. In 
this plot, the partial solubility parameter for the disperse interactions, δd, and a partial 
solubility parameter δa, which combines the non-disperse interactions δp and δh (9), are used 
as coordinates for each solvent. 
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22
hpa δδδ +=  (9) 
The introduction of the partial solubility parameter δa allows for a two-dimensional 
illustration, as it combines δp and δh. Furthermore, this particular reduction from using three 
to two dimensions to characterize the solvent does not affect δd, which is described as the 
dominant parameter in terms of polymer-solvent interactions [28].  
The alcohols and acids are located in the upper left quadrant of this plot due to high values of 
δp and δh. Hydrocarbons can be found on the x-axis since only dispersive forces contribute to 
the cohesive forces in such solvents. The exceptional characteristics of DMSO, which is a 
solvent for many hydrophilic and lipophilic macromolecules, are well illustrated by its 
isolated position in the upper right quadrant of the plot (δd > 16 and δa > 12.5). Typical 
polymer solvents, such as chloroform (ICH class 2), however, show many dispersive 
interactions and few non-dispersive interactions, locating them in the lower right quadrant 
(δd > 16 and δa < 12.5). Tetrahydrofurane is the only class 3 solvent that appears in this 
quadrant.
 
The coordinates of the target, the acetone-chloroform-mixture (65:35 (v/v)), are located on a 
line between acetone and chloroform. MEK, THF and ethyl acetate can be identified as the 
three solvents exhibiting the closest distance to the target in this plot. Together with acetone, 
these solvents were additionally tested as polymer solvent alternatives. 
4.3. Polymer processing using alternative solvents 
In order to check for the effectiveness of the solvent search utilizing HSPs, PLGA scaffolds 
were processed with different solvents or solvent mixtures using the processing parameters 
developed for the acetone-chloroform-mixture (65:35 (v/v)). Additionally, n-heptane was 
employed as extraction solvent instead of n-hexane. The macro- and microstructure of the 
resulting macroporous polymer cylinders and scaffolds was analyzed by light microscopy and 
SEM. We investigated the following polymer solvents: MEK:THF (59:41 (v/v)), which was 
the result of the systematic solvent search,  MEK, THF and ethyl acetate, three different pure 
solvents positioned closest to the target mixture in the two-dimensional solvent plot (Fig. 3), 
and pure acetone, which displays a larger distance to the target mixture, as the main 
component of the original solvent mixture.  
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Fig. 3: Two-dimensional solvent map. 24 ICH class 3 solvents, n-hexane, chloroform, and the 
acetone-chloroform-mixture were illustrated in this coordinate plane using the disperse 
solubility parameter (δd) and a partial parameter (δa), which combines the non-disperse 
interactions, as coordinates. 
PLGA scaffolds processed with the calculated best alternative polymer solvent mixture, 
MEK:THF (59:41 (v/v)), were nearly unaffected in their macroscopic and microscopic 
appearance. SEM revealed slightly thinner polymer bridges and smaller pore interconnections 
than with the target polymer solvent mixture (Fig. 4a,b; 5a,b). When either MEK or ethyl 
acetate was used as the polymer solvent alternative for the processing of PLGA, slight 
deformations of the polymer cylinders were observed. Additionally, the macrostructure of the 
resulting scaffolds appeared to be less regular (Fig. 4c,d). Nonetheless, SEM showed 
unaffected interconnected frameworks with these solvents. Acetone and THF, on the other 
hand, turned out to be unsuitable for the processing of the polymers under the established 
conditions. 
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a) Acetone : Chloroform b) MEK : THF 
 
   
    
c) MEK d) Ethyl acetate 
    
    
e) Acetone f) THF  
 
   
Fig. 4: Photographs depicting the macro- and microstructure of PLGA scaffolds fabricated 
according to the established protocol (a) and with alternative polymer solvents and 
n-heptane as extraction media (b-f). The arrow in (e) points to a mm-sized cavity 
(macrocavity) on the surface of the polymeric cylinder. 
When using acetone as an alternative polymer solvent, large cavities developed during 
polymer processing, which compromised the homogeneity of the generated polymer cylinders 
(Fig. 4e, 5e). In areas between these macrocavities (diameter > 1 mm), however, a 
macroporous framework was formed by condensed polymer bridges (Fig. 4e, 5e). Although 
the position of THF in the solvent plot is closer to the target mixture than that of ethyl acetate, 
the use of THF as the polymer solvent severely impaired scaffold macroporosity and pore 
interconnectivity (Fig. 4f, 5f). Furthermore, an incomplete extraction of the porogen materials 
was found in scaffolds fabricated with THF as the polymer solvent (data not shown). 
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a) Acetone : Chloroform  c) MEK e) Acetone 
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Fig. 5:  PLGA scaffold microstructures as observed by SEM. Scaffolds were fabricated according to 
the established protocol (a) and with alternative polymer solvents and n-heptane as 
extraction media (b-f). 
Macroscopic effects on MeO-PEG2PLA40 scaffolds processed with the MEK-THF-mixture 
(59:41 (v/v)), acetone and THF as polymer solvents were comparable to those observed for 
PLGA (Fig. 6). As found for the processing of PLGA, the best results were obtained by using 
the calculated thermodynamically similar solvent mixture (Fig. 6a,b). Processing with acetone 
as the solvent severely impaired the structural integrity of the resulting constructs as a result 
of extended phase separation. In the inner areas of the polymeric constructs, an almost 
complete phase separation was observed, which resulted in the formation of large polymer 
droplets instead of a continuous polymeric framework (Fig. 6c). MeO-PEG2PLA40 scaffolds 
fabricated with THF as the polymer solvent demonstrated a lack of macro- and microporosity 
(Fig. 6d) 
 
100 µm 100 µm 100 µm 
100 µm 100 µm 100 µm 
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a) Acetone : Chloroform b) MEK : THF 
 
 
  
c) Acetone d) THF 
  
Fig. 6: Macrostructure of MeO-PEG2PLA40 scaffolds fabricated according to the established 
protocol (a) and by using polymer solvents and n-heptane as extraction media (b-d). The 
inserted figure (c) shows solid polymer droplets that were formed in the inner areas of the 
scaffold. 
Table 3: Distance values and viscosity data for solvents and solvent mixtures tested in this study. 
∆ex represents the geometric distance of the solvent to the extraction media, n-heptane. 
Additionally, the kinematic viscosity (η) of the solvents and the reduced viscosity (ηred) of a 
PLGA solution (1% (m/v)) in the respective solvent is given. 
Solvent ∆geo ∆poly ∆ex δd η [mm2/s] ηred [cm3/g] 
Acetone:Chloroform (65:35) 0.0 0.0 10.3 16.3 0.3886 0.5321 
MEK:THF (59:41) 0.3 0.1 10.0 16.3 0.4643 0.5384 
       
Methyl ethyl ketone (MEK) 1.9 2.0 10.4 16.0 0.4545 --- 
Tetrahydrofurane (THF) 2.6 2.8 10.0 16.8 0.5077 --- 
Ethyl acetate 2.7 2.8 9.0 15.8 0.4699 --- 
Acetone 2.7 3.1 12.5 15.5 0.3714 --- 
 
2 mm 2 mm 
2 mm 2 mm 2 mm 
Chapter 4 Solvent Replacement 
- 111 - 
5. Discussion 
The interconnected porous microstructure of the scaffolds is generated during porogen 
extraction in warm n-hexane or n-heptane. Ideally, the porogen microparticle starts to melt 
shortly after the dispersion is brought into contact with the warm extraction medium. 
Subsequently, the molten triglycerides form a continuous phase that separates from the liquid 
polymer solution before the polymer solvent and the triglyceride phase are completely 
extracted by the extraction media. In other words, an interconnected porous network is only 
generated when the two liquid phases coexist for a sufficient amount of time before the 
polymer precipitates, forming condensed polymer sponges. Processing conditions that induce 
this phase separation were experimentally optimized for the acetone-chloroform-mixture 
(65:35 (v/v)). By using three-dimensional HSPs to theoretically determine a 
thermodynamically equivalent solvent mixture composed of ICH class 3 solvents, this solvent 
mixture was successfully replaced. Scaffolds exhibiting comparable macro- and 
microstructures were fabricated without any alteration of the other processing conditions. 
MEK, ethyl acetate, acetone and THF were also tested as polymer solvent alternatives due to 
their proximity to the target parameters (Fig. 3, Table 3). Scaffolds fabricated with  
MEK (∆geo = 1.9; ∆poly = 2.0) or ethyl acetate (∆geo = 2.7; ∆poly = 2.8) as the polymer solvent 
displayed only minor deformations and irregularities. Therefore, these solvents may be 
considered to be suitable solvent alternatives, requiring little adaptation of process parameters.  
THF (∆geo = 2.6; ∆poly = 2.8), which is located closer to the target than ethyl acetate, however, 
turned out to be an unsuitable substitute. The observed macro- and microstructures indicated 
that the phase separation was insufficient, most likely because of the considerable solubility 
of the triglyceride porogen in THF (data not shown). The macrocavities that were observed 
when acetone (∆geo=2.7; ∆poly=3.1) was tested as the polymer solvent, however, are indicative 
of an extended phase separation before polymer precipitation. Taken together, the HSPs 
proved to be a suitable means to systematically determine alternative solvents. The calculated 
distance alone, however, could not conclusively indicate whether a solvent is suitable for 
polymer processing or not (Table 3). 
Recently, we investigated the solubility of the porogen triglyceride mixtures in the 
investigated solvents (data not shown). Attempting to correlate the determined solubility with 
the HSPs of the corresponding solvent revealed that the solubility exclusively correlates with 
the dispersive solubility parameter (δd). The onset of triglyceride solubility was determined at 
a solvent δd value of 16.5 and triglyceride solubility increased with increasing values of δd. 
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Liao et al. measured the dissolution rates of PLGA particles in different solvents [29]. High 
dissolution rates were found in chloroform (δd = 17.8) and dichloromethane (δd = 18.2). In 
solvents with lower and higher values of δd, significantly lower dissolution rates were 
measured. This data underlines the dominant influence of the solvent’s dispersive solubility 
parameter on polymer and triglyceride solubility. With regard to δd, the solvents tested in this 
study are ranked as follows: δd (acetone) < δd (ethyl acetate) < δd (MEK) < δd (MEK:THF) = 
δd (acetone:chloroform) < 16.5 < δd (THF). This ranking correlates with the observed solvent 
effects on scaffold macro- and microstructure. THF (δd > 16.5) was unsuitable for scaffold 
fabrication most likely due to mixing with the molten triglyceride phase. Conversely, acetone 
(δd = 15.5) did not mix with the triglyceride phase, but due to its high ∆ex (Table 3),  the 
geometric distance to the parameters of the extraction media n-heptane, polymer solvent 
extraction was retarded, resulting in an extended demixing of polymer solution and 
triglyceride phase and subsequent formation of large cavities and polymer droplets  
(Fig. 4e, 5d). This effect was more pronounced when MeO-PEG2PLA40, a diblock copolymer 
of PEG and PLA, was processed. Generally, the processing of this diblock copolymer was 
more susceptible to parameter changes due to the polymer’s lower molecular weight and glass 
transition temperature [12]. 
Based on these observations, the three-dimensional HSPs, and especially the partial parameter 
δd, proved as useful means to compare solvents in terms of their suitability for the established 
scaffold fabrication technique. Nevertheless, minor differences in microstructure between the 
scaffolds fabricated with the acetone-chloroform-mixture (65:35 (v/v)) and the 
thermodynamically similar MEK-THF-mixture (59:41 (v/v)) were observed. Since thinner 
polymer bridges and smaller pore interconnections resulted from processing with the  
MEK-THF-mixture, this structural difference likely resulted from polymer precipitation at an 
earlier time point in the phase separation. As two thermodynamically similar solvent mixtures 
are compared, the viscosity of the polymer solution is the remaining parameter that influences 
the time point of polymer precipitation. Consequently, we determined the kinematic 
viscosities of both solvent mixtures and the reduced viscosities of PLGA (1% (m/v)) solutions 
in both solvent mixtures (Table 3). According to the solubility parameter theory, we obtained 
comparable reduced viscosities for PLGA in both solvent mixtures.  Substantial differences, 
however, were found for the kinematic viscosities of the pure solvent mixtures. In other 
words, a PLGA solution in the MEK-THF-mixture generally exhibits a higher viscosity than 
an equally concentrated solution in the acetone-chloroform-mixture. Together with data 
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gathered during another study (chapter 6), this viscosity difference was identified as the 
reason for the observed dissimilarity in scaffold microstructure. 
In summary, solvents exhibiting HSPs similar to those of the acetone-chloroform-mixture 
proved to be suitable for polymer processing into macroporous, interconnected scaffolds if 
their dispersive solubility parameter value was smaller than 16.5. Additionally, the geometric 
difference between the HSPs of the solvent and extraction media should not exceed a value of 
10.5 (Table 3). 
 
 
6. Conclusion 
This study described the replacement of two ICH class 2 solvents from an established scaffold 
fabrication procedure that makes use of two solvent dependant processes, namely solvent 
extraction and phase separation, to generate interconnected pore structures. The HSPs of the 
originally developed acetone-chloroform-mixture (65:35 (v/v)) were determined to 
systematically search for a thermodynamically comparable solvent mixture composed of class 
3 solvents using a geometric algorithm. A MEK-THF-mixture (59:41 (v/v)) resulted from this 
search as suitable alternative. Scaffolds were fabricated using this mixture as the polymer 
solvent, with n-heptane replacing n-hexane as the extraction media without any alteration of 
other processing parameters. These results proved that three-dimensional HSPs are a useful 
means to compare and replace solvents with regard to their thermodynamic properties in 
biodegradable polymer processing. By illustrating the class 3 solvents in a two-dimensional 
solubility parameter map, ethyl acetate and MEK were identified as further polymer solvent 
alternatives. THF, which was also tested as solvent alternative, proved to not be suitable, 
identifying the dispersive solubility parameter (δd) as the key parameter. Generally, this 
solubility parameter based strategy holds great potential as a tool to replace halogenated 
solvents from other polymeric release device fabrication procedures. 
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Abstract 
The three-dimensional Hansen solubility parameters (HSPs) of a polymer provide detailed 
information on the thermodynamic properties of the molecule. Based on these parameters, 
molecular interactions with solvents, other polymers, plasticizers, dyes and therapeutic 
substances can be estimated. In this way, the HSPs are a means for the development and 
optimization of polymer processing and drug encapsulation techniques. This study utilizes 
both theoretical (group contribution method) and experimental (solubility measurements and 
the determination of viscosity numbers) methods to determine the HSPs of poly(D,L-lactic 
acid) (PLA) and copolymers with glycolic acid and poly(ethylene glycol). Different group 
contribution data sets were compared and discussed. The absolute HSP values calculated by 
this method appeared unrealistically high. On the basis of the solubility tests, a solvent map 
was introduced to distinguish between solvents and non-solvents for the polymers. Detailed 
information on the polymer-solvent interactions was obtained from the viscosity 
measurements. 
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1. Introduction 
Lipophilic, biodegradable poly(α-hydroxy acids), such as poly(lactic acid) (PLA) or 
copolymers with poly(glycolic acid) (PLGA), are widely used in medical applications, 
ranging from sutures to orthopedic implants, cell carriers for tissue engineering, and depots 
for the long-term release of drugs, therapeutic proteins and genes [1-5]. Further attention has 
been drawn to block copolymers (MeO-PEG-PLA) synthesized from PLA and monomethyl 
ether-poly(ethylene glycol) (MeO-PEG), because they exhibit a reduced protein adsorption on 
their surfaces due to the hydrophilic PEG block [6,7]. Several biomedical devices, e.g. stealth 
nanoparticles and tissue engineering scaffolds have already been fabricated from MeO-PEG-
PLA [8,9]. Due to their insolubility in water, organic solvents are required to process these 
biodegradable polymers and have to be removed after processing to avoid any risk to human 
health and to the stability of the encapsulated substances. However, finding suitable and 
minimally toxic organic solvents for polymer and drug processing can be the subject of long 
lasting empirical approaches that may culminate in a less than optimal result. In order to find 
a more systematic approach, we investigated the suitability of using solubility parameters to 
circumvent the problem (Chapter 4). The solubility parameters of solvents, polymers, and 
drugs are accepted tools to describe the thermodynamic properties of these molecules and 
estimate their interactions during biomaterial processing and/or drug encapsulation [10-13]. 
Solubility parameters can provide the means for a tailored solvent selection for 
pharmaceuticals [14] or a systematic replacement of halogenated and other toxic solvents 
from polymer processing techniques (Chapter 4).  
Hildebrand defined the solubility parameter (δ) as the square root of the cohesive energy 
density (CED) of a non-polar, non-associated solvent [15]. The CED is the energy of 
vaporization (∆Ev) per molar volume (Vm), 
 
m
v
V
ECED ∆==δ . (1) 
This theory has been extended to include polar solvents, polymers and drugs. Along with 
these developments, the Hildebrand solubility parameter was decomposed into several terms, 
representing different contributions to the cohesive energy [16]. According to Hansen, the 
cohesive energy arises from dispersive interactions, polar (permanent dipole-dipole) 
interactions and hydrogen bonding forces [17,18]. Consequently, the Hildebrand parameter 
was divided into three partial solubility parameters (δd: representing dispersive interaction 
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forces, δp: polar (permanent dipole-dipole) interactions and δh: hydrogen bonding and induced 
dipole interactions) that account for the different cohesive forces: 
 
2222
hpd δδδδ ++=  (2) 
The three-dimensional Hansen solubility parameters (HSPs) give detailed information on the 
thermodynamic properties of a molecule and have already been determined for a variety of 
solvents [19].  
It is common knowledge that poly(α-hydroxy acids) dissolve in a variety of solvents ranging 
from highly toxic ones, e.g. chloroform or toluene, to water-miscible solvents with low 
toxicity like N-methyl-2-pyrrolidone (NMP), which has been used as polymer solvent to 
develop injectable drug delivery systems [20,21]. However, only a few studies have focused 
on the determination of the related solubility parameters for these systems. Siemann 
calculated a total solubility parameter value of 9.8 – 10.2 cal1/2cm-3/2 for PLA, which is equal 
to 20.1 – 20.9 MPa1/2, by means of high precision density measurements and viscosity 
numbers [22]. Other studies have estimated the three-dimensional HSPs of PLA or PGA using 
a molecular group contribution method [10,23-25]. Interestingly, different HSP values 
resulted from these estimations, although they all based on the same method. This 
inconsistency and the lack of experimental data for the HSPs for these polymers likely 
account for the limited success of solubility parameter based thermodynamic approaches to 
model drug encapsulation [26].  
This study reflects theoretical approaches and employs simple (in terms of instrumental 
equipment) methods to determine the three-dimensional HSPs of PLA, PLGA and PEG-PLA 
(MeO-PEG2PLA40). Polymer solubility parameters were calculated according to different 
group contribution methods and experimentally determined in solubility tests and from 
intrinsic viscosity data, according to a recently described method [27]. The theoretically and 
experimentally determined parameters are compared and discussed.  
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2. Materials and Methods 
2.1. Materials 
Poly(D,L-lactic acid) (PLA), Resomer® R206, Mw = 126 kDa (i.v. 0.6 dl/g) and 
poly(D,L-lactic-co-glycolic) (PLGA), synthesized from 75% lactic acid (LA) and 25% 
glycolic acid (GA), Resomer® RG756, Mw = 90 kDa (i.v. 0.6 dl/g) were kindly provided by 
Boehringer Ingelheim (Ingelheim, Germany). Monomethyl ether-poly(ethylene glycol)-block-
poly(D,L-lactic acid) (PEG-PLA; MeO-PEG2PLA40; MeO-240), Mn = 42 kDa, which consists 
of a 2 kDa MeO-PEG block covalently bound to a 40 kDa PLA block, was synthesized and 
characterized as previously described [7]. The polymer structures are depicted in Figure 1. 
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Fig. 1: Polymer structures. (a) Poly(D,L-lactic acid) (PLA); (b) Poly(D,L-lactic-co-glycolic acid) 
(PLGA); (c) Monomethyl ether-poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG-PLA; 
MeO-240). End-capped polymers were employed in this study (R: C2H5). 
n-Hexane, diethyl ether, 1,4-dioxane, tetrahydrofurane (THF), acetone, methyl ethyl ketone 
(MEK), ethyl acetate, ethanol, 2-propanol, benzyl alcohol, and dimethyl sulfoxide, which 
were used as solvents in the solubility study, were purchased in analytical grade from Merck 
(Darmstadt, Germany). Acetonitrile (Baker, Deventer, The Netherlands) as well as 
chloroform, methylene chloride, and N-methyl-2-pyrrolidone (Carl Roth GmbH & Co, 
Karlsruhe, Germany) were purchased in HPLC grade.  All solvents used for the viscosity 
measurements were purchased in analytical quality from Merck (Darmstadt, Germany), 
except acetone (Fluka, Taufkirchen, Germany). 
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The Hansen solubility parameters (HSPs) of the solvents are tabulated in the literature [19]. 
HSPs are additive components of the total Hildebrand value (δ) (Equation 2). Fractional 
parameters are mathematically derived from Hansen values and indicate the percent 
contribution that each Hansen parameter contributes to the Hildebrand value: 
 
hpd
d
df δδδ
δδ
++
=  
hpd
p
pf δδδ
δδ
++
=   
hpd
h
hf δδδ
δδ
++
=   (3) 
Thus, the sum of the three fractional HSP parameters is 1 or 100%.  
2.2. Group contribution method 
The Hansen solubility parameters (HSPs) for PLA, PGA, and PEG were estimated using 
group contribution methods according to Hoy and Hoftyzer and van Krevelen (HvK) 
[18,19,28]. These estimations are based on the repetitive structural unit of the polymers 
(Fig. 1). Details on these methods and the determination of the molar volume are described 
and discussed in the ‘results and discussion’ section.  
2.3. Solubility tests 
The solubility of the polymers in several solvents was tested using the following method: 
Stainless steel meshes of known weight (2 cm x 2 cm – mesh size: 0.5 mm) were coated with 
polymer by submerging the meshes in a concentrated solution (0.5 g/mL) of the polymer in 
acetone. After drying to constant weight, the loading with polymer was determined by 
measuring the weight increase of the meshes. To determine the polymer-solvent interactions, 
the polymer coated meshes were submerged in solvent (20 mL). After 1 min the meshes were 
removed from the solvent. Solvent droplets were removed from the meshes by intense 
shaking. The meshes were stored on Teflon®-coated paper and dried to constant weight under 
vacuum. The percent values, which are listed (Table 3), result from the amount of dissolved 
polymer normalized to the mass of polymer on the mesh. The values represent the average of 
2 to 3 independent measurements.  
2.4. Viscosity measurements 
The kinematic viscosity of the solvents was determined at 25°C using a calibrated Ubbelohde 
capillary viscometer (size: 0c, Schott AG, Mainz, Germany) with a Lauda S5 detector (Lauda, 
Lauda-Königshofen, Germany), which was connected to a Lauda PVS1 Processor Viscosity 
System with a PVS 2.28a analysis program (Lauda, Germany) (n = 10). 
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In order to determine the intrinsic viscosity of the three polymers (PLA, PLGA, PEG-PLA) in 
different solvents, we measured the kinematic viscosity of polymer solutions (c1 = 0.01 gcm-3 
and c2 = 0.005 gcm-3) at 25°C using the described measurement set-up. The polymer solutions 
were stirred in sealed glass flasks for at least 24 h before use. Prior to the measurement, the 
solutions were filtered through a 0.2 mm solvent resistant regenerated nitrocellulose 
membrane filter (Spartan 30/A from Schleicher & Schuell, Dassel, Germany). All solutions 
were prepared in triplicate and each solution was measured 2-3 times (n ≥ 6). The relative 
viscosity was calculated from the average kinematic viscosity of each solution: 
 
solvent
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The reduced viscosity resulted from: 
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Finally, the intrinsic viscosity was calculated from the reduced viscosity at c1 and c2: 
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2.5. Hansen solubility parameter determination of the investigated polymers 
Following a method described in the literature [27], the measured solubility and viscosity data 
were used to determine the polymer HSPs. This approach is based on the quantification of 
interactions between the polymer and a solvent. These interactions are reflected in certain 
properties of the polymer solution, such as the intrinsic viscosity or the solubility of the 
polymer in the solvent. With increasing interactions between a polymer and a solvent, the 
solubility and the intrinsic viscosity of the polymer in that solvent increase. Therefore, a 
multiplication of each solvent solubility parameter with the unity-normalized intrinsic 
viscosity [η]’i or a unity-normalized solubility value of a polymer in that solvent allows for 
the creation of a weighted solubility parameter,
 
reflecting the interaction between the polymer 
and the solvent. In this system, large values of this weighted parameter stand for high levels 
of interaction with the polymer. 
The Hansen solubility parameters of a polymer are calculated from the weighted partial 
solubility parameters according to the following equations (shown here for the unity-
normalized intrinsic viscosity): 
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Subscript index p designates the polymer and [η]’i is the normalized intrinsic viscosity of 
polymer in solvent i. Normalization of the intrinsic viscosity to unity was performed by 
dividing the intrinsic viscosity values by the maximum obtained intrinsic viscosity.  
This parameter determination using weighted solubility parameters has also been described as 
the projection of the tested solvents in a 3-dimensional system with the coordinates δd; δp; δh. 
For each solvent, a weighted interaction sphere is defined by the unity-normalized interaction 
value (intrinsic viscosity or solubility). The sphere, including all individual polymer-solvent 
interaction spheres, has a center point at the HSP coordinates of the polymer and its radius 
represents the radius of interaction of the polymer. 
To calculate this radius of interaction, the distance between the polymer HSPs (7) and the 
solvent coordinates were computed: 
      
222 )()()(4 hphipppidpdiiR δδδδδδ −+−+−=  (8) 
The highest value of Ri is considered the radius of interaction, R. 
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3. Results  
3.1. Theoretical estimation of solubility parameters (Group contribution 
methods) 
Group contribution methods have been extensively reviewed and data tables are provided for 
the estimated Hildebrand and Hansen solubility parameters of solvents, drugs and polymers 
[18,19,28-31]. The sets of group constants provided by Hoy and Hoftyzer together with van 
Krevelen seem to be the most widely used and comprehensive lists [28]. For polymers, the 
solubility parameters are generally estimated on the basis of the repetitive chemical units 
(Fig. 1). Thomasin et al. estimated a HSP triplet (δd; δp; δh) of 15.4; 8.5; 11.1 for PLA 
according to the Hoftyzer-van Krevelen (HvK) method (Table 1) [24].  
Table 1: Solubility parameters as estimated for different polymers using the group contribution 
methods according to Hoftyzer-van Krevelen (HvK) or Hoy. 
Polymer Solubility Parameters [MPa1/2]
 
Vm Method Ref. 
 δd δp δh δ
 
[cm3/mol] 
 
 
PLA 15.8 8.7 11.1 20.8 56.5a HvK [24] 
PLA 17.6 9.7 11.8 23.3 50.5 HvK / Fedors [25]  
PLA 16.0 8.8 11.2 21.4 55.7 HvK / general this study 
PLA 14.4 13.1 8.8 21.3 54.8 Hoy this study 
PLA (average)c 16.0 11.4 10.3 22.2 
  
 
PGA 19.4 14.4 14.3 28.0 34.1 HvK / Fedors [25]  
PGA 16.8 12.4 13.3 24.7 39.4 HvK / general this study 
PGA 13.7 15.3 12.7 24.2 39.3 Hoy this study 
PGA (average)c 16.6 14.9 13.5 26.0    
PLGA (75:25) 18.1 10.9 12.4 24.5 --- HvK / Fedors this study 
PLGA (75:25) 16.2 9.7 11.7 22.2 --- HvK / general this study 
PLGA (75:25) 14.2 13.6 9.8 22.0 --- Hoy this study 
PLGA (75:25) (av.)c 16.2 12.3 11.1 23.1    
PEG 17.8 11.1 9.1 22.9 37.0 HvK / Fedors [25]  
PEG (crystalline) 17.2 10.7 9.0 22.2 37.3b HvK / general this study 
PEG 16.7 10.1 8.8 21.4 37.5 Hoy this study 
PEG (average)c 17.2 10.6 9.0 22.1    
 
a
 Value calculated from the partial solubility parameters and the group contributions 
b
 Molar volume was calculated according to the general method [34] applying the contributions for crystalline substances 
c: Average values were calculated from the parameters estimated according to Hoy and HvK/Fedors 
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This method allows for the estimation of the three HSP terms, as follows (Table 2) [18,19,32]: 
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Fdi, Fpi and Ehi refer to the specific functional group contributions: van der Waals dispersion 
forces (Fdi), dipole-dipole interactions (Fpi), and hydrogen-bonding (Ehi). Vm represents the 
total molar volume. 
Table 2: Component group contributions as proposed by Hoftyzer and van Krevelen. Contributions to 
the molar volume are adapted from a general method [35] and from Fedors [33,34]. 
Group Component group contributions Contribution to Vm 
 
Fd 
[J1/2cm3/2/mol] 
Fp 
[J1/2cm3/2/mol] 
Uh 
[J/mol] 
general 
amorphous 
method 
crystalline Fedors 
-CH3 420 0 0 --- --- 33.5 
>CH2 270 0 0 16.37 14.68 16.1 
>CH- 80 0 0 --- --- -1.0 
>CH-CH3 --- --- --- 32.72 29.35 --- 
-COO- 390 490 7000 23 21.5 18.0 
-O- 100 400 3000 8.5 7.9 3.8 
 
The values estimated by Thomasin et al. could not be reproduced using the listed group 
contributions (Table 2), as it was not clear how the molar volume (Vm) of the PLA unit was 
estimated. One possible data set to estimate Vm is provided by Fedors (Table 2) [19,32-34]. 
Nevertheless, this estimation leads to a molar volume of 50.5 cm3/mol, which is much lower 
than the value used by Thomasin et al. (Table 1). Consequently, relatively high values (17.6; 
9.7; 11.8) resulted from this combination of HvK data with the Fedors Vm (HvK / Fedors) 
[25]. However, it is questionable whether a combination of the HvK data set and the Fedors 
data set is permissible or not. Consequently, we calculated the molar volume according to a 
general group contribution method presented in the literature [35]. This data set provides 
different values for crystalline or amorphous substances (Table 2). A molar volume of 
55.7 cm3/mol was calculated for PLA from the values listed for amorphous substances. 
Intermediate HSP results (16.0; 8.8; 11.2), approaching those published by Thomasin et al., 
resulted from the calculation employing this molar volume in combination with the HvK data 
set (HvK /general). Additionally, we calculated the HSPs of PLA (14.4; 13.1; 8.8) on the 
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basis of an additional data set proposed by Hoy according to the listed values and equations in 
[32]. According to van Krevelen [32], the average values from between the two methods, 
HvK and Hoy, can be regarded as representative. Due to the considerable differences of both 
methods and the described ambiguity concerning the appropriate molar volume for the 
Hoftyzer-van Krevelen method, we kept both parameter triplets for later comparisons. The 
HSP values for poly(glycolic acid) (PGA) and poly(ethylene glycol) (PEG) were also 
determined according to both the Hoftyzer-van Krevelen and the Hoy methods. The molar 
volume of the polymer’s repeating unit was estimated using both Fedors data and the general 
method (Table 1) for parameter estimation acccording to the HvK method. The HSPs of 
poly(lactic-co-glycolic acid) (PLGA) (75% lactic acid) were calculated from the HSP values 
estimated for PLA and PGA applying the following equations and listed in Table 1: 
 PGAdPLAdPLGAd δδδ ⋅+⋅= 25.075.0   
 PGApPLApPLGAp δδδ ⋅+⋅= 25.075.0  (9) 
 PGAhPLAhPLGAh δδδ ⋅+⋅= 25.075.0   
This way, the group contribution method can only be applied to determine the HSPs of 
random copolymers. For block copolymers such as MeO-PEG-PLA, however, this method is 
not suitable. 
A high variability in the solubility parameter values was observed when they were estimated 
using different data sets (Table 1). The HvK method, in combination with the Fedors 
parameters to estimate Vm, led to the highest solubility parameter values (δ), while the lowest 
values resulted from the Hoy method. This inconsistency and the fact that neither the 
molecular weight nor the end group modification are taken into account, are the main 
concerns with group contribution methods. Since the absolute HSP values obtained from 
different data sets varied strongly, the fractional parameters (δdf; δpf; δhf) that represent the 
relative values were computed and compared (Fig. 2). Differences were observed between the 
different polymers. Both group contribution methods, HvK and Hoy, resulted in a pronounced 
contribution of δp and δh to δ for PGA compared to PLA. This means that a solvent with a 
permanent dipole moment (δp) would interact stronger with PGA or PLGA than with PLA. In 
PEG the dispersive interactions are dominant. 
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Fig. 2: Fractional parameters (percent contribution that each partial Hansen parameter contributes 
to the whole Hildebrand value) as determined for different polymers according to both group 
contribution methods (Hoftyzer-van Krevelen (HvK) and Hoy). 
3.2. Experimental solubility parameter determination  
The determination of Hanson solubility parameters of a polymer by classical methods 
includes testing the polymer solubility in different solvents with known solubility parameters 
or measuring polymer-solvent interactions by different methods, such as inverse phase gas 
chromatography [19]. Generally, solvents that interact with the polymer are represented by 
points in a three-dimensional space surrounded by a sphere with a radius defined by the 
quality and quantity of interaction. The coordinates of the center point of another sphere 
containing all these individual spheres derived from solvent-polymer interactions finally 
represent the Hansen solubility parameters of the polymer. The precise determination of the 
polymer-solvent interactions is essential, but accomplished with laborious testing when based 
on solubility experiments. Alternatively, inverse phase gas chromatography requires costly 
equipment and a column made from the investigated polymer. Capillary viscosimetry, 
however, is a widely established experimental method in polymer chemistry labs. A new 
method determines the quality and quantity of the polymer-solvent interactions by measuring 
the intrinsic viscosities, normalized to unity, of the polymer in several solvents [27]. The 
HSPs of the polymer are finally calculated from the parameters of the solvents used and the 
determined interaction values (7). 
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3.2.1. Map-Projection of the determined solubility data 
The solvents used in these experiments were represented as points in a two-dimensional 
solvent map having as coordinates (δd; δp,h = 22 hp δδ + ) (Fig. 3a). 
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Fig. 3: Two-dimensional plot (solvent map) of the solvents used in this study. The plot is based on 
the Hansen solubility parameters of the solvents. The solvents are represented as 
points having as coordinates: a) (δd; δp,h = 22 hp δδ + ) or b) (δd,p = 22 pd δδ + ; δh). 
Symbols indicate the three best solvents for PEG-PLA (×) and PLGA (◊) as determined in 
the solubility tests.  
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This illustration is frequently used because it separates the dispersive interactions from 
interactions resulting from permanent and induced dipoles and hydrogen bonding. To 
illustrate the observed and documented solubility data, however, this plot was unfavorable as 
acetone and methylene chloride, two excellent polymer solvents, were located in different 
quadrants. Furthermore, no rule of thumb for suitable polymer solvents could be defined on 
the basis of this plot. Many non-solvents, such as n-hexane, diethyl ether, 2-propanol and 
ethanol are characterized by a dispersive partial solubility parameter below 16. The same 
characteristic, however, applies for good polymer solvents, such as acetone, acetic anhydride 
and ethyl acetate. Based on the observation that the polar solubility parameter is a major 
factor for PLA and PGA solubility, we defined a new plot using a combined parameter 
δd,p = 22 pd δδ +  and δh as axes  (Fig. 3b). In the new plot one solubility center is located 
around acetone and methylene dichloride. Other polymer solvents are located near this 
triangle and at higher values of δd,p. Furthermore, non-solvents are described by δd,p < 15.5 
and/or δh > 11. This way, a suitable solvent plot was defined to discriminate between solvents 
and non-solvents for poly(lactic acid) and the investigated copolymers. Moreover, further 
evidence is provided that δp significantly contributes to the solubility of the polymers. 
3.2.2. Solubility parameter calculation from solubility data 
In our first attempt to determine the polymer solubility parameters, we set up a new solubility 
screening method. Following the described viscosity method, the dissolution rate of the 
polymers from a stainless steel mesh was determined in several solvents as a measure of 
polymer-solvent interactions. This experiment was performed with PLGA and PEG-PLA 
(Table 3). Solubility data for PLA was adapted from product information provided by 
Boehringer Ingelheim (Table 3). For each polymer, the HSPs were calculated from the solvent 
solubility parameters and the corresponding normalized dissolving capacities (Table 4). 
Realistic solubility parameter values resulted from this method for all three polymers, 
indicating that the highest solubility of the polymers was measured in methylene dichloride 
and thermodynamically similar solvents. The determined HSP values were lower compared to 
those obtained by the group contribution method. For PLA and PEG-PLA, similar relative 
contributions of the partial parameters were computed. The pronounced influence of δp on the 
cohesive properties of PLGA, which was discussed above, however, was not reflected by the 
determined partial HSPs. 
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Table 3: Solubility parameters of solvents employed in the solubility tests and viscosity 
measurements; Solubility of the polymers and the determined intrinsic viscosities [η]. 
Solvent HSPs [MPa1/2] Solubility Tests [η] [cm3/g] 
 δd δp δh PEG-PLA PLGA PLAa PEG-PLA PLGA PLAb 
Paraffinic Hydrocarbons          
n-Hexane 14.9 0.0 0.0 3.5% 3.8%     
Aromatic Hydrocarbons          
Benzene 18.4 0.0 2.0      (63.0) 
Toluene 18.0 1.4 2.0   >17%   (59.0) 
Halohydrocarbons          
Methylene chloride 18.2 6.3 6.1 71.2% 23.0% >40%   (98.0)c 
Chloroform 17.8 3.1 5.7 52.7% 15.4% >40% 41.77c 94.80c 89.75c 
Ethers          
Diethyl ether 14.5 2.9 5.1 3.7% 3.7%     
1,4-Dioxane 19.0 1.8 7.4 14.0% 6.2% >30%   (69.0) 
Tetrahydrofurane 16.8 5.7 8.0 52.5% 9.2% >30% 28.66 61.29 62.08 
(62.5) 
Ketones          
Acetone 15.5 10.4 7.0 85.9% 23.3% >40% 28.11 56.05 53.45 
Methyl ethyl ketone 16.0 9.0 5.1 50.2% 14.6%  24.53 47.89 51.72 
Esters          
Ethyl acetate 15.8 5.3 7.2 68.3% 13.9%  26.48 39.49 42.87 
(66.0) 
Acids and Derivatives          
Acetic anhydride 16.0 11.7 10.2 20.0% 9.0%     
Propylene carbonate 20.1 18.0 4.1   >30%    
Alcohols          
Ethanol 15.8 8.8 19.4 3.6%  <1%    
2-Propanol 15.8 6.1 16.4 0.1% 3.9%     
Benzyl alcohol 18.4 6.3 13.7 2.8%      
N-Containing Solvents          
Acetonitrile 15.3 18.0 6.1  24.8% >30%   (31.0) 
N-Mehyl-2-pyrrolidone 18.0 12.3 7.2 13.9% 1.8%     
S-Containing Solvents          
Dimethyl sulfoxide 18.4 16.4 10.2   >30%    
 
a
 Product information on Resomer® (Boehringer Ingelheim, Ingelheim, Germany): Solubility of PLA (high viscosity) 
b
 Values in brackets were adapted from the literature [22] 
c
 The maximum value of intrinsic viscosity to which the other values were normalized 
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3.2.3. Solubility parameter calculation from viscosity data 
In a second attempt, the intrinsic viscosities of PLA, PLGA and PEG-PLA were determined 
in acetone, methyl ethyl ketone (MEK), ethyl acetate, tetrahydrofurane (THF) and 
chloroform. The weighted interaction capacities were computed by relating the measured 
intrinsic viscosities to the maximum intrinsic viscosity, which was determined for chloroform 
(Table 3). The HSPs that were calculated from the unity-normalized intrinsic viscosities and 
the corresponding solvent solubility parameters turned out to be nearly equal for the three 
investigated polymers (Table 4). 
Table 4: Experimentally determined solubility parameter values for different biodegradable polymers. 
Polymer Solubility Parameters [MPa1/2] R Method 
 δd δp δh δ
 
[MPa1/2]  
      
 
PLA 17.1 9.8 6.9 20.8  Solubilitya 
PLA (R 206) 16.6 6.3 6.5 18.9 4.7 Viscosity 
PLA 17.6 4.7 5.6 19.0 14.1 Viscosityb 
       
PLGA (RG 756) 15.7 7.5 8.8 19.4  Solubility 
PLGA (RG 756) 16.6 6.2 6.5 18.9 4.8 Viscosity 
       
PEG-PLA (MeO-240) 16.7 7.1 6.8 19.4  Solubility 
PEG-PLA (MeO-240) 16.5 6.3 6.6 18.9 4.6 Viscosity 
 
a
 Values calculated from the solubility data listed in the product information on Resomer® (see Tab. 3)  
b
 Values calculated from intrinsic viscosity data published in the literature [22] (data reprinted in Tab. 3) 
 
In good accordance with the solubility measurements, we measured almost equal polymer-
solvent interactions in THF, MEK, ethyl acetate, and acetone, four solvents with entirely 
different HSPs, for all three polymers (Fig. 4a, Table 3). 
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Fig. 4: a) Unity-normalized intrinsic viscosities determined for PLA, PLGA and PEG-PLA in 
different solvents (left axis). Disperse solubility parameter of the solvent (right axis). 
b) Fractional parameters of the solvents applied for the viscosity measurements. 
Consequently, the polymer solubility parameters were computed as the center point of these 
solvents and chloroform (Fig. 5a). We might achieve a better discrimination between the 
different polymers by additionally testing solvents or solvent mixtures nearer to the 
determined parameters. Nevertheless, a closer insight in polymer-solvent interactions was 
enabled by comparing the unity-normalized intrinsic viscosities (Fig. 4a; Table 3). The 
interactions between the tested solvents and PLA and PLGA decreased with decreasing values 
of δd. Acetone, which offered the highest absolute and relative value of δp (Fig. 4b), was the 
exception to this correlation. As already discussed, δp contributes significantly to the 
thermodynamic interactions between PLA and PLGA and suitable solvents. In accordance to 
the values derived from the group contribution methods, this effect was more pronounced in 
the case of PLGA than with PLA. This result again indicates that the relation of the partial 
solubility parameters was predicted well by the applied group contribution methods (Table 1, 
Fig. 2). Like PLA and PLGA, PEG-PLA showed strong interactions with chloroform (Fig. 
4a). In the other solvents, almost constant interactions were observed, most likely as an effect 
of the amphiphilic character of the diblock copolymer. To complete our studies, we calculated 
the HSPs for PLA on the basis of the viscosity data published by Siemann [22] (Table 3,4). 
The resulting parameters (17.6; 4.7; 5.6) were shifted towards a higher value for δd and lower 
values for δp and δh compared to the values obtained in our study (16.6; 6.3; 6.5) (Fig. 5b). 
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Fig. 5: Solvent map including PLA illustrating the viscosity measurements conducted in this study 
(a) or by Siemann [22] (solubility parameters of PLA were calculated as described in this 
study) (b).  
This parameter alteration mainly resulted from the different solvents that were used by 
Siemann. Toluene, benzene and methylene dichloride are solvents that are described as 
having high δd and low δp and δh values compared to acetone, ethyl acetate and MEK (Table 
3). Since Siemann’s study examined a wider solvent range, including acetonitrile, which is 
characterized by a very high δp value, a large radius of interaction (14.1 MPa1/2) resulted from 
this data (Table 4). This high value, exceeding the typical range of interaction radii (2-12 
MPa1/2) [27,36,37], nicely represents the broad range of solubility that was observed for these 
biodegradable polymers.  
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4. Discussion 
The solubility parameter estimations, solubility test and viscosity measurements revealed that 
the solubility parameters of biodegradable poly(α-hydroxy acids) likely range near the values 
of methylene dichloride and chloroform. The highest intrinsic viscosity, as a measure for the 
interactions between solvent and polymer, was measured in chloroform for all of the tested 
polymers. The solubility tests showed that methylene dichloride was the best solvent for the 
polymers. Additional viscosity measurements might clarify whether methylene dichloride or 
chloroform shows higher interactions with the polymers. The average HSP values of both 
solvents are (δd; δp; δh = 18.0; 4.7; 5.9) resulting in a Hildebrand solubility parameter (δ) of 
19.5, which is fairly close to the parameters calculated on the basis of the viscosity 
measurements (δd; δp; δh = 16.6; 6.3; 6.5 and δ = 18.9) (Table 4). The group contribution 
methods, however, led to much higher δp and δh values. Therefore, the experimentally 
determined parameters are considered more precise to those estimated by the group 
contribution methods. 
In order to display the suitability of a solvent, it was important to not only focus on the HSP 
triplet, but also to consider a combined partial parameter δd,p, resulting from δd and δp. 
Acetone, for example, proved to be a good solvent for the investigated polymers, although 
this solvent has a rather low δd, as is characteristic for most non-solvents (Table 3). However, 
acetone has a high δp. Therefore, the combination of δd and δp to a combined partial parameter 
δd,p versus δh seems to describe the solvent interactions with the polymers more precisely than 
the δd versus the δp,h plot. Figure 3b illustrates that the polymers were soluble in solvents with 
a δd,p exceeding 16 in combination with a δh smaller than 11. Only by introducing δd,p were 
we able to describe solubility trends for the investigated polymers.  
Generally, no significant differences between the different biodegradable polymers 
investigated in this study were consistently evident across all of the methodologies. The 
viscosity measurements, however, enabled a closer insight into polymer-solvent interactions. 
Fig. 4a shows a decrease in the intrinsic viscosity of the solubilized polymers with decreasing 
solvent δd values. However, this trend did not apply to acetone, probably due to the high δp 
value of this solvent, highlighting the importance of the polar interactions. Moreover, with the 
different solvents, we always found a lower unity-normalized intrinsic viscosity for PLGA 
than for PLA (Fig. 4a). This did not hold true for acetone in accordance with the increased δp 
values calculated by the group contribution methods. Accordingly, the group contribution 
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methods can be regarded as useful tools to estimate the fractional solubility parameters for the 
investigated polymers. The fractional parameters highlight the ratio of the partial parameters 
and allow for an easier comparison of the different solvents and polymers. The absolute HSP 
values including those obtained by averaging the different methods, however, appeared too 
high with regard to δp and δh (Table 1). Compared to the experimentally determined values, 
the HSP computation performed according to the HvK method using the molar volumes
 
approximated
 
according to the general method (HvK/general) fit best (Table 1).  
Among the tested methods, the viscosity measurements were found to be most suitable to 
investigate polymer-solvent interactions. As in many other methods, however, the resulting 
HSPs depend on the parameter range of the investigated solvents (Fig. 5). In a similar manner, 
the outstanding HSPs of propylene carbonate (20.1; 18.0; 4.1) influenced the HSPs of PLA 
calculated from the solubility data provided by Boehringer Ingelheim. Based on this data set, 
we determined a HSP triplet of (17.1; 9.8; 6.9) (Table 3); without propylene carbonate the 
values (16.7; 8.8; 7.2) would have been closer to those resulting from the viscosity study. 
Ideally, solvents near the borders of the solubility parameter maps should initially be included 
in any study attempting to determine a polymer’s solubility parameters. Thereafter, solvents 
located close to the determined center point of solubility should be tested for a precise 
determination of the solubility parameter values. 
 
 
5. Conclusion 
Theoretical and experimental methods were applied to determine the Hansen solubility 
parameters of PLA (Resomer® R206), PLGA (Resomer® RG 756) and PEG-PLA  
(MeO-PEG2PLA40).  HSPs computed according group contribution methods resulted in 
artificially high absolute values for δp and δh. The fractional parameters predicted by these 
methods, however, proved valuable. In solubility tests, the polymers demonstrated the best 
solubility in solvents offering a δd,p from 17 to 20 and a δh between 5 and 8. These parameters 
correlated well to the values calculated from the viscosity measurements. Although partial 
solubility parameter discrimination between the investigated polymers was not achieved, 
viscosity measurements provided detailed information on polymer-solvent interactions. 
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1. Introduction 
The engineering of functional tissues from isolated mammalian cells and macroporous three-
dimensional (3-D) biomaterial constructs holds great potential for applications in the medical 
and natural sciences [1-3]. A typical tissue engineering approach uses biocompatible, 
biodegradable, polymeric cell carriers (scaffolds) as an artificial extracellular matrix in 
combination with morphogenetic effectors (e.g. growth, differentiation and adhesion factors) 
and host cells that will respond to the signals of the effector substance [4]. In these attempts, 
the scaffolds play a pivotal role in cell seeding, proliferation, and new tissue formation in 
three dimensions [5]. Biodegradable poly(α-hydroxy acids), namely poly(D,L-lactic acid) 
(PLA) and copolymers (PLGA) with poly(glycolic acid) (PGA), are attractive and widely 
applied scaffolding materials with advantages over ceramics and metals because they degrade 
as the new tissues are formed [6,7]. In contrast to natural scaffolding materials, such as 
collagen, chitosan or chitin, these synthetic polymers can be supplied in reproducible quality 
and free of pathogenic or immunogenic organic residues. Depending on the mechanical 
properties of the tissue to be engineered and the extent of cell-material interaction desired, a 
suitable polymer has to be selected with regard to its degradation kinetic, composition and 
molecular weight. Consequently, materials with different characteristics, such as molecular 
weight, glass transition temperature and solubility, have to be processed into macroporous cell 
carriers with reproducible microstructure. Various techniques such as salt leaching [8,9], 
fibrous fabric processing [6], gas foaming [10], thermally induced phase separation [11] and 
several solid freeform fabrication techniques [12] have been developed to generate highly 
porous polymer scaffolds from biodegradable polymers. Despite the remarkable potential that 
some of these scaffolds have shown in attempts to engineer a variety of tissues, the “ideal” 
scaffold has not yet been developed [13,14]. The critical scaffold properties and demands on 
the fabrication procedure are the following: Architectural features, namely pore size and 
shape, pore wall morphology, porosity, surface area and pore interconnectivity, have to be 
controlled, as they have a direct impact on cell seeding, migration, growth, transport of 
oxygen, nutrients and wastes, and new tissue formation in three dimensions [15,16]. 
Therefore, control over architectural features, especially pore size and interconnectivity, 
during scaffold fabrication is essential. Fibrous fabrics, for instance, offer the ideal porosity 
and permeability. Their mechanical stability, however, is very low and only a few materials 
can be processed into such scaffolds. Salt leaching, on the other hand, is a technique that 
offers good control over the scaffold pore size and porosity. But even improved salt fusion 
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techniques result in scaffolds that lack sufficient pore interconnectivity [17,18]. The 
applicability of the processing method to a variety of polymers and polymer properties, which 
in large part predetermine the mechanical and degradation characteristics of a scaffold, is a 
further prerequisite for an ideal processing method. As some applications use experimental 
polymers that may contain hydrolysable functional groups [19] or require the encapsulation of 
growth factors during scaffold fabrication, an anhydrous fabrication technique is generally 
preferred. Moreover, lab-scale processing enables scaffold fabrication from small amounts of 
newly developed biodegradables and allows for the systematic testing of different 
architectural designs. Nevertheless, the fabrication should not be limited to a certain scaffold 
size. A recently published hydrocarbon templating technique met most of the described 
demands [20]. This technique was further improved with regard to biocompatibility and 
adaptability to low molecular weight block copolymers by our group [21]. The developed 
solid lipid templating technique uses solid lipid microparticles as porogens and non-
halogenated polymer solvents to process biodegradable polymers into macroporous scaffolds, 
providing an interconnected pore structure. Pore interconnectivity is obtained by adjusting the 
porogen melting point and extraction conditions to the polymer’s glass transition temperature. 
This way, a continuous molten lipid phase is formed during porogen extraction in warm 
n-hexane. Simultaneously, the polymer is precipitated at the phase boundary, leading to the 
formation of condensed polymer sponges [21].  
In this study, we demonstrate the wide applicability of this technique. Processing conditions 
are described to fabricate tissue engineering scaffolds from several biodegradable polymers of 
different compositions and molecular weights. The pore size of the scaffolds was controlled 
by the size distribution of the porogen microparticles. During processing, the rheological 
behavior of the dispersion prepared from the polymer solution and porogen microparticles has 
major influence on micro- and microstructure of the resulting scaffolds. We observed that 
highly viscous dispersions resulted in low interconnectivity, while a low viscosity caused 
macroscopic deformation of the scaffold as well as coarsening of the microstructure. To 
address this process parameter, oscillating rheological measurements were performed. Since 
the viscosity of the dispersion also depends on the size of the particles of the solid phase, we 
controlled the viscosity by increasing the polymer concentration with increasing porogen 
particle size. The suitability of the fabricated scaffolds was tested using an established 
cartilage cell culture model [22].  
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2. Materials and Methods 
2.1. Materials 
Poly(D,L-lactic acid) (PLA), Resomer® R207, Mw = 160 kDa, Tg = 54.8 °C, poly(D,L-lactic-
co-glycolic) (PLGA), Resomer® RG756, synthesized from 75% lactic acid (LA) and 25% 
glycolic acid (GA), Mw = 90 kDa, Tg = 50.7 °C, were kindly provided by Boehringer 
Ingelheim (Ingelheim, Germany). Monomethyl ether-poly(ethylene glycol)-block-poly(D,L-
lactic acid) (MeO-PEG2PLA40; MeO-240), Mn = 42 kDa, Tg = 43.0 °C, which consist of a 2 
kDa MeO-PEG block covalently bound to a 40 kDa PLA block, was synthesized and 
characterized as previously described [23]. 
The solid lipids that were used as porogen materials, namely Softisan® 154 and Witepsol® 
H42, were kindly provided by SASOL Germany GmbH (Witten, Germany). Methyl ethyl 
ketone (MEK), tetrahydrofurane (THF), ethyl acetate and n-hexane were purchased in 
analytical grade from Merck (Darmstadt, Germany).  
 
2.2. Methods 
2.2.1. Preparation of solid lipid microparticles 
Microparticles were prepared using a melt dispersion technique. 10 g of the solid lipid 
mixture prepared from Softisan® 154 und Witepsol® H42 (SH), either SH 1:1 or SH 2:1, 
were weighed in a poly(propylene) tube. After the addition of 7.5 mL water, the tube was 
heated to 65 °C. In a normal batch, eight tubes were processed in parallel. The mixture was 
emulsified by turning the tube upside down 10 times and subsequently cast into a larger 
volume (600 mL) of stirred, cold (15 °C) water. After 10 min of constant stirring, the 
hardened particles were collected by filtration, rinsed with cold water and dried under laminar 
air flow for 3 days. Finally, the microparticles were separated into different size ranges by 
sifting with sieves (100µm, 300µm, 500µm, 710µm) (Retsch GmbH & Co. KG, Haan, 
Germany).  
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2.2.2. Particle size analysis 
The size distribution of the prepared lipid microparticles was investigated using laser 
diffraction (Mastersizer 2000 Hydro 2000S, Malvern Instruments, Herrenberg, Germany) as 
follows: approximately 100 mg of lipid microparticles were directly added to the dispersion 
unit (Hydro 2000S), which was filled with an ethanol-water-mixture (68.2% (v/v), ρ = 0.89 
gcm-3, refractive index: 1.36). The particles were dispersed by stirring at 3000 rpm for 5 min. 
The volume based particle size distribution was calculated using the Fraunhofer 
approximation (Malvern Software V5.1). Further values provided by the software included 
the average particle size (d3,2) (surface weighted mean diameter) and specific surface area. 
The measurements were repeated in triplicate. 
2.2.3. Scaffold fabrication procedure  
To fabricate macroporous scaffolds from biodegradable polymers, we recently developed an 
anhydrous technique that uses solid lipid microparticles as porogens [21] (Fig. 1). 
 
dispersionpolymer
solution
porogen
microparticles
+
 
pretreatment in
n-hexane (0°C, tpre)
porous polymer
cylinder 
two step extraction in
n-hexane (T1, t1 / T2, t2)
 
Fig. 1: Schematic illustration of the Solid Lipid Templating procedure. An organic solution of the 
polymer is mixed with the solid lipid microparticles. The resulting dispersion is transferred 
into molds, which were submerged in warm n-hexane for polymer precipitation and porogen 
extraction subsequent to a pretreatment in cold n-hexane.  
Briefly, scaffold fabrication started with a polymer solution. Appropriate solvents and 
polymer concentrations are described in the results section. Under ice cooling, the polymer 
solution was mixed with the solid lipid microparticles. A polymer to porogen ratio of 1:4 
(w/w) was used if not otherwise stated. The homogeneous dispersion was transferred into 
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Teflon® molds (1.9 cm x 1.9 cm x 1.2 cm) with a cylindrical cavity 0.8 cm in diameter. After 
a pre-extraction treatment step in n-hexane at 0°C (MeO-PEG2PLA40: 90min; other polymers: 
15min), the molds were submerged in warm n-hexane to induce solvent extraction followed 
by the precipitation of the polymer and extraction of the lipid porogen. This procedure was 
carried out in two separate n-hexane baths of different temperatures T1 and T2 for t1 and t2 
with t1 + t2 = 30 min. The resulting porous, cylindrical polymer constructs were allowed to 
cool in cold (0°C) n-hexane and were removed from the molds. After drying under vacuum 
for 48 h, the constructs were cut into 2 mm slices, which were then described as scaffolds. 
Table 1 gives a summary of the applied processing conditions. 
Table 1: Porogen characteristics and processing parameters for the fabrication of scaffolds from 
different polymers. Porosity data of different PLGA (RG756) scaffolds was determined 
(mean ± standard deviation; n=3). 
Polymer Porogen 
material 
Size 
range 
 
d3,2 
 
Polymer
content  
Conc. 
(polymer 
solution)  
Extraction 
conditions 
Porosity  
 
Softisan 154: 
Witepsol H42 [µm] [µm] (w/w) [mg/mL] step 1 (T1; t1) 
step 2 
(T2; t2) [%] 
Pore size / 
Rheology         
PLGA (RG756) 2:1 100 - 300 200 20 % 330 52°C; 10’ 40°C; 20’ --- 
PLGA (RG756) 2:1 300 - 500 360 20 % 350 52°C; 10’ 40°C; 20’ --- 
PLGA (RG756) 2:1 500 - 710 590 20 % 365 52°C; 10’ 40°C; 20’ --- 
MeO-240 1:1 100 - 300 180 25 % 435 45°C; 10’ 35°C; 20’ --- 
Porosity 
        
PLGA (RG756) 2:1 100 - 300 200 20 % 330 52°C; 10’ 40°C; 20’ 90.4 ± 0.5 
PLGA (RG756) 2:1 100 - 300 210 15 % 265 52°C; 10’ 40°C; 20’ 91.5 ± 0.4 
PLGA (RG756) 2:1 100 - 300 210 10 % 185 52°C; 10’ 40°C; 20’ 94.1 ± 0.4 
Polymer type 
        
MeO-240 1:1 100 - 300 200 20 % 400 45°C; 10’ 35°C; 20’ --- 
MeO-240 1:1 300 - 500 400 20 % 410 45°C; 10’ 35°C; 20’ --- 
PLA (R207) 2:1 100 - 300 180 20 % 230 52°C; 10’ 40°C; 20’ --- 
PLA (R207) 2:1 300 - 500 255 20 % 250 52°C; 10’ 40°C; 20’ --- 
 
2.2.4. Microscopic assessment of scaffold macro- and microstructure 
The macrostructure of the porous polymer cylinders and scaffolds was examined using a 
zoom stereo microscope (Wild M7A, Wild Heerbrugg Ltd., Heerbrugg, Switzerland). The 
scaffold microstructure was visualized by scanning electron microscopy (SEM). For this 
procedure, samples were mounted on aluminum stubs with conductive carbon tape and coated 
with gold-palladium. All micrographs were obtained at 10 kV on a DSM 950 (Zeiss, 
Oberkochen, Germany). 
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2.2.5. Oscillatory rheological measurements 
The dispersions of porogen particles in polymer solution prepared during scaffold fabrication 
were characterized using a Physica MCR 300 rheometer (Anton Paar GmbH, Graz, Austria) 
with a 2.5 cm sandblasted steel plate according to the following protocol: Under ice cooling, 
the polymer solution was mixed with the solid lipid microparticles for 3 min. The mixture was 
transferred to the rheometer using a polypropylenes syringe and equilibrated at 5°C. The 
measurement gap was set to 2 mm. After 60 sec, the first frequency sweep (100 – 0.1 Hz) was 
measured at a displacement of 0.01% and a temperature of 5°C. A second frequency sweep 
(100 – 0.1 Hz at 0.01% displacement) at 5°C followed another equilibration period of 3 min. 
The parameters recorded during the second frequency sweep were analyzed to determine the 
complex viscosity (η’) of the dispersion. To compare different formulations, the values of the 
complex viscosity at 1Hz were interpolated. 
2.2.6. Determination of residual porogen material 
The detection of triglyceride residues inside the scaffolds was realized through modulated 
differential scanning calorimetry (MDSC). The samples were precisely weighed in non-
hermetic AutoDSC aluminum sample pans (TA Instruments, Alzenau, Germany). The sample 
pans were sealed using the sample encapsulating press (TA Instruments, Alzenau, Germany) 
and analyzed on a DSC 2920 equipped with a refrigerated cooling system and an autosampler 
(TA Instruments, Alzenau, Germany). An empty, sealed pan served as reference. 
All measurements were carried out between –20 °C and 120 °C. Typically, samples were 
equilibrated at –20 °C for 15 min and heated to 120 °C at a heating rate of 5 °C/min. After an 
isothermal phase of 15 min, samples were cooled to –20 °C at 5 °C/min. Finally, after another 
15 min isothermal phase, samples were again heated to 120 °C at 5 °C/min. A sinusoidal 
temperature modulation with a period of 60 s and temperature amplitude of 0.8 °C was 
applied to both heating cycles. 
The resulting thermograms (total heat flow of the second heating cycle) were analyzed for 
melting enthalpy (peak area) of the peak attributed to the melting lipid residuals located near 
the glass transition step of the polymer with the Universal Analysis for NT® software 
provided with the DSC system. 
2.2.7. Determination of scaffold porosity 
The porosity of the scaffolds was determined by measuring the dimensions and the mass of 
the porous polymer cylinders as obtained from fabrication (cylinder ends were cut away) [24]. 
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The skeletal density of the cylinder (ρ) was calculated from the mass (m), the diameter (d) 
and the height (h) of the cylinder: 
 
hd
m
⋅⋅
⋅
= 2
4
π
ρ  (1) 
The porosity (ε) was calculated from the density of the construct (ρ) and density (ρp) of the 
polymer (ρp(RG756) = 1.26 gcm-3): 
 
pρ
ρ
ε −= 1  (2) 
 
2.2.8. Chondrocyte cell culture 
Primary chondrocytes were isolated from full-thickness bovine articular cartilage by digestion 
with type II collagenase (CellSystem, St. Katharinen, Germany) as previously described [25] 
and resuspended in culture medium (DMEM) containing 4.5 g/l glucose (Life Technologies 
GmbH, Karlsruhe, Germany), 584 mg/l glutamine, 10% FBS (Life Technologies GmbH, 
Karlsruhe, Germany), 50 U/mL penicillin, 50 µg/mL streptomycin (Sigma-Aldrich Steinheim, 
Germany), 10 mM HEPES (Sigma-Aldrich Steinheim, Germany), 0.1 mM non-essential 
amino acids (Life Technologies GmbH, Karlsruhe, Germany), 0.4 mM proline (Sigma-
Aldrich Steinheim, Germany), and 50 µg/mL ascorbic acid (Sigma-Aldrich Steinheim, 
Germany). This medium was also used for cell seeding and cultivation.  
The cells were seeded in spinner flasks, as described elsewhere [22]. In brief, a cell 
suspension containing 5 x 106 chondrocytes per scaffold was stirred at 80 rpm in a humidified 
(37 °C / 5% CO2) incubator for two days to allow for cell attachment to the polymers. 
Cell-polymer constructs were transferred into 6-well plates (one construct and 6 mL culture 
medium per well) and cultured for three weeks on an orbital shaker at 50 rpm. Medium 
supplemented with different amounts of insulin (0 µg/mL, 0.05 µg/mL, 2.5 µg/mL) was 
completely exchanged three times per week. 
At the end of the culture period, each cell-polymer construct was weighed (= wet weight) and 
cut in half. One part was prepared as histological sample by fixing in 2% glutaraldehyde in 
PBS for 30 min and then in 10% formalin. The samples were embedded in paraffin and cross-
sectioned (5 µm thick). Deparaffinized sections were stained with hematoxylin and eosin 
(H&E) (C.I.: 45380, Sigma-Aldrich, Steinheim, Germany) for cells and safranin-O for 
glycosaminoglycans (GAG). The other half of the construct was used for biochemical analysis 
of the collagen content and GAG content [22].  
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3. Results 
3.1. Control of pore size during scaffold fabrication 
3.1.1. Porogen microparticle preparation  
The solid lipid templating technique described here uses triglyceride microparticles prepared 
from a mixture of two solid lipids, Softisan® 154 und Witepsol® H42, as pore forming 
templates [21]. Despite the principle of melting the porogen particles during extraction and 
simultaneous polymer precipitation to generate interconnected pore networks, the pore 
forming particles are intended as a means to control the pore size distribution in the resulting 
scaffolds (Fig. 1). Solid lipid microparticles ranged in size from 50µm to 1000µm and were 
fractionated by sieving. The following size ranges were collected for scaffold fabrication: 
100 - 300 µm, 300 - 500 µm and 500 - 710 µm. Figure 2 shows the particle size distribution 
within the three porogen classes, as determined by laser diffraction. The representative graphs 
depict narrow distributions characterized by D(0.5) values (the diameter below which 50% of 
the volume of particles are found) of about 210 µm (fraction: 100 - 300µm), 365 µm 
(fraction: 300 - 500µm) and 580 µm (fraction: 500 - 710µm) that corresponded to the d3,2 
(surface weighted mean) values (Table 1). 
10 100 1000 10000
particle size [µm]
0
50
100
 
Fig. 2: Differential and cumulative porogen microparticle size distribution of different sieve 
fractions. ?: 100 - 300 µm, ?: 300 - 500 µm, ×: 500 - 710 µm. Particles were 
prepared from the 2:1 mixture of Softisan® 154 and Witepsol® H42. 
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3.1.2. Influence of polymer concentration on the scaffold structure 
The solid lipid mixture consisting of two parts Softisan® 154 and one part Witepsol® H42 
(SH 2:1), which melted at 47°C [21],  was chosen as porogen material to process Resomer® 
RG756, a variety of PLGA with a glass transition temperature (Tg) of 50.7°C. This 
combination of polymer and porogen material with the porogen’s melting point located a few 
degrees below the polymer’s Tg was recently proposed as ideal [21].  
The parameters that were used to process PLGA (Resomer® RG756) are listed in Table 1. 
Ethyl acetate, which has been identified as a low-toxic solvent suitable for the generation of 
well interconnected pore structures in a previous study (chapter 4), was used as solvent for all 
polymers, except PEG-PLA. If not otherwise stated, the polymer to porogen ratio was 20% 
(w/w). The extraction conditions depend on the melting point of the porogen microparticles 
and Tg of the polymer. The initial extraction step was carried out in n-hexane heated to 52°C 
for 10min and extraction continued at 40°C for 20 min. This way, the swift melting of the 
porogen particles during extraction generates pore interconnections.   
During polymer processing, the rheological characteristics of the dispersion of porogen in the 
polymer solution have a major influence on the scaffold microstructure. In addition to the 
molecular weight and composition of the polymer and the type of polymer solvent, the 
concentration of the polymer solution influences the viscosity of the dispersion (Fig. 1). 
 
 
 
 
Fig. 3: Scanning electron micrographs of PLGA (RG756) scaffolds fabricated using 
different polymer concentrations. a) 380 mg/mL, b) 330 mg/mL, c) 300 mg/mL. 
Porogen particles were 100 - 300 µm in size. Scale bars represent 100 µm. 
Figure 3 depicts the dependence of the scaffold microstructure on the concentration of the 
polymer solution used for processing. The scaffolds were prepared from PLGA (Resomer® 
RG756) using SH 2:1 microparticles (100 - 300 µm) as porogens and ethyl acetate as the 
polymer solvent. Polymer processing at the highest concentration (380 mg/mL) resulted in a 
a) b) c) 
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scaffold microstructure characterized by interconnected pores in the shape of the porogen 
microparticles (Fig. 3). Lower polymer concentrations (330 mg/mL and 300 mg/mL), in 
contrast, resulted in a highly permeable network of well condensed polymer sponges. The 
structure achieved with the lower concentrations closely resembles natural spongy bone [26]. 
An excessive decrease in polymer concentration (300 mg/mL), however, resulted in a 
dispersion with low viscosity that partly ran out of the mold (Fig. 4a). The deformation of the 
resulting polymer cylinder was described by the difference in length between the top and the 
bottom of the resulting scaffold cylinder (Fig. 4b). Hardly any deformation was observed for 
scaffolds prepared from the 380 mg/mL and 330 mg/mL polymer solutions. A significant 
scaffold deformation, however, was found when the polymer concentration was reduced to 
300 mg/mL. Based on the data shown in Figures 3 and 4, a polymer concentration of 
330 mg/mL is suitable to process PLGA (RG756) with SH 2:1 microparticles (100 - 300µm) 
into macroporous scaffolds with a spongy microstructure. 
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Fig. 4: a) Macroscopic view of a deformed scaffold as a result of low dispersion viscosity. 
To characterize the deformation the length difference (∆l) is calculated. b) Length 
difference measured on PLGA (RG756) scaffolds fabricated from differently 
concentrated polymer solutions. Columns represent average ± standard deviation 
(n=4). Statistical significance (p < 0.01) is denoted by a . 
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3.1.3. Rheological characterization of the scaffolding dispersions  
The experiments conducted to determine a suitable polymer concentration highlighted the 
pivotal role of dispersion viscosity for the scaffolding process. To evaluate whether the 
empirical approach could be rationalized by a rheological characterization of the scaffolding 
dispersion, we applied oscillation rheology. On a control stress rheometer equipped with a 
plate-plate geometry, frequency sweep measurements were performed. The complex viscosity 
(η’) and the complex moduli, storage and loss modulus (G’ and G’’), were determined over a 
frequency range of 100 to 0.1 Hz. Figure 5 shows the frequency sweeps of the three 
dispersions with 300, 330 and 380 mg/mL PLGA. 
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Fig. 5: Rheological measurements of dispersion prepared from differently concentrated 
RG756 solutions and SH 2:1 microparticles (100 – 300 µm). Frequency dependence 
of the dynamic moduli (G’, G’’) and the complex viscosity (η’) of the dispersions at 
5°C. Rheograms 1, 2 and 3 (η’, G’, G’’) originate from a polymer concentration of 
300 mg/mL; Rheograms 4, 5 and 6 (η’, G’, G’’) correspond to a concentration of 
330 mg/mL; Rheograms 7, 8 and 9 correspond to 380 mg/mL. 
All systems displayed storage and loss moduli that were frequency dependant. Typically, 
increasing the oscillatory frequency increased both the storage and loss modulus, whereas the 
dynamic viscosity decreased. In all three formulations, the storage modulus (G’) exceeded the 
loss modulus (G’’) and the systems may accordingly be described as gels. The logarithm of η’ 
at 1Hz was determined as a measure of the dispersion viscosity. The resulting complex 
viscosities are shown in Fig. 6. 
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Fig. 6: Complex viscosity (η’) at 1 Hz of dispersion prepared from different combination of 
polymer type, polymer concentration and porogen microparticle size. Statistical 
significance (p < 0.05) is denoted by a . 
A value of 5.01 ± 0.22 was determined for the dispersion prepared from PLGA (RG756) in 
ethyl acetate (330 mg/mL) and SH 2:1 microparticles (100 - 300µm). For polymer processing 
using larger porogen particles, the polymer concentration was adapted to the surface area of 
the particles in order to match the complex viscosity to approximately 105 Pas at 1 Hz. Since 
an increase in average particle size results in a decrease in surface area, higher polymer 
concentrations were used in conjugation with larger particles (Table 1). The corresponding 
microstructures of the fabricated scaffolds are depicted in Figure 7. 
 
  
 
Fig. 7: Scanning electron micrographs of PLGA (RG756) scaffolds fabricated using 
porogen microparticles (SH 2:1) of different size ranges. a) 100 – 300 µm, b) 300 – 
500 µm, c) 500 – 710 µm. Scale bars represent 200 µm. 
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By adjusting the dispersion viscosity to values between 105.0 and 105.2 Pas, highly 
interconnected scaffolds were generated from PLGA (RG756). The complex viscosity values 
of the dispersions prepared from the high- and the low-concentration PLGA solutions (380 
mg/mL and 300 mg/mL) together with SH 2:1 microparticles (100 - 300µm) flank the 
viscosity range (Fig. 6) that was suitable range for scaffold fabrication from PLGA (RG756) 
dissolved in ethyl acetate. However, we found large standard deviations for dispersions with 
the low and intermediate PLGA concentration, 300 mg/mL and 330 mg/mL, respectively, as 
well as with large porogen particles. Hence a clear definition of a viscosity range 
distinguishing the optimal dispersion systems from non-optimal systems was not possible. 
Furthermore, a transfer of this viscosity range to considerably different polymer-solvent 
combinations was also not applicable. For the processing of MeO-PEG2PLA40 in a methyl 
ethyl ketone-tetrahydrofurane mixture, for example, a significantly higher viscosity proved to 
be optimal (Fig. 6). Correspondingly, optimal processing conditions for PLA (R207), a 
polymer with a higher molecular weight than PLGA (RG756), resulted in a dispersion 
characterized by a η’ about one order of magnitude lower than that for PLGA (RG756) (data 
not shown).  
The high variability in the viscosities of dispersions with low polymer content or high 
porogen particle size, however, seems to reflect the heterogeneity of their rheological 
behavior over the investigated frequency range. To describe this heterogeneity, we analyzed 
the relation between G’ and G’’ addressed by the loss factor (tan δ = G’’/G’) (Fig. 5). We 
observed that the loss factor first decreased and then increased during the frequency sweep in 
the case of the low viscosity preparations correlating to G’’. The more highly concentrated 
dispersion, on the other hand, showed a more or less linear correlation between G’’ and the 
oscillation frequency. The independent movement of porogen particles and polymer solution 
at low frequencies could provide an explanation for the heterogeneity observed for the less 
concentrated systems. Large non-linear frequency-dependent variations in G’’ were found for 
dispersions with 300 mg/mL PLGA, while these variation were only weak with 330 mg/mL, 
indicating a mainly homogeneous system. Almost no variations were found with 380 mg/mL. 
Thus, a suitable dispersion system should behave homogeneously over the investigated 
frequency range. However, if the dispersion contained very low amounts of solvent such as 
the 380 mg/mL PLGA system, non-desired pore structures as shown in Figure 3a result. With 
polymer of higher molecular weight, such as the PLA (R207), lower polymer concentrations 
and viscosities result in homogeneous behavior, while a lower molecular weight polymer, 
MeO-PEG2PLA40, appears to need higher viscosities. As can be seen in Figure 7, the porogen 
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size distribution determined the pore size distribution in the resulting scaffolds, while 
comparable spongy microstructures could be generated.  
3.1.4. Determination of lipid residuals in the scaffolds 
As shown in Figure 8, the described extraction conditions (Table 1) are capable for a 
successful extraction of the porogen microparticles independent of the size distribution. Less 
than one percent (lipid per scaffold (w/w)) of residual porogen material was found by DSC 
analysis of the scaffolds. 
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Fig. 8: Residual triglyceride content as determined by MDSC for PLGA (RG756) scaffolds 
fabricated using triglyceride microparticles of different size ranges. 
3.2. Processing of different polymers 
The processing parameters were determined and optimized for a variety of biodegradable 
polymers to demonstrate the versatility and adaptability of the solid lipid templating 
technique. First, MeO-PEG2PLA40, as a representative for low molecular weight polymer with 
glass transition temperatures slightly above body temperature, was processed into 
macroporous scaffolds with an interconnected pore structure. The scaffolds were fabricated 
from 20% (w/w) MeO-PEG2PLA40 dissolved in a methyl ethyl ketone-tetrahydrofurane-
mixture (59:41 (v/v)) (400 mg/mL) and 80% (w/w) lipid microparticles with a low melting 
point (SH1:1, Tm = 44°C) adapted to the low glass transition temperature of the polymer [21]. 
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Following a 90 min (tpre) pretreatment in cold n-hexane to stabilize the dispersion, the 
extraction conditions were adapted to the melting point of the porogen microparticles and the 
glass transition temperature of the polymer (step 1: 45°C for 10’; step 2: 35°C for 20’) 
(Table 1 and Fig. 9a). The pore size of the scaffolds corresponded to the porogen particle size 
(100 - 300 µm or 300 - 500 µm) (Fig. 9a,b). The processing conditions are listed in Table 1. 
 MeO-240  PLA (R207) 
 
 
100 – 300µm 100 – 300µm 
 
 
300 – 500µm 300 – 500µm 
Fig. 9: Scanning electron micrographs of scaffolds fabricated from several polymers using 
porogen particles of different composition and sizes. a) MeO-PEG2PLA40 / SH 1:1 
(100 - 300 µm), a) MeO-PEG2PLA40 / SH 1:1 (300 - 500 µm), c) PLA (R207) / SH 
2:1 (100 - 300 µm), d) PLA (R207) / SH 2:1 (300 - 500 µm). Scale bars represent 
100 µm. 
As a representative for high molecular weight biodegradables, PLA (R207) was processed. A 
sufficient dispersion viscosity was achieved with comparably low polymer concentrations 
(Table 1). Lipid microparticles with a melting point of 49°C (SH 2:1) were used as porogen 
material and extracted under the corresponding conditions (step 1: 52°C for 10’; step 2: 40°C 
for 20’). Control experiments (data not shown) revealed that the microstructure was not 
improved by using solid lipid microparticles with a higher melting point in combination with 
higher extraction temperatures. Control over the pore size was again achieved by varying the 
size of the porogen particles and adapting the amount of polymer solvent (Table 1 and 
Fig. 9c,d). 
a) c) 
b) d) 
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3.3. Control of scaffold porosity 
The use of different size porogens had no effect on the bulk porosity of PLGA (RG756) 
scaffolds (data not shown). A significant increase in porosity was achieved by reducing the 
polymer content during processing (Table 1). PLGA (RG756) scaffolds fabricated from 20% 
(w/w) polymer and 80% (w/w) solid lipid microparticles displayed a porosity of 90.4% ± 0.5. 
An increase in porogen content to 85% resulted in a porosity of 91.5% ± 0.4. A (high) 
porosity of 94.1% ± 0.4 was found for scaffolds fabricated with 90% pore forming 
microparticles (Table 1). The suitable processing conditions are also listed in Table 1. The 
increase of the porogen concentration necessitated a relative increase in the amount of 
polymer solvent to homogeneously disperse the porogen microparticles, resulting in 
decreasing concentrations of the polymer solutions.  
3.4. Scaffold testing: Engineering of cartilaginous tissue  
An established, insulin-dependent three-dimensional culture system to engineer cartilage from 
bovine chondrocytes [22] was transferred from fiber meshes to PLGA (RG756) scaffolds 
fabricated by solid lipid templating to test the applicability of the scaffolds. The scaffolds that 
were used in this experiment were fabricated with a polymer content of 17.5% using a 
porogen size of 100 - 300 µm. 
Generally, the resulting tissue quality was comparable to that typically obtained with fiber 
meshes. An insulin dependent tissue development and extracellular matrix production was 
indicated by increasing wet weights along with the dose of exogenously administered insulin 
(Table 2). After 3 weeks, the wet weight of scaffolds receiving no exogenous insulin was 
88.3 mg ± 18.9. The dry weight of an empty scaffold after fabrication was 10 mg. Scaffolds 
receiving exogenous insulin had a significantly higher weight. A 2.5-fold increase in the wet 
weight was found from 88 mg for controls to 211 mg for 2.5 µg/mL insulin. In all constructs, 
the cells deposited collagen and glycosaminoglycan (GAG), two major extracellular matrix 
(ECM) components of cartilaginous tissue. The ECM production was stimulated by 
exogenous insulin in a dose-dependent manner. The collagen fraction (amount of collagen per 
wet weight) was increased by insulin supplementation. No difference in the amount of 
collagen was identified between the two insulin concentrations (Table 2). The 
glycosaminoglycan (GAG) fraction also increased with the dose of supplemented insulin. The 
constructs of the insulin (2.5 µg/mL) group showed an approximately 2-fold higher GAG 
fraction than constructs receiving no insulin (Table 2). 
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Table 2: Construct characteristics of chondrocytes cultured on PLGA scaffolds for 21 days with and 
without supplementation of insulin. Data represents the mean ± standard deviation of four 
independent measurements. 
 control insulin [µg/mL] 
  0.05  2.5 
wet weight (ww) [mg] 88.3 ± 18.9 143.5 ± 8.9 211.4 ± 19.8 
collagen [mg] 1.9 ± 0.3 3.8 ± 0.4 5.6 ± 0.5 
collagen / ww [%] 2.2 ± 0.0 2.7 ± 0.0 2.7 ± 0.0 
GAG [mg] 2.1 ± 0.5 5.3 ± 0.8 9.0 ± 1.0 
GAG / ww [%] 2.4 ± 0.2 3.7 ± 0.4 4.3 ± 0.1 
 
The different amounts of GAG were also reflected in histological sections of the cell-polymer 
constructs, stained red with safranin-O for GAG. The extracellular matrix (ECM) of control 
constructs receiving no insulin stained unevenly for GAG (Fig. 10a). Even with the low 
insulin concentration (0.5 µg/mL), the staining was evenly distributed (Fig. 10b). The ECM in 
constructs receiving 2.5 µg/mL, showed strong positive staining for GAG up to the edge of 
the tissue (Fig. 10 c).  
 
 
 
 
   
a) no insulin b) insulin (0.05 µg/mL) c) insulin (2.5 µg/mL) 
Fig. 10: Histological cross sections of three week constructs (bovine chondrocytes on PLGA 
(RG756) scaffolds) cultured with (0.05 µg/mL and 2.5 µg/mL) and without the 
supplementation of insulin. GAG in extracellular matrix was stained red with 
safranin-O. 
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4. Discussion 
Macroporous biodegradable cell carriers (scaffolds) are a major component of many tissue 
engineering techniques, because they provide the three-dimensional matrix for cell seeding, 
migration, growth, and the new tissue formation [16]. Living tissue constructs, engineered in 
vitro or in vivo, hold great promise to advance basic research on tissue development and 
function, drug development and testing as well as transplantation and reconstructive medicine. 
To match the wide variety of applications and tissue types, scaffold properties have to be 
variable and easily adaptable in terms of mechanical stability, degradation kinetics and 
architectural features, such as pore size and shape. Since mechanical properties and 
degradation kinetics are predetermined by the scaffolding material, an appropriate fabrication 
technique must be capable of processing a wide range of polymers [27]. Additionally, the 
control of key architectural properties, such as high porosity and pore interconnectivity that 
result in a high scaffold permeability, has to be guaranteed by the scaffold fabrication 
technique. 
In the present study, we present the fabrication of macroporous scaffolds with high interpore 
connectivity from different biodegradable polymers using the recently developed solid lipid 
templating technique [21]. Solid lipid templating combines the principles of phase separation 
and porogen leaching to generate spongy scaffolds. Starting with a polymer solution and solid 
lipid microparticles, a dispersion is prepared and subsequently transferred into molds, which 
are finally submerged in warm n-hexane to precipitate the polymer and extract the porogens 
(Fig. 1). Mechanistically, the interconnected porous microstructure of the scaffolds is 
generated during this extraction step. Ideally, the solid lipid microparticles start to melt 
shortly after the dispersion is brought into contact with the warm extraction medium. 
Subsequently, the molten triglycerides form a continuous phase that separates from the liquid 
polymer solution before the polymer solvent and the triglyceride phase are completely 
extracted by the extraction media.  
Various biodegradable polymers that differ in molecular weight, glass transition temperature, 
composition and hydrophilicity were processed into scaffolds with a microstructure similar to 
that of spongy bone [26] by adapting the processing parameters to three different polymers 
(Table 1 and Fig. 9). Ideally, porogen materials with melting points a few degrees below the 
glass transition temperature of the polymers were chosen. Ethyl acetate was used to dissolve 
all of the polymers except MeO-PEG2PLA40, which was dissolved in a MEK-THF-mixture. 
The concentration of the polymer solution had to be adapted to the type and molecular weight 
Chapter 6 Solid Lipid Templating 
- 161 - 
of the polymer and the amount and average particle size of the solid lipid microspheres. The 
dispersion prepared from the porogen particles and the polymer solution optimally contains a 
sufficient amount of solvent to prolong the phase separation period until the final polymer 
precipitation in order to create highly interconnected frameworks (Fig. 3). At the same time, 
the dispersion has to be viscous enough to not flow out of the mold, which limits the amount 
of solvent (Fig. 4). Oscillatory rheological measurements were conducted to characterize the 
suitable viscosity range (Fig. 5). A complex viscosity of 105 Pas at 1 Hz was appropriate for 
the processing of PLGA (RG756). Different viscosity values were found to be optimal when 
polymers that differ in composition and/or molecular weight were processed. A higher 
dispersion viscosity than that described for PLGA (RG756) was required for the processing of 
a low molecular weight polymer. For the processing of high molecular weight polymers, 
however, a lower dispersion viscosity is suggested. Suitable viscosities for all of the 
investigated polymers were in the range from 104 to 106 Pas, as determined at an oscillation 
frequency of 1 Hz. A fine tuning of the scaffold properties based on the viscosity of the 
scaffolding dispersion, however, seems to be unsuitable. More detailed data may be provided 
by frequency sweeps and the analysis frequency dependent loss factor. Non-linear changes in 
the loss factor may indicate a non-homogeneous dispersion system, while a strictly linear 
correlation seems to be a sign for dispersion with an excessively high polymer content 
resulting in honeycomb-like scaffold pore structures. 
With the objective of controlling the pore size of the scaffolds by varying the size of the 
porogen microparticles, different sieve fractions were processed. The concentration of the 
polymer solution that was mixed with the microparticles was adapted to the surface area of 
the particles, so as to keep the dispersion viscosity constant and the rheological behavior 
unchanged (Fig. 6). This adaptation enabled the fabrication of spongy scaffolds with pore 
sizes ranging from 100 µm to more than 700 µm (Fig. 7 and 9). Control over this architectural 
property offers the possibility for systematic pore size testing and optimization focused on the 
individual application. For special applications, this technique allows one to fill a mold with 
dispersions containing different porogen size fractions to fabricate scaffolds with a pore size 
gradient [28]. In addition to the pore size, the scaffold porosity is another architectural 
property, which could be influenced by changing the polymer to porogen ratio. Porosities 
higher than 90% are achievable with this protocol.   
PLGA (RG756) scaffolds fabricated by solid lipid templating were tested using an established 
insulin-dependant cartilage cell culture system [22]. Bovine chondrocytes could be 
homogeneously seeded on the highly permeable polymeric scaffolds. After 3 weeks of in vitro 
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culture, considerable amounts of extracellular matrix were synthesized by the chondrocytes. 
Histological staining with safranin-O confirmed the presence of glycosaminoglycans (GAG), 
a cartilage-specific extracellular matrix component, in the scaffolds, albeit unevenly 
distributed. The supplementation of exogenous insulin dose-dependently increased the wet 
weight of the constructs as well as collagen and GAG production. Histological cross-sections 
of the constructs showed a strong and homogenous staining for GAG throughout the entire 
scaffold. Thus, the scaffolds proved to be sufficiently permeable to cells, nutrients and wastes 
and allowed for cartilage tissue development throughout the whole scaffold. In fact, the 
results were comparable to those obtained on fiber meshes, which represent the “gold-
standard” for porosity and permeability. No sign of dedifferentiation was observed, but rather 
the chondrocytes reacted strongly to the exogenous insulin stimuli, resulting in an improved 
tissue development. In summary, the generated microstructure proved to be suitable for 
cartilage tissue engineering and will be used for the cultivation of other tissue types in future 
experiments.         
As shown in this study, solid lipid templating is a technique that can be adapted to a variety of 
different polymers, offers easy control of architectural properties, such as pore size and 
porosity, and generates spongy frameworks characterized by high pore interconnectivity. In 
addition, this technique avoids aqueous media so that experimental polymers bearing 
hydrolysable functional groups or water-soluble polymers can be incorporated into the 
scaffolding. Further advantages of this technique include: First, bioactive proteins, such as 
growth factors, can be directly encapsulated as solids during scaffold fabrication and will be 
released when the scaffold is brought into contact with body fluids or cell culture medium. 
Second, there is no requirement for sophisticated equipment, unlike the textile technology, 
solid free-form fabrication or three-dimensional printing. Third, the porogen extraction is 
completed after 30 min, while conventional porogen leaching techniques require extraction 
times from hours up to days. Fourth, the scaffold can be directly fabricated into a specific 
anatomical shape with a mold. Fifth, the process can be easily expanded or automated for 
large-scale production. 
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5. Conclusion 
In conclusion, the solid lipid templating technique is capable of producing tailored cell 
carriers for a variety of tissue engineering and biomedical applications. Processing conditions 
can be adapted to a variety of polymers offering different physical, mechanical and 
degradation properties. Architectural properties, such as pore size and porosity can be easily 
controlled and pore interconnectivity can be guaranteed.  
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1. Introduction 
In living tissues, cells are embedded in a three-dimensional hydrated, insoluble network of 
proteins and glycosaminoglycans, the extracellular matrix (ECM). The ECM proteins interact 
with cells via integrins, which are heterodimeric receptors in the cell membrane, and regulate 
their development, migration, proliferation and metabolic function. In recent years, a variety 
of hydrogel materials have been explored for use as ECM substitutes. Both natural and 
synthetic hydrogel forming materials have been studied as a means of cell transplantation to 
reconstruct tissue defects. Natural materials, such as fibrin and especially collagen, are of 
interest since they are ECM proteins and susceptible to cell-triggered proteolysis by matrix 
metalloproteases, which enables cell invasion and migration and subsequent remodeling of 
the gel matrix. Furthermore, the highly ordered nanostructure of collagen plays an important 
role in various biological events in the body during development and regeneration processes. 
Consequently, these materials have been employed as cell carriers in numerous studies that 
were focused on the regeneration of various tissues, ranging from vascular grafts to bone  
[1-5]. However, natural materials have some inherent limitations in clinical use, primarily 
because of handling issues, the difficulty in engineering desired properties, the importance 
(necessity) of pathogen removal and immunogenicity. Alternatively, synthetic materials based 
on acrylamides, poly(vinyl alcohol) and poly(ethylene glycol) have been extensively studied 
as hydrogel cell carriers for tissue engineering applications [6,7]. In particular, injectable, in 
situ gel forming systems based on synthetic polymers offer several advantages beyond the 
ease of mass production and assurance of pathogen removal: a moldable material can fill the 
shape of any defect, may easily incorporate cells and therapeutic agents or signaling 
molecules (e.g. growth factors) and only requires a minimally invasive surgical procedure for 
placement. Different mechanisms, such as chemical or ionic crosslinking, solvent exchange, 
or gelation in response to temperature or pH change, may be involved in the in situ gel 
formation [8].  Particularly, thermally gelling hydrogels that employ the principles of (lower 
critical) phase separation are promising injectable ECM substitutes. Such hydrogel systems 
gel exclusively in response to a temperature increase above the lower critical solution 
temperature (LCST), the temperature at which phase separation starts and results in the 
formation of a gel. Poly(N-isopropylacrylamide) (PNiPAAm) exhibits an LCST of 
approximately 32°C but the hydrogels formed by unmodified PNiPAAm collapse 
substantially as the temperature is increased above the LCST. Copolymers containing small 
amounts of acrylic acid, poly(ethylene glycol), or hyaluronic acid, however, demonstrated 
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reversible gelation around body temperature without significant syneresis [9] [10]. This study 
aimed at the synthesis of a thermoreversibly gelling ECM substitute based on a PNiPAAm 
composite. Since PNiPAAm has to be crosslinked or copolymerized with hydrophilic 
macromolecules to obtain stable hydrogels, we intended to develop a PNiPAAm-gelatin 
conjugate. Gelatin, which is derived from collagen, was selected because it shows many 
collagen-like characteristics, but exhibits no antigenicity [11].  Like collagen, gelatin interacts 
with cells and is a substrate for matrix metalloproteinases. Gelatin is known to form gels 
below room temperature and liquefies upon heating. Crosslinked gelatin is widely used as a 
biological glue in surgical operations and a material for tissue engineering scaffolds [12,13]. 
By copolymerization with PNiPAAm, we aimed at developing a hydrogel that is a sol at room 
temperature and below is injectable and gels exclusively upon heating. These properties allow 
for easy preparation of homogenous cell suspensions and drug carriers in the liquid state of 
the hydrogel system that will gel upon injection into the body. Moreover, solutions of growth 
factors in the liquid form of the hydrogel could be stored at low temperatures, ready for use. 
In this study, we synthesized PNiPAAm-gelatin-conjugates from three different type A 
gelatins and characterized the educts and products by size exclusion chromatography and 
oscillating rheology. The LCSTs of the conjugates was determined by turbidity titration and 
differential scanning calorimetry. Bone marrow stromal cells and primary chondrocytes were 
encapsulated in the gel and cultivated to access cell viability in the matrix. 
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2. Materials and Methods 
2.1. Materials 
Type A gelatin with bloom values of 140 (G140, IEP = 8.5) and 300 (G300, IEP = 9.0) was 
provided by DGF Stoess AG (Ebersberg, Germany). G220, a type A gelatin with a bloom 
value of 220, was provided by Rousselot (Paris, France). 
N-acryloylsuccinimide, N-isopropylacrylamide (NiPAAm) and poly(N-isopropylacrylamide) 
(PNiPAAm), were purchased from Sigma-Aldrich (Deisenhofen, Germany). Ammonium 
persulfate (APS) and N,N,N',N’-tetramethylethylenediamine (TEMED) were obtained from 
Serva (Serva Electrophoresis GmbH, Heidelberg, Germany). 
  
2.2. Methods 
2.2.1. Synthesis of the PNiPAAm-gelatin conjugates 
500 mg of gelatin were dissolved in 50 mL phosphate buffer, pH 7.4, at 27°C and 10 mg of 
N-acryloylsuccinimide were added. The solution was stirred in the absence of light for three 
days at 27°C to introduce acrylol groups into the gelatin via acrylation of amine groups at the 
peptide chain termini or lysine side chains. Following dilution with distilled water to 600 mL, 
the solution was concentrated to 100 mL by ultrafiltration using a Vivaflow® 50 crossflow 
unit with a 50 cm2 30,000 Da nominal molecular weight cutoff (nMWCO) polyethersulfone 
membrane (Vivascience AG, Hannover, Germany). The diluting and concentrating process 
was repeated three times to remove unreacted acrylic acid. After the final concentrating step, 
the solution volume was raised to 250 mL with phosphate buffer and 1.25 g (G140) or 1.5 g 
(G220, G300) of N-isopropylacrylamide were added.  Polymerization was performed at 27°C 
under nitrogen atmosphere by the addition of 0.2 mL of 10% aqueous APS solution and 
0.2 mL of TEMED to the reaction mixture. After a 4 h reaction time under UV irradiation, the 
solution was diluted with distilled water to 600 mL. The diluted solution was concentrated to 
100 mL by using a Vivaflow® 50 crossflow unit (nMWCO: 30 kDa). The diluting and 
concentrating process was repeated three times to remove unreacted monomer and low 
molecular weight substances. After the final concentrating process, the PNiPAAm-gelatin 
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conjugates were obtained by lyophilization (Christ Beta 2-16, Martin Christ 
Gefriertrocknungsanlagen GmbH, Osterode am Harz, Germany) with a yield of about 75%. 
2.2.2. Investigation of the PNiPAAm-gelatin conjugates using gel-filtration 
chromatography (GFC) 
PNiPAAm-gelatin conjugates and the gelatins were investigated by GFC using a HPLC 
system with a LC-10AT pump, SIL-10ADVP autosampler, SPD-10AV UV-detector, and SCL-
10AVP controller (all from Shimadzu, Duisburg, Germany). Typically, 50 µL of each sample 
(20 mg/mL) were analyzed on a TSK-Gel G 4000SWX column with a TSK guardcolumn SW 
XL (Tosoh Bioscience, Phenomenex, Aschaffenburg, Germany). The mobile phase, which 
was also used as sample solvent, was a 0.05 M phosphate buffer, pH 6.8, supplemented with 
0.5% sodium dodecylsulfate (SDS) and 0.1 M Na2SO4. The chromatograms were recorded at 
a flow rate of 0.5 mL/min by UV detection at 210 nm. For data acquisition and analysis, the 
ClassVP 5.03 HPLC software (Shimadzu) was used.  
2.2.3. Size exclusion chromatography (SEC)   
To determine the molecular weight distribution of the PNiPAAm chains in the conjugates, the 
samples were digested with 3 mL of a papainase solution (4.5 U/mL in PBE buffer) 
(CellSystem, St. Katharinen, Germany) for two days at room temperature. After freeze drying, 
3 mL of HPLC-grade chloroform (Carl Roth GmbH, Karlsruhe, Germany) were added and the 
samples were shaken for 6 h. After centrifugation (Beckmann GS-15 R Centrifuge, Beckmann 
Instruments Inc., Fullerton, CA, USA) at 1500 rpm for 10 min, the supernatant was filtered 
through a solvent-resistant regenerated nitrocellulose membrane filter with a 0.2 µm pore 
diameter (Spartan 30/A, Schleicher & Schuell, Dassel, Germany). To determine the weight 
and number average molecular weight of the PNiPAAm chains, a 50 µL volume of the filtrate 
was analyzed by gel-permeation chromatography. The samples were separated by passage 
through a Phenogel 1000Å column (5µm, 300 x 7.8 mm, Phenomenex, Torrance, CA, USA) 
and a pre-column (Phenogel 5µm, 50 x 7.8 mm) using a Shimadzu 10AVP HPLC system with 
RID 10 refractive index detector and an SPD 10AVVP UV-detector. The columns were 
maintained at 35°C, using a CTO-10ACVP column oven. The mobile phase was HPLC-grade 
chloroform (Roth) at a flow rate of 0.9 mL/min. Chromatograms were recorded using RI 
detection. The molecular weights were calculated from the elution volume of poly(styrene) 
standards with narrow molecular weight distribution (Phenomenex) using the Class VP GFC 
software package included with Class VP 5.03 software (Shimadzu). 
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2.2.4. 1H-NMR spectroscopy 
For recording 1H nuclear magnetic resonance (1H-NMR) spectra, 30 mg of the conjugate, 
gelatin, or PNiPAAm were dissolved in 1 mL of D2O (Deutero, Kastellaun, Germany). 
Spectra were taken at 300.13 MHz on a Bruker Advance 300 spectrometer (Rheinstetten, 
Germany) equipped with a dual sample head and an autosampler. 
2.2.5. Determination of the lower critical solution temperature (LCST) 
To determine the lower critical solution temperature (LCST), which is the temperature at 
which the conjugates start to phase separate, we used both a spectrometric method and 
differential scanning calorimetry (DSC). Spectropic measurements were taken on a 941 
Spectrophotometer (Bio-Tek Kontron Instruments, Neufahrn, Germany). The transmittance of 
visible light (λ = 500 nm; path length = 1cm) through the conjugate or PNiPAAm solutions 
(5% (w/v)) was recorded as the hydrogel temperature was varied from 25 to 35°C at 
0.1 - 0.25°C/min. The initial break point of the curve on the plot of transmittance versus 
temperature indicates the LCST [14]. In addition, the LCST of the hydrogels was determined 
by differential scanning calorimetry on a DSC 2920 equipped with a refrigerated cooling 
system and an autosampler (TA Instruments, Alzenau, Germany). 15 µl hydrogel (5% (w/v) 
in PBS) were sealed in hermetic sample pans. A sealed pan containing 15 µl PBS served as 
reference. Sample and reference, were cooled to 0°C, kept isothermal for 10 min and then 
heated to 45°C at 2°C/min. The LCST was determined as the onset point of the endothermic 
signal upon heating using the Thermal Solutions for NT software provided with the system. 
All samples were repeated in triplicate. 
2.2.6. Rheometry studies 
The samples were dissolved in phosphate-buffered saline (PBS) (Gibco, USA) at a 
concentration of 5% (m/v) and the dynamic viscoelastic properties of the aqueous solutions 
were examined by using a rheometer (Rheolyst AR1000, TA Instruments, New Castle, DE, 
USA) with a 6 cm steel cone (1 degree). The dynamic moduli, G’ (storage modulus) and G’’ 
(loss modulus), were measured during the course of heating, cooling and heating. To this end, 
the samples were equilibrated at 5°C for 10 min, heated from 5 to 40°C, cooled down from 40 
to 5°C, and finally heated up again to 40°C. The heating and cooling rate during these 
experiments was 1°C/min. The measurements were performed at the observing frequency of 
1 Hz and a displacement of 4x10-3 rad. In addition, G’ and G’’ were also observed over the 
frequency range of 0.02 to 100 Hz at 5 and 40°C. 
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2.2.7. Viability testing 
Rat mesenchymal stromal cells (rMSCs) were harvested, selected and expanded as described 
in the literature [15]. After the first subculture, the rMSCs were encapsulated in 300 µL 
PNiPAAm-gelatin hydrogels in 12-well plates (Corning Costar, Bodenheim, Germany) by 
mixing equal volumes of an rMSC dispersion in medium (2x106 cells/mL) and a conjugate 
solution (10% CG140 (m/v)) (n = 4). After gelation in a humidified incubator (37°C, 5% 
CO2), 1 mL of medium containing 10% serum was added. Samples were harvested on day 3. 
In brief, after washing the gels with PBS, 0.25% trypsin/EDTA was added to digest the 
matrix. The cells were collected by centrifugation at 200 g at 4°C for 5 min. After washing 
the pellet with PBS, cells were again centrifuged and resuspended in PBS. Samples were 
analyzed with a FACSCalibur flow cytometer (Becton Dickinson, Heidelberg, Germany) 
before and subsequent to the addition of propidium iodide (1 µg/mL). Propidium iodide 
fluorescence was measured on the FL3 emission channel through a 670 nm longpass filter, 
following excitation with an argon ion laser source at 488 nm. For each sample, 2x104 cells 
were collected. To determine the number of dead cells in the samples, two parameter dot plots 
of cell size (forward scatter) versus propidium iodide (FL3) were used. The dot plots were 
divided into four quadrants. Dead cells were assessed by counting the events in the upper 
right quadrant. Prior to the addition of propidium iodide, less than 0.1% of cells appeared in 
this region. 
2.2.8. Chondrocyte cell culture 
Primary chondrocytes were isolated from full-thickness bovine articular cartilage by digestion 
with type II collagenase [16]. Cells were then resuspended in DMEM (Dulbecco´s Modified 
Eagle´s Medium; Life Technologies GmbH, Karlsruhe, Germany) supplemented with 0.4 mM 
proline (Sigma-Aldrich, Steinheim, Germany), 10 mM HEPES buffer (Sigma-Aldrich, 
Steinheim, Germany), 0.1 mM non-essential amino acids (Life Technologies GmbH, 
Karlsruhe, Germany), 50 U/mL penicillin, 50 µg/mL streptomycin (Sigma-Aldrich, 
Steinheim, Germany), 50 µg/mL ascorbic acid (Sigma-Aldrich, Steinheim, Germany), and 
10% FBS. The same medium was also used for cell cultivation. Chondrocyte-loaded 
hydrogels were prepared by mixing a cell suspension (5*106 chondrocytes per mL) with an 
equal volume of CG140 (10% (w/v)) in DMEM. 600 µl of chondrocyte-loaded hydrogel 
(1.5*106 cells) were filled into a glass ring (diameter: 8 mm), which was centered in a well in 
a 6 well plate. To gel the hydrogels, the plates were placed in a humidified incubator (37°C, 
5% CO2). After gelation, the glass rings were carefully removed and 6 mL of culture medium 
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containing either 0 or 2.5 µg/mL insulin were added. Finally, the well plates were placed on 
an orbital shaker (Stuart Scientific, Surrey, United Kingdom) at 50 rpm and cultured for 
14 days. The culture medium, containing either 0 or 2.5 µg/mL insulin, was changed every 
two to three days.  
Samples were prepared for histological analysis by incubation in 2% glutaraldehyde in PBS 
for 30 min and subsequent storage in 10% formalin. After careful rinsing, the formalin-fixed 
samples were embedded in Tissue Tek (Sakura Finetek, Torrane, CA, USA) and sectioned 
(10 µm) using a Microtome Cryostat (Microm, Walldorf, Germany). The sections were 
stained with hematoxylin and eosin (H&E) for cells and safranin-O for glycosaminoglycans 
(GAG) [17].  
 
3. Results 
3.1. Synthesis of PNiPAAm-gelatin conjugates 
PNiPAAm-gelatin conjugates were synthesized from three different type A gelatins with a 
bloom value of 140, 220 and 300. Synthesis started with the acrylation of gelatin in aqueous 
solution at pH 7.4. N-Acryloylsuccinimide reacted with free amine groups on both the chain 
terminus and the lysine residues of the peptide (Fig. 1).  
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Fig. 1: Synthesis of PNiPAAm-gelatin. a) Acrylation of gelatin by reaction with 
N-acryloylsuccinimide. b) Polymerization of NiPAAm. Please note that more than 
one amine group is derivatized per gelatin molecule. 
This way, several electron-poor double bounds were introduced per gelatin molecule. 
N-isopropylacrylamide was polymerized on the olefins, forming poly(N-isopropylacrylamide) 
chains linked to the gelatin backbone. All PNiPAAm-gelatin conjugates (CG140, CG220 and 
CG300) were soluble in water, PBS and cell culture medium and gave viscous solutions at 
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ambient temperatures. Figure 2a-c shows representative gel-filtration chromatograms of the 
gelatin types used in this study. All of the gelatins exhibited a wide molecular weight 
distribution. Gelatin G140 and G 300, which were provided by the same supplier, consist of 
mainly the same factions of high molecular weight peptide fragments. The different bulk 
properties, expressed by the bloom value, result from a significant fraction of low molecular 
weight peptide chains that is present in G140. G220, which is characterized by an 
intermediate bloom values, correspondingly exhibits a peak molecular weight located between 
the low molecular weight fraction of G140 and the high molecular weight fractions of G300. 
A representative chromatogram of the conjugate CG140 is shown in Figure 2d. A 
considerable increase in molecular weight was exhibited, while no considerable fractions of 
unreacted gelatin were visible. Between the different conjugates (CG140, CG220 and 
CG300), no differences were observed by GFC (data not shown).  
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Fig. 2: Molecular weight distribution of: a) gelatin G140, b) gelatin G220, c) gelatin G300 
and d) PNiPAAm-gelatin CG140 as obtained by gel filtration chromatography 
(GFC). 
Since the conjugate molecular weights seemed to reach or even exceed the exclusion limit of 
the column, the conjugates were digested to investigate the size distribution of the synthesized 
PNiPAAm chains for any differences between the conjugates. To this end, the PNiPAAm 
chains were extracted from the lyophilized, papainase-digested conjugates in chloroform. The 
filtered chloroform fractions were analyzed using size exclusion chromatography (SEC). As 
displayed by the chromatograms (Fig. 3), again no backbone size dependent differences were 
observed. Chromatograms 3a and 3c show the chloroform-soluble fractions of digested 
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gelatin G140 and G300, respectively. The two peaks (onset at 12 and 13 min) represent amino 
acids that were extracted by chloroform. The digestion enzyme papainase faintly appears 
(8.5 - 11 min) in the chromatograms. In chromatograms of the digested conjugates (Fig. 3b,d), 
however, a peak at 7.5 min indicates the presence of high molecular weight polymers, the 
PNiPAAm chains. Molecular weight analysis (calibrated with polystyrene standards) of these 
peaks resulted in Mw = 5.6x104 Da, Mn = 4.9 x104 Da (PI = 1.15) for CG300 and 
Mw = 4.7x104 Da, Mn = 4.1x104 Da (PI = 1.15) for CG140. Commercially available 
PNiPAAm was also exposed to papainase, lyophilized, extracted with chloroform and 
analyzed. This experiment confirmed that PNiPAAm was not affected by the digestion 
procedure (data not shown). 
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Fig. 3: Evaluation of the molecular weight distribution of the grafted PNiPAAm chains: 
Chromatograms obtained from the following papainase-digested samples by SEC: a) 
gelatin G140, b) PNiPAAm-gelatin CG140, c) gelatin G300 and d) PNiPAAm-
gelatin CG300. 
1H-NMR spectra of G140, CG140 and PNiPAAm, all dissolved in D2O are shown in Figure 4. 
The CG140 spectrum contained the characteristic peaks of PNiPAAm and the peaks attributed 
to G140. The peak at 4.7 ppm resulted from residual water in the conjugate and/or in D2O. 
The four characteristic peaks that can be found in the spectra of CG140 and PNiPAAm 
represent the –CH3 groups (1.2 ppm) in NiPAAm, the –CH2 (1.6 ppm) and –CH (2.0 ppm) 
groups in the PNiPAAm backbone, and the isopropyl –CH group (3.8 ppm) in NiPAAm. 
These NMR data are consistent with both the chemical structure of the macromolecules and 
other published reports [18,19]. 
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Fig. 4: 1H-NMR spectra of a) gelatin G140, b) PNiPAAm-gelatin CG140, c) PNiPAAm in 
D2O. 
3.2. Gelation of the conjugates on heating 
At room temperature, aqueous solutions of the conjugates (typically: 5% (m/v) in PBS) were 
colorless, transparent and liquid. When heated to 37°C, the conjugate solutions turned into 
stiff, white-colored opaque hydrogels without any volume change and loss of water (Fig. 5). 
PNiPAAm solutions, however, exhibited a considerable amount of collapse and released a 
large fraction of water. The photographs depicted in Figure 5 were taken 6 h after gelation in 
an incubator. 
CG140 CG220 CG300 PNiPAAm
 
Fig.  5: Photographic images of thermogelled PNiPAAm-gelatin conjugates and PNiPAAm 
(concentration: 5% (m/v)) obtained 6h after gelation at 37°C. 
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The lower critical solution temperatures (LCSTs) of the thermoreversible gelling conjugate 
solutions (5% (m/v) in PBS) were determined by both a spectroscopic method and differential 
scanning calorimetry (DSC) [14]. By measuring the effect of temperature on the transmittance 
of visible light (λ=500 nm) through the conjugates, LCSTs of around 31°C were determined 
for the conjugates and PNiPAAm (Table 1). For all substances, a sharp phase transition was 
recorded, spanning approximately 0.6°C. The LCSTs determined are in agreement with the 
LCST published for PNiPAAm [14,20]. Similar values resulted from the LSCT determination 
using DSC. Repeated heating and cooling cycles had no effect on the phase transition 
temperature of the conjugates, indicating the thermoreversible properties of the hydrogels. 
Compared to the photospectrometric method, the calorimetric method can be automated and 
might be advantageous for routine measurements.  
Table 1 Lower critical solution temperature (LCST) of the synthesized gelatin-PNiPAAm conjugates 
and PNiPAAm, as determined by photospectrometry and differential scanning calorimetry 
(DSC).   
Hydrogel LCST [°C] 
 Photospectrometry DSC 
CG140 30.8 ± 0.2 30.2 ± 1.2 
CG220 31.1 ± 0.2 30.2 ± 0.5 
CG300 31.2 ± 0.0 29.8 ± 1.9 
PNiPAAm 30.9 ± 0.3 28.1 ± 2.8 
 
3.3. Rheological behavior of PNiPAAm-gelatin conjugates 
Figure 6 shows the frequency dependence of the dynamic moduli, storage (G’) and loss (G’’) 
modulus, observed on the PNiPAAm-gelatin conjugate solution (5% (w/v) in PBS) at 
characteristic temperatures. At a low temperature (5°C) and a mid-temperature (20°C) (data 
not shown) the loss modulus G’’ was larger than the storage modulus G’ and both dynamic 
moduli increased with the oscillating frequency in the frequency range from 0.02 to 80 Hz. 
Typically, this rheological behavior is attributed to a sol. At higher frequencies, a shear-
induced destruction of the system was observed. In contrast, at a temperature (40°C) above 
the LCST the dynamic moduli showed much larger values than those at temperatures below 
the LCST and remained constant over a wide range of oscillatory frequencies, indicating a 
gelled, rigid system. Correspondingly, G’ significantly exceeded G’’. 
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Fig. 6: Frequency dependence of the dynamic moduli (G’ and G’’) of the PNiPAAm-gelatin 
conjugate CG 140 (5% (w/v) in PBS): a) Storage modulus (G’) at 5°C, b) loss 
modulus (G’’) at 5°C, c) loss modulus (G’’) at 40°C and d) storage modulus (G’) at 
40°C. 
 
Representative plots of the dynamic moduli as well as the phase angle (δ) as a function of 
temperature are shown for CG140 (5% (w/v) in PBS) in Figure 7. 
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Fig. 7: Temperature dependence of the dynamic moduli (G’, G’’) and phase angle of the 
PNiPAAm-gelatin conjugate CG 140 (5% (w/v) in PBS): a) Storage modulus (G’), 
b) loss modulus (G’’) and c) phase angle. 
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Upon heating from 5°C to 30°C, both the storage and the loss modulus only decreased about 
one order of magnitude. Additionally, the loss modulus (G’’) was higher than the storage 
modulus (G’) along this temperature range, indicating that even at low temperatures the 
conjugate solution did not form a gel. Correspondingly, a phase angle of 45° was measured at 
5°C, which increased to 80° upon heating. This rheological behavior of the conjugate is 
indicative for an almost complete quenching of the rheological properties of gelatin by the 
PNiPAAm chains.  A solution of the gelatin G140 (5% (w/v) in PBS), however, did form a 
gel at 5°C, which was characterized by a phase angel of 1° at 5°C and a G’ exceeding G’’ by 
about two orders of magnitude. This gelatin gel liquefied at 27°C, which was accompanied by 
the characteristic cross-over of the moduli and an increase of the phase angle (data not 
shown). When the temperature of the conjugate (CG140) solution was further increased, a gel 
was formed, as indicated by an increase of the dynamic moduli and the typical cross-over of 
G’ and G’’ at a temperature near the determined LCST. Correspondingly, the phase angle 
dropped below 10°. During the temperature increase from 30°C to 40°C, the storage modulus 
(G’) increased by four orders of magnitude. 
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Fig. 8: Thermoreversible rheological behavior the PNiPAAm-gelatin conjugate CG 140 (5% 
(w/v) in PBS): G’ (?) and G’’ (?) on the first heating cycle (5-40°C), G’ (?) and 
G’’ ( ) on cooling (40-5°C) and G’ (?) and G’’ (◊) on the second heating cycle 
(5-40°C). 
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With the objective of demonstrating the reversibility of the phase transition and 
thermogelation, the dynamic moduli were recorded during a heating, a cooling and another 
heating cycle (Fig. 8). During the three cycles, the curves were almost identical; note that G’ 
and G’’ reached exactly the same values after the first and the second gelation and no 
syneresis was observed. Again, conjugate gelation was only observed at temperatures above 
30°C and not on cooling. 
3.4. Viability test  
Rat marrow stromal cells (rMSCs) were encapsulated in the hydrogels and cultivated for 
3 days. After 3 days, the cells were isolated from the hydrogels. Dead cells were stained with 
propidium iodide and counted by a flow cytometer. 11.7% ± 1.4 of the counted cells were 
fluorescent, indicating that around 90% of the encapsulated rMSC were viable after 3 days of 
culture and the isolation procedure.     
3.5. Chondrocyte cell culture  
3.5.1. Chondrocyte cell culture  
To test the applicability of the developed conjugates in tissue engineering, bovine 
chondrocytes were encapsulated in the thermogelling matrices. After 14 days of cultivation, 
viable extracellular matrix-producing chondrocytes were found encapsulated in CG140 
hydrogels (Fig. 9). Without the supplementation of insulin, only a few of the chondrocytes in 
the inner areas of the hydrogel produced a GAG (glycosaminoglycan)-rich extracellular 
matrix, stained red with safranin-O (Fig. 9a). Insulin supplementation (2.5 µg/mL) over 
14 days, however, induced a considerably increased production of GAG. As can be seen from 
the photomicrographs, the GAG production originates from the encapsulated cells (Fig. 9b). 
As a result of the low cell density, which has to be increased in future experiments, the 
chondrocytes lay isolated and not in lacunae, which are typical for mature cartilaginous tissue. 
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a) w/o insulin 
 
  
 
  
b) 2.5 µg/mL insulin 
 
 
 
Fig.  9: Safranin-O/fast green-stained histological cross-sections of two week constructs, 
bovine chondrocytes encapsulated in thermogelled CG 140 (5% (w/v) in medium), 
grown in culture medium with 10% FBS: a) without supplementation of insulin, 
b) supplementation of 2.5 µg/mL insulin. GAG-rich extracellular matrix appears red, 
other extracellular matrix components are stained green. The large image (original 
magnification x100) represents the marked section in the small image (x4). 
1mm 
1mm 
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4. Discussion 
With the objective of developing an injectable extracellular matrix (ECM) substitute, we 
synthesized a conjugate of gelatin, a protein derived from the natural extracellular matrix 
protein collagen, and poly(N-isopropylacrylamide) (PNiPAAm), a polymer offering unique 
thermoresponsive phase transition characteristics with a LCST slightly below body 
temperature. Hoffman and co-workers first applied PNiPAAm-based polymers to injectable 
drug delivery systems and other functional matrices for biomedical applications [6,21-23]. By 
copolymerization with other polymers, several thermogelling biomaterials for cell 
encapsulation were developed [9,10]. Gelatin, the other component of the conjugate, is known 
as a cell adhesive matrix but is soluble in water at physiological temperature. Therefore, 
various insolubilization techniques, mainly crosslinking procedures, have been applied to 
make use of gelatin as an ECM substitute in tissue engineering devices [24-26]. Evidently, 
these techniques are often not suitable to in vivo gelation due to the toxicity of the available 
crosslinking agents. Ideally, the grafting of PNiPAAm chains to a gelatin backbone would 
change the rheological properties of gelatin in such a way that gelation of conjugate solutions 
occurs on heating and not on cooling, which would be typical for gelatin hydrogels. 
Additionally, the gelatin backbone would support the formation of a stable, non-shrinking 
hydrogel, as linear PNiPAAm hydrogels alone collapse at body temperature [20]. Two other 
research groups have recently synthesized similar conjugates [10,27,28]. Matsuda and co-
workers synthesized PNiPAAm-gelatin conjugates from a multiply derivatized 
dithiocarbamylated low molecular weight gelatin (9.5x104 Da) by iniferter-based 
photopolymerization. They successfully employed their conjugates as a matrix for cartilage 
tissue engineering [29,30]. Cell viability inside these conjugates strongly depended on the 
concentration of PNiPAAm-gelatin and the molecular weight of the PNiPAAm graft chain. 
Acceptable viability was only found for a gel prepared at low concentration (5%) of the 
conjugate with high molecular weight PNiPAAm graft chains (1.3x105 Da) [29]. Yoshioka et 
al. synthesized the conjugate from acrylated gelatin by a thermally induced polymerization of 
NiPAAm that is similar to our approach. The resulting conjugate demonstrated gelation upon 
either heating or cooling. Unfortunately, no information was provided on the molecular 
weight of the gelatin used and the synthesized conjugate [27]. 
Based on the synthesis described by Yoshioka et al., we synthesized PNiPAAm-gelatin 
conjugates from high molecular weight type A gelatins (Fig. 2). The investigated gelatin types 
showed a broad molecular weight distribution, characteristic for gelatin, with an onset 
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retention time of 12 min, corresponding to a molecular weight (Mw) of more than 4x105 Da. 
While no details are provided in the literature concerning the pH, we kept the pH at 7.4 during 
acrylation and polymerization by using phosphate buffer as the reaction medium. The 
synthesis led to high molecular weight conjugates of about 106 Da or more. For a more 
detailed analysis of the conjugates, the molecular weight of the grafted PNiPAAm chains was 
investigated after conjugate digestion with papainase. This procedure allows for the 
characterization of the PNiPAAm chains that had been formed at the gelatin backbone under 
the conditions of conjugate preparation. To our knowledge, no other author has performed this 
characterization step in connection to these conjugates. Molecular weights of approx. 
5x104 Da were determined for PNiPAAm, similar to those obtained by Ibusuki et al. [29,31]. 
The theoretical gelatin content of the conjugates was 28.6% (CG140) and 25% (CG220, 
CG300). This gelatin content seems to be sufficient for e.g. cartilage tissue engineering, since 
a successful product with a similar gelatin content was described in the literature [30,31]. 
The PNiPAAm-gelatin conjugates exhibited a LCST of around 31°C (Table 1) and formed 
form-filling, stiff hydrogels at physiological temperature without any loss of water (Fig. 5). 
Figure 5 also depicts the collapse of a hydrogel formed by linear PNiPAAm chains of similar 
molecular weight as the grafted chains. Similar phenomena were observed for crosslinked 
PNiPAAm-gelatin conjugates or mixtures of gelatin and PNiPAAm (data not shown). In 
contrast to PNIPAAm, complete precipitation was not obtained for the developed high 
molecular weight PNiPAAm-gelatin conjugates, suggesting that, although PNiPAAm chains 
collapsed at temperatures above LCST, gelatin molecules appeared to hinder intramolecular 
aggregation, thus avoiding the complete precipitation in the diluted state at the investigated 
concentration (5% (w/v)). 
The rheological characterization of the synthesized conjugates revealed that the gelatin is 
ideally masked by the grafted PNiPAAm chains. Using oscillating rheological measurements, 
the real and imaginary parts, G’ and G’’, as well as the phase angle of the complex shear 
modulus are examined. The observed G’ and G’’ represent the elasticity term and the 
viscosity term of the material at the oscillatory frequency. A solution of CG140 (5% (w/v) in 
PBS) was a viscoelastic fluid (G’ < G’’ and δ > 45°) at temperatures below the LCST (Fig. 6 
and 7). At temperatures above the LCST, it behaved as viscoelastic solid (G’ > G’’ and 
δ < 45°). In other words, the PNiPAAm-gelatin conjugate perfectly fulfills the demands on an 
injectable cell and/or drug carrier. At low temperatures, conjugate solutions formed a viscous 
liquid that can be easily mixed with cells in suspensions or dissolved drugs. The moldable 
liquids can be injected and quickly form a rigid gel at body temperature without any loss of 
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water. The perfect reversibility of this phase transition behavior was shown for the 
synthesized conjugates by rheological measurements and DSC. In no other study we did find 
this exact reversibility of gelation, highlighting the purity of the product. 
Since the developed conjugates offered the desired gelation characteristics, cell encapsulation 
experiments were conducted to assess the cytocompatibility of the conjugates and the gelation 
procedure. A viability of around 90% was found for rat mesenchymal stromal cells (rMSCs) 
after encapsulation in the synthesized conjugates for 3 days. As described in the literature, any 
cytotoxic effect of the matrix would have become visible within the first 3 days [28].   
In order to finally test the applicability of the developed conjugates as cell carriers for tissue 
engineering applications, we encapsulated bovine chondrocytes and cultured them under 
conditions that have been shown to support cartilage formation on polymeric fiber meshes 
[32]. To stimulate extracellular matrix formation and to check for the biochemical activity of 
the cells, insulin was supplemented to some cultures. Generally, no cytotoxic effects were 
observed over the cultivation time of 14 days. Moreover, exogenous insulin stimulated GAG 
formation, indicating that the encapsulated chondrocytes maintained differentiation and 
biological function. Obviously, a much higher cell density is required to engineer coherent 
tissues. Nevertheless, the PNiPAAm-gelatin conjugates demonstrated great potential for their 
use as injectable ECM substitutes for tissue engineering applications.  
Generally, a variety of applications for injectable extracellular matrix substitutes can be 
imagined in the field of tissue engineering. These hydrogels may serve as cell carriers for the 
engineering of several soft tissues, such as skin or adipose tissue, or even cartilage and bone 
tissue. In combination with suitable growth factors, injectable ECM substitutes can be 
designed as biomimetic matrices that promote and guide nerve regeneration or 
neovascularization of large defects. Furthermore, the micrometer-scale pore network of 
polymeric cell carriers (scaffolds) can be filled with the injectable, artificial ECM. This way, 
the nanofibrous structure of the gel-forming conjugate molecules mimics the natural 
nanoscale interactions between cells and extracellular matrix proteins, while the scaffold 
provides additional mechanical strength. 
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5. Conclusion 
In this study, PNiPAAm-gelatin conjugates were synthesized from several type A gelatins in a 
two-step reaction. The resulting high molecular weight conjugates underwent 
thermoreversible gelation upon heating above their LCST, which was determined by 
photospectrometry and DSC. Oscillating rheological measurements were employed to 
investigate this phase separation and gelling behavior. Finally, high cell viability in the 
hydrogels was demonstrated for mesenchymal stromal cells. Chondrocytes that were 
encapsulated in the conjugates could be stimulated for GAG production over 14 days. 
Altogether, the developed conjugates are promising ECM substitutes for many tissue 
engineering applications. 
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1. Summary 
Cell carriers (scaffolds) play a pivotal role in attempts to engineer living tissues from isolated 
cells for tissue reconstruction and basic research. In these attempts, cell carriers serve as an 
artificial extracellular matrix that accommodates mammalian cells and guides their growth, 
differentiation and tissue development in three dimensions [1]. Generally, an appropriate cell 
carrier is designed to mimic the cell’s natural environment. Thus, the scaffolding material and 
architecture differ according to the tissue type [2]. The appropriate scaffolds for 
musculoskeletal tissue, bone and cartilage are preferably made from ceramics, metals or 
lipophilic polymers to obtain sufficient mechanical stability. Conversely, hydrophilic, gel-
forming polymers are widely used as extracellular matrix substitutes for cell encapsulation 
and the engineering of soft tissue [3]. For the design of functional, biomimetic cell carriers, 
both material concepts are of interest and addressed in this thesis. 
This work focused primarily on the fabrication of functional, macroporous cell carriers from 
biodegradable polymers. Several important design criteria and characteristics have been 
identified for such scaffolds during the last decade. Ideally, the scaffolds should: (i) be three-
dimensional and highly porous with an interconnected pore network for cell growth and flow 
transport of nutrients and metabolic waste; (ii) be biocompatible and resorbable with 
controllable degradation and resorption rates to match cell/tissue growth in vitro and/or in 
vivo; (iii) have a suitable surface chemistry for cell attachment, proliferation, and 
differentiation and (iv) have mechanical properties to match those of the tissues at the site of 
implantation [4]. 
The design of a functional scaffold starts with the selection of the appropriate scaffolding 
material. In light of the enormous number of biodegradable polymers that have been 
developed and characterized so far, it might be relatively simple to find an ideal material in 
terms of mechanical properties and degradation kinetics. The surface chemistry of these 
polymers, however, is far from optimal. The major concern is that the interaction of these 
lipophilic polymers with the surrounding biological environment may lead to the non-
selective adsorption of proteins. This process in turn triggers a number of non-specific cellular 
responses and may lead to uncontrollable tissue development and growth [5]. To overcome 
these limitations, biodegradable polymers were recently developed that contain a hydrophilic 
polymer block to suppress the adsorption of proteins and a linker molecule activated for 
reaction with biologically active molecules, such as adhesion peptides or growth factors [6]. 
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These biodegradable, activated diblock copolymers are promising materials for the fabrication 
of cell carriers with a biomimetic surface design. Furthermore, polymer degradability and 
mechanical properties can be varied and adapted to different types of tissue by altering the 
copolymer ratio and crystallinity of the lipophilic block. Using two different bifunctional 
linkers, namely disuccinimidyl tartrate and N-succinimidyl 3-maleinimido propionate, which 
were covalently attached to monoamine poly(ethylene glycol)-block-poly(D,L-lactic acid) 
(H2N-PEG-PLA), amine-reactive (ST-NH-PEG-PLA) and thiol-reactive diblock copolymers 
(MP-NH-PEG-PLA) were recently synthesized and their functionality was demonstrated 
using fluorescent dyes and model proteins containing free amine or thiol groups [6,7]. 
The first objective towards the fabrication of functional cell carriers was to affect cell 
adhesion to these reactive diblock copolymers by covalently attaching adhesion-mediating 
peptides (Chapter 2). To this end, films of both amine-reactive (ST-NH-PEG2PLA20) and 
thiol-reactive derivatives (MP-NH-PEG2PLA40) were modified with cyclic αvβ3/αvβ5 
integrin subtype specific RGD peptides simply by incubation of the films with buffered 
solutions of the peptides. A non-binding RAD peptide analogue served as a control. Human 
osteoblasts, known to express these integrins, were used to determine cell-polymer 
interactions. The adhesion experiments revealed that less than 20% of the seeded cells 
adhered to the unmodified ST-NH-PEG2PLA20 surfaces (PEG-content: 9 %) and about 50 % 
of seeded cells were found on buffer treated MP-NH-PEG2PLA40 films (PEG-content: 5%). 
The adhered cells exhibited a round shape indicating only a low level of cell-biomaterial 
interaction. This correlation between the PEG-content of the PEG-PLA diblock copolymers 
and the amount and shape of adhered cells was consistent with the data known for marrow 
stromal cells on non-reactive MeO-PEG-PLA surfaces [8,9]. On all RGD-modified polymer 
films, however, the adhesion of human osteoblasts was significantly increased (up to 100% 
adhesion) compared to the RAD-modified or unmodified surfaces. In addition, cells were 
widely spread on the RGD-modified films, indicating strong cell-surface interactions, whereas 
cells on the RAD-modified films retained their round morphology. Several control groups 
proved the covalent attachment of the peptides. This study was able to demonstrate the 
envisioned surface modification concept and show the biological efficacy of the instant 
surface modification procedure.  
To process these diblock copolymers into tissue engineering scaffolds, a suitable fabrication 
technique was developed (Chapter 3). This technique had to account for the physicochemical 
properties of the polymers as well as the general demands on scaffold microstructure, namely 
high porosity, control of pore size and high interconnectivity. Furthermore, the absence of 
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water during polymer processing was a key prerequisite to prevent hydrolysis of the amine-
reactive N-hydroxysuccinimide ester. To this end, an anhydrous technique was developed, 
which utilizes solid lipid microparticles dispersed in the polymer solution as pore forming 
devices. Simultaneous polymer precipitation and porogen extraction in warm n-hexane 
generated macroporous scaffolds. The adjustment of the porogen particle’s melting point to 
the polymer’s glass transition temperature was shown to be a key step in generating the 
interconnected pore networks. Scaffolds from amine-reactive polymers were successfully 
fabricated and, as a model protein, insulin was covalently attached to the scaffold surface in a 
simple incubation procedure. The success of this experiment indicated the preservation of the 
polymer’s amine-reactivity during processing. Recently, the covalent attachment of bFGF was 
also demonstrated on such scaffolds. In preliminary experiments, bFGF modified scaffolds 
promoted vascular ingrowth after subcutaneous implantation in nude mice. To confirm these 
findings, bFGF loaded scaffolds are currently being investigated in two different in vivo 
models. 
For processing, the polymers were dissolved in an acetone-chloroform-mixture (65:35 (v/v)) 
and the triglyceride microparticles were extracted in n-hexane. According to the ICH 
guidelines on residual solvents, chloroform and n-hexane are classified as class 2 solvents and 
their use should be limited. A thermodynamically equivalent polymer solvent mixture of less 
toxic solvents (ICH class 3) was systematically determined using Hansen Solubility 
Parameters (HSPs) to eliminate chloroform from the fabrication technique without changing 
other processing parameters (Chapter 4). The HSPs of a mixture containing methyl ethyl 
ketone 59% (v/v) and tetrahydrofurane 41% (v/v) were found to best fit the parameters 
calculated for the acetone-chloroform-mixture. Using this alternative solvent mixture and n-
heptane as an alternative extraction medium, PLGA and MeO-PEG2PLA40 were processed 
into tissue engineering scaffolds without parameter changes. Moreover, the solvent exchange 
had only negligible effects on the macro- and microstructure of the resulting scaffolds. 
A follow-up study focused on determining the solubility parameters of PLA, PLGA and 
MEO-PEG-PLA (Chapter 5). Theoretical and experimental methods, namely group 
contribution methods, solubility and viscosity measurements, were employed to determine the 
solubility parameters of the polymers. A two-dimensional solvent map was introduced that 
allows for discrimination between solvents and non-solvents for the polymers. Viscosity 
measurements provided further information on the partial polymer-solvent interactions. 
In addition to the surface chemistry (Chapter 2 and 3) and biocompatibility (Chapter 4), the 
architectural and mechanical properties of a cell carrier greatly influence cell proliferation, 
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differentiation and tissue development. Control over these properties during polymer 
processing is mandatory for scaffold adaptation to different applications and types of tissue. 
Processing parameters that allow for the processing of various biodegradable polymers of 
different compositions and molecular weights (22 - 160 kDa) were determined for the solid 
lipid templating technique (SLT). Pore interconnectivity, as one important architectural 
feature, was controlled by the extraction temperature and the porogen’s melting point. The 
pore size of the scaffolds was controlled by the size distribution of the porogen microparticles. 
During processing, the rheological behavior of the dispersion prepared from the polymer 
solution and porogen microparticles, which has major influence on micro- and macrostructure 
of the resulting scaffolds, was characterized by oscillating rheological measurements. The 
suitability of the fabricated scaffolds was tested using an established cartilage cell culture 
model [10] (Chapter 6). 
To overcome limitations in the nutrient and oxygen supply inside tissue engineered cell-
polymer constructs, strategies to promote the ingrowth of blood vessels are under intensive 
investigation [11,12]. Our strategy to promote angiogenesis within cell-polymer-constructs 
started with the development of a hydrogel matrix, which is injectable inside cell seeded 
scaffolds and consists of a combination of cell-adhesive and non-adhesive domains to support 
the migration of endothelial cells and smooth muscle cells (Chapter 7). In detail, 
poly(N-isopropylacrylamide) (PNiPAAm) chains were covalently attached to gelatin type A 
as a cell-adhesive core protein to obtain an injectable, thermoreversibly gelling hydrogel. The 
synthesis of these conjugates involved the acrylation of gelatin in the first step and the 
polymerization of NiPAAm in the second step. Different types of gelatin type A were tested 
and conjugates were synthesized with varying gelatin contents. The conjugates, containing 
gelatin types with bloom values ranging from 140 to 300, underwent gelation slightly below 
body temperature (approx. 31°C). Oscillating rheological measurements were employed to 
investigate this phase separation and gelling behavior, and revealed the characteristic cross-
over of G´ (storage modulus) and G´´ (loss modulus) during gelation. Finally, high cell 
viability in the hydrogels was demonstrated for mesenchymal stromal cells. Chondrocytes that 
were encapsulated in the conjugates could be stimulated for glycosaminoglycan production 
over 14 days. Altogether, the developed conjugates represent injectable and cytocompatible 
ECM substitutes.  
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2. Conclusions 
In conclusion, a biocompatible, anhydrous scaffold fabrication technique was developed that 
allows for the fabrication of functional cell carriers: (i) The process allows for the fabrication 
of spongy scaffolds from amine-reactive diblock copolymers polymers that have been shown 
to bind adhesion peptides in a simple incubation procedure and enhance osteoblast adhesion 
in their RGD-modified form. This way, surface-reactive cell carriers were fabricated that can 
be easily modified to mimic a biological environment and specifically guide cell adhesion 
and/or development. The reactive polymers are designed to bind peptides and proteins within 
a short reaction time even after the prolonged storage of prefabricated scaffolds. A 
preliminary study with bFGF-modified scaffolds that were subcutaneously implanted in nude 
mice showed that the ingrowth of blood vessels was enhanced by the attached peptide. To 
strengthen these findings, bFGF-modified scaffolds are currently being investigated in two 
different animal models, including a rat cranial defect. (ii) Solid lipid templating (SLT) has 
proved to be a widely adaptable technique to fabricate well-structured scaffolds with different 
pore sizes and pore structures from various polymers in a controlled manner. Therefore, 
polymer development may profit from this technique, as it can be adapted to fabricate 
scaffolds from small amounts of newly developed materials in the absence of water. Thus, 
new polymers can be easily screened in three-dimensional cell culture experiments. 
Generally, the solid lipid templating technique seems to be advantageous over state-of-the-art 
polymer casting-particulate leaching techniques for several reasons: Firstly, in SLT, the 
porogen particles are extracted concomitantly to polymer precipitation, which promotes pore 
interconnectivity. Secondly, the porogen extraction is finished after 30 min, while salt 
leaching techniques require extraction times lasting from hours to days. Thirdly, the absence 
of water during polymer processing allows for the processing of hydrolysable polymers and 
the direct incorporation of water-soluble compounds, such as growth factors or hydrophilic 
polymers. (iii) As a result of the permeable, highly interconnected microstructure, rat 
mesenchymal stromal cells (rMSCs) and bovine chondrocytes could be homogenously seeded 
on poly(lactic-co-glycolic acid) scaffolds. rMSC-seeded constructs have already been 
successfully induced towards adipose and bone tissue. 
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Finally, an injectable hydrogel-forming conjugate from gelatin and PNiPAAm was 
synthesized to address the need for neovascularization in tissue engineered scaffolds. On the 
basis of the thermogelling conjugates, an injectable system will be developed that also 
incorporates release devices, e.g. calcium-alginate microparticles, loaded with angiogenetic 
growth factors, such as VEGF, PDGF or bFGF. The fabrication of these release systems was 
established during this work and is currently being optimized [13]. Additionally, the 
angiogenic potential of the developed matrices is being investigated in the rat aortic model 
[14]. 
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1. Abbreviations 
λem emission wavelength 
λex excitation wavelength 
∆Ev energy of vaporization 
1H-NMR  proton nuclear magnetic resonance  
AAc acrylic acid 
aFGF acid fibroblast growth factor 
ANOVA analysis of variance 
APS ammonium persulfate 
bFGF basic fibroblast growth factor 
BMBF Bundesministerium für Bildung und Forschung 
BMP(s) bone morphogenetic protein(s) 
CAD computer-aided design 
CED cohesive energy density 
CO2 carbon dioxide 
cyclo(-RADfE-)- cyclo(-Arg-Ala-Asp-D-Phe-Glu-) 
cyclo(-RADfK-) cyclo(-Arg-Ala-Asp-D-Phe-Lys-) 
cyclo(-RGDfE-)- cyclo(-Arg-Gly-Asp-D-Phe-Glu-) 
cyclo(-RGDfK-) cyclo(-Arg-Gly-Asp-D-Phe-Lys-) 
Da Dalton 
DMEM Dulbecco’s modified eagle’s medium 
DSC differential scanning calorimetry 
ECM extracellular matrix 
EGF Epidermal Growth Factor 
Ehi  hydrogen bonding 
EMK ethyl methyl ketone 
FBS fetal bovine serum 
FDA Food and drug administration 
Fdi group contribution for dispersive forces 
Fpi  group contribution for polar forces (permanent dipoles) 
GA glycolic acid 
GAG glycosaminoglycan 
GFC gel filtration chromatography 
GPC gel permeation chromatography 
H2N-PEG-PLA monoamine-poly(ethylene glycol)-block-poly(D,L-lactic acid) 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC high performance liquid chromatography 
HPMC hydroxypropyl methylcellulose 
HSP(s) Hansen solubility parameter(s) 
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HvK Hoftyzer - van Krevelen 
ICH International Conference on Harmonization 
IEP isoelectric point 
kDa kilo Dalton 
kV kilo volt 
LA lactic acid 
LCST lower critical solution temperature 
MDSC modulated differential scanning calorimetry 
MeO-PEG monomethyl ether-poly(ethylene glycol) 
MeO-PEG-PLA monomethyl ether-poly(ethylene glycol)-block-poly(D,L-lactic acid) 
MeO-PEGxPLAy see above 
Mn number average molecular weight 
MPa megapascal 
MP-NH-PEG2PLA40 MP-NH-PEG-PLA (42 kDa) 
MP-NH-PEG-PLA 3-maleimido propylamido-poly(ethylene glycol)-block-poly(D,L-lactic acid) 
MW molecular weight 
Mw weight average molecular weight 
N2H-PEG2PLA20 monoamine-poly(ethylene glycol)-block-poly(D,L-lactic acid) (22 kDa) 
NGF nerve growth factor 
NiPAAm N-isopropylacrylamide 
NMP N-methyl-2-pyrrolidone 
NMWCO nominal molecular weight cutoff 
OPF oligo(poly(ethylene glycol)-fumarate) 
OPTN Organ Procurement and Transplantation Network 
OsO4 osmium tetroxide 
P 42 paraffin microparticles (Tm ≈ 42°C)  
P 46  paraffin microparticles (Tm ≈ 46°C)  
P 50  paraffin microparticles (Tm ≈ 50°C) 
PBS phosphate buffered saline 
PDGF platelet-derived growth factor 
PEG poly(ethylene glycol) 
PEG2PLA20 poly(ethylene glycol)-block-poly(D,L-lactic acid) (22 kDa) 
PEG-PLA poly(ethylene glycol)-block-poly(D,L-lactic acid) 
PEO poly(ethylene oxide) 
PEO-PPO-PEO poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) 
PGA poly(glycolic acid) 
PI polydispersity index 
PLA poly(D,L-lactic acid) 
PLGA poly(D,L-lactic-co-glycolic acid) 
PLLA poly(L-lactic acid) 
PNiPAAm poly(N-isopropylacrylamide) 
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poly(PF-co-EG) poly(propylene fumarate-co-ethylene glycol) 
PPF poly(propylene fumarate) 
PPO poly(propylene oxide) 
PVA poly(vinyl alcohol) 
RAD tripeptide: Arg-Ala-Asp 
RGD tripeptide: Arg-Gly-Asp 
RI refractive index 
RID refractive index detector 
rMSCs rat mesenchymal stromal cells 
rpm rotations per minute 
SD standard deviation 
SDS sodium dodecylsulfate 
SEC size exclusion chromatography 
SEM scanning electron microscopy 
SH mixture of Softisan® 154 and Witepsol® H42 
SLT  Solid Lipid Templating 
spacerAA spacer amino acid 
ST-NH-PEG2PLA20 
Succinimidyl tartrate-amido-poly(ethylene glycol)-block-poly(D,L-lactic 
acid) (22 kDa) 
TCPS tissue culture polystyrene 
TEMED N,N,N’,N’-tetramethylethylenediamine 
Tg glass transition temperature 
TGF-ß1 transforming growth factor ß1 
THF tetrahydrofurane 
TIPS thermally induced phase separation 
Tm melting temperature (point) 
UV ultraviolet light or irradiation 
V/v volume per volume 
VEGF vascular endothelial growth factor 
Vm molar volume 
δ
 
Hildebrand (total) solubility parameter 
δd, δp, δh partial solubility parameters (dispersive, polar and hydrogen-binding forces) 
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2. Hansen Solubility Parameters of common solvents (25°C) 
Solvent CAS Number 
Molar 
volume Solubility Parameters (MPa
1/2) 
  
(cm3/mol) δd δp δh δ 
PARAFFINIC HYDROCARBONS       
n-Butane 106-97-8 101.4 14.1 0.0 0.0 14.1 
n-Pentane 109-66-0 116.2 14.5 0.0 0.0 14.5 
Pentane (iso) 78-78-4 117.4 13.7 0.0 0.0 13.7 
n-Hexane 110-54-3 147.4 14.9 0.0 0.0 14.9 
n-Heptane 142-82-5 147.4 15.3 0.0 0.0 15.3 
n-Octane 111-65-9 163.5 15.6 0.0 0.0 15.6 
Cyclohexane 110-82-7 108.7 16.8 0.0 0.2 16.8 
Methylcyclohexane 108-87-2 128.3 16.0 0.0 1.0 16.0 
AROMATIC HYDROCARBONS       
Benzene 71-43-2 89.4 18.4 0.0a 2.0 18.6 
Toluene 108-88-3 106.8 18.0 1.4 2.0 18.2 
Naphthalenenb 91-20-3 111.5 19.0 2.0 5.9 20.0 
Styrene 1-42-5 115.6 18.6 1.0 4.1 19.0 
o-Xylene 95-47-6 121.2 17.8 1.0 3.1 18.0 
HALOHYDROCARBONS       
Methylene dichloride 75-09-2 63.9 18.2 6.3 6.1 20.3 
Chloroform 67-66-3 80.7 17.8 3.1 5.7 19.0 
Dichlorodifluoromethane 75-71-8 92.3 12.3 2.0 0.0 12.5 
Trichlorofluoromethane 75-69-4 92.8 15.3 2.0 0.0 15.5 
Bromotrifluoromethane 75-63-8 97.0 9.6 2.5 0.0 10.0 
Carbon tetrachloride 56-23-5 97.1 17.8 0.0 0.6 17.8 
Chlorobenzene 108-90-7 102.1 19.0 4.3 2.0 19.6 
Perfluoro-n-heptane 335-57-9 227.3 12.1 0.0 0.0 12.5 
ETHERS       
Furan 110-00-9 72.5 17.8 1.8 5.3 18.6 
Epichlorohydrin 106-89-8 79.9 19.0 10.2 3.7 21.9 
Tetrahydrofuran 109-99-9 81.7 16.8 5.7 8.0 19.4 
1.4-Dioxane 123-91-1 85.7 19.0 1.8 7.4 20.5 
Diethyl ether 60-29-7 104.8 14.5 2.9 5.1 15.8 
KETONES       
Acetone 67-64-1 74.0 15.5 10.4 7.0 20.1 
Methyl ethyl ketone (2-butanone) 78-93-3 90.1 16.0 9.0 5.1 19.0 
Cyclohexanone 108-94-1 104.0 17.8 6.3 5.1 19.6 
Diethyl ketone (3-pentanone) 96-22-0 106.4 15.8 7.6 4.7 18.2 
Acetophenone 98-86-2 117.4 19.6a 8.6 3.7 21.7 
Methyl iso-butyl ketone (2-hexanone) 591-78-6 125.8 15.3 6.1 4.1 17.0 
ALDEHYDES       
Acetaldehyde 75-07-0 57.1 14.7 8.0 11.3 20.3 
2-Furfuraldehyde (Furfural) 98-01-1 83.2 18.6 14.9 5.1 24.3 
Butyraldehyde 123-72-8 88.5 14.7 5.3 7.0 17.2 
Benzaldehyde 100-52-7 101.5 19.4 7.4 5.3 21.5 
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Solvent (cont.) CAS Number 
Molar 
volume Solubility Parameters (MPa
1/2) 
  
(cm3/mol) δd δp δh δ 
ESTERS       
Methyl acetate 79-20-9 79.7 15.5 7.2 7.6 18.8 
Ethyl formate 109-94-4 80.2 15.5 8.4 8.4 19.6 
Propylene carbonate 
(1.2-propanediol cyclic carbonate) 108-32-7 85.0 20.1 18.0 4.1 27.2 
Ethyl acetate 141-78-6 98.5 15.8a 5.3 7.2a 18.2 
Diethyl carbonate 105-58-8 121.0 16.6 3.1 6.1 18.0 
Diethyl sulfate 64-67-5 131.5 15.8 14.7 7.2 22.7 
2-Ethoxyethyl acetate 
(Cellusolve acetate) 111-15-9 136.2 16.0 4.7 10.6 19.6 
Dimethyl phthalate 131-11-3 163.0 18.6a 10.8a 4.9 22.1 
Diethyl phthalate 84-66-2 198.0 17.6 9.6 4.5 20.5 
Di-n-butyl phthalate 84-74-2 266.0 17.8a 8.6 4.1 20.3 
n-Butyl benzyl phthalate 85-68-7 306.0 19.0 11.3 3.1 22.3 
Iso-propyl palmitatec 2239-78-3 330.0 14.3 3.9 3.7 15.3 
Di-n-butyl sebacate 109-43-3 339.0 14.5 3.9 3.7 15.5 
Methyl oleated 112-62-9 340.0 14.5 3.9 3.7 15.5 
Dioctyl phthalate 
(bis(2-ethylhexyl) phthalate) 117-81-7 377.0 16.6 7.0 3.1 18.2 
NITROGEN-CONTAINING COMPOUNDS       
Acetonitrile 75-05-8 52.6 15.3 18.0 6.1 24.6 
Acrylonitrile 107-13-1 67.1 16.5 17.4 6.8 24.8 
Propionitrile 107-12-0 70.9 15.3 14.3 5.5 21.7 
Butyronitrile 109-74-0 87.0 15.3 12.5 5.1 20.5 
Nitromethane 75-52-5 54.3 15.8 18.8 5.1 25.0 
Nitroethane 79-24-3 71.5 16.0 15.5 4.5 22.7 
Ethanolamine (2-aminoethanol) 141-43-5 60.2 17.2 15.5 21.3 31.5 
Ethylene diamine 107-15-3 67.3 16.6 8.8 17.0 25.4 
2-Pyrrolidone (2-pyrrolidinone) 616-45-5 76.4 19.4 17.4 11.3 28.4 
Pyridine 110-86-1 80.9 19.0 8.8 5.9 21.7 
Morpholine 110-91-8 87.1 18.8 4.9 9.2 21.5 
Aniline 62-53-3 91.5 19.4 5.1 10.2 22.5 
N-Methyl-2-pyrrolidone 872-50-4 96.5 18.0 12.3 7.2 22.9 
Diethylamine 109-87-7 103.2 14.9 2.3 6.1 16.4 
Formamide 75-12-7 39.8 17.2 26.2 19.0 36.6 
Dimethylformamide 68-12-2 77.0 17.4 13.7 11.3 24.8 
N,N-Dimethylacetamide 127-19-5 92.5 16.8 11.5 10.2 22.7 
SULFUR-CONTAINING COMPOUNDS        
Carbon disulfide 75-15-0 60.0 20.5 0.0 0.6 20.5 
Dimethyl sulfoxide (methyl sulfoxide) 67-68-5 71.3 18.4 16.4 10.2 26.6 
Ethanethiolc (ethyl mercaptan) 75-08-1 74.3 15.8 6.5 7.2 18.4 
Dimethyl sulfoneb (methyl sulfone) 67-71-0 75.0 19.0 19.4 12.3 29.9 
ACID HALIDES AND ANHYDRIDES       
Acetyl chloride 75-36-5 71.0 15.8 10.6 3.9 19.4 
Succinic anhydrideb 108-30-5 66.8 18.6 19.2 16.6 31.5 
Acetic anhydride 108-24-7 94.5 16.0a 11.7a 10.2a 22.3 
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Solvent (cont.) CAS Number 
Molar 
volume Solubility Parameters (MPa
1/2) 
  
(cm3/mol) δd δp δh δ 
ALCOHOLS       
Methanol 67-56-1 40.7 15.1 12.3 22.3 29.7 
Ethanol 64-17-5 58.5 15.8 8.8 19.4 26.6 
Allyl alcohol (2-propen-1-ol) 107-18-6 68.4 16.2 10.8 16.8 25.8 
1-Propanol 71-23-8 75.2 16.0 6.8 17.4 24.6 
2-Propanol 67-63-0 76.8 15.8 6.1 16.4 23.5 
Furfuryl alcohol 98-00-0 86.5 17.4 7.6 15.1 24.3 
1-Butanol (butyl alcohol) 71-36-3 91.5 16.0 5.7 15.8 23.1 
Benzyl alcohol 100-51-6 103.6 18.4 6.3 13.7 23.7 
Cyclohexanol 108-93-0 106.0 17.4 4.1 13.5 22.5 
1-Pentanol 71-41-0 109.0 16.0 4.5 13.9 21.7 
Ethyl lactate 687-47-8 115.0 16.0 7.6 12.5 21.7 
Ethylene glycol monomethyl ether 
(2-methoxyethanol) 109-86-4 79.1 16.2 9.2 16.4 24.8 
Diethylene glycol monomethyl ether 
(2-(2-methoxyethoxy)ethanol) 111-77-3 118.0 16.2 9.2 12.3 22.3 
Ethylene glycol mono-n-butyl ether 
(2-butoxyethanol) Butyl Cellusolve 111-76-2 131.6 16.0 5.1 12.3 22.3 
1-Octanol (capryl alcohol) 111-87-5 157.7 17.0 3.3 11.9 20.9 
Triethylene glycol mono-oleyl ether  418.5 13.3 3.1 8.4 16.0 
ACIDS       
Formic acid 64-18-6 37.8 14.3 11.9 16.6 25.0 
Acetic acid 64-19-7 57.1 14.5 8.0 13.5 21.3 
Benzoic acidb 65-85-0 100.0 18.2 7.0 9.8 21.9 
n-Octanoic acidc 124-07-2 159.0 15.1 3.3 8.2 17.6 
Oleic acid 112-80-1 320.0 14.3 3.1 5.5 15.8 
Stearic acidb 57-11-4 326.0 16.4 3.3 5.5 17.6 
PHENOLS       
Phenol 108-95-2 87.5 18.0 5.9 14.9 24.1 
1.3-Benzenediolb (resorcinol) 108-46-3 87.5 18.0 8.4 21.1 28.8 
m-Cresol 108-39-4 104.7 18.0 5.1 12.9 22.7 
Methyl salicylate 119-36-8 129.0 16.0 8.0 12.3 21.7 
WATER       
Waterc 7732-18-5 18.0 15.5a 16.0a 42.4a 47.9 
POLYHYDRIC ALCOHOLS       
Ethylene glycol 107-21-1 55.8 17.0 11.0 26.0 32.9 
Glycerol 56-81-5 73.8 17.4 12.1 29.3 36.2 
Propylene glycol (1.2-propanediol) 57-55-6 73.6 16.8 9.4 23.3 30.3 
 
a
 Altered from previously published value 
b
 Solid, treated as supercooled liquid 
c
 Values uncertain 
d
 Impure commercial product of this nominal formula 
 
Data adapted from: 
Grulke EA. 'Solubility Parameter Values'. In: Brandrup J, Immergut EH, Grulke EA, editors. 
Polymer Handbook. New York: John Wiley, 1999. p. VII/675-714. 
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3. Solubility Parameter Map 
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Solvent-Map: Two-dimensional illustration of several solvents based on their Hansen Solubility 
Parameters. Filled symbols: ICH class 3 solvents; Open symbols: ICH class 2 
solvents. X-axis: dispersive solubility parameter (δd); Y-axis: partial solubility 
parameter (δa) that combines all non-dispersive interaction forces.   
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4. Program Listing 
Listing of the algorithm used for the calculation of Hansen Solubility Parameters of binary 
solvent mixtures (GFA Basic 4.1 for Windows): 
 
REM 3D Hansen-Löslichkeitsparameterberechnung von LM-Mischungen von Michael Hacker 2000/2001 
DIM lm$(50), lpd(50), lpp(50), lph(50), lpg(50), 
tlpd(50,50),tlpp(50,50),tlph(50,50),elpd(50,50),elpp(50,50),elph(50,50),et3(50,50),tsumme(50,50),esumme(50,50),psumme(50,50),tdist(50,50),e
dist(50,50) 
cn|=1,lm$(cn|)="Aceton", lpd(cn|)=15.5, lpp(cn|)=10.4 , lph(cn|)=7, lpg(cn|)=20.1 
cn|=2,lm$(cn|)="Ameisensäure",lpd(cn|)=14.3,lpp(cn|)=11.9,lph(cn|)=16.6,lpg(cn|)=25 
cn|=3,lm$(cn|)="1-Butanol", lpd(cn|)=16.0, lpp(cn|)=5.7, lph(cn|)=15.8, lpg(cn|)=23.1 
cn|=4,lm$(cn|)="2-Butanol", lpd(cn|)=15.8, lpp(cn|)=5.7, lph(cn|)=14.5,lpg(cn|)=22.1 
cn|=5,lm$(cn|)="Butylacetat", lpd(cn|)=15.8, lpp(cn|)=3.7, lph(cn|)=6.3, lpg(cn|)=17.4 
cn|=6,lm$(cn|)="Dimethylsulfoxide",lpd(cn|)=18.4,lpp(cn|)=16.4,lph(cn|)=10.2,lpg(cn|)=26.6 
cn|=7,lm$(cn|)="Essigsäure", lpd(cn|)=14.5, lpp(cn|)=8, lph(cn|)=13.5, lpg(cn|)=21.3 
cn|=8,lm$(cn|)="Ethanol", lpd(cn|)=15.8, lpp(cn|)=8.8, lph(cn|)=19.4, lpg(cn|)=26.6 
cn|=9,lm$(cn|)="Ethylacetat", lpd(cn|)=15.8, lpp(cn|)=5.3, lph(cn|)=7.2, lpg(cn|)=18.2 
cn|=10,lm$(cn|)="Ethylether", lpd(cn|)=14.5, lpp(cn|)=2.9 , lph(cn|)=5.1, lpg(cn|)=15.8 
cn|=11,lm$(cn|)="Ethylformat",lpd(cn|)=15.5,lpp(cn|)=8.4,lph(cn|)=8.4,lpg(cn|)=19.6 
cn|=12,lm$(cn|)="Heptan", lpd(cn|)=15.3, lpp(cn|)=0 , lph(cn|)=0, lpg(cn|)=15.3 
cn|=13,lm$(cn|)="Isobutylacetat", lpd(cn|)=15.1, lpp(cn|)=3.7,lph(cn|)=6.3,lpg(cn|)=16.8 
cn|=14,lm$(cn|)="Isopropylacetat", lpd(cn|)=14.3, lpp(cn|)=8.4 , lph(cn|)=5.7, lpg(cn|)=17.6 
cn|=15,lm$(cn|)="Methylacetat", lpd(cn|)=15.5, lpp(cn|)=7.2,lph(cn|)=7.6,lpg(cn|)=18.8 
cn|=16,lm$(cn|)="Methylethylketon",lpd(cn|)=16,lpp(cn|)=9.0,lph(cn|)=5.1,lpg(cn|)=19 
cn|=17,lm$(cn|)="Methylisobutylketon",lpd(cn|)=15.3,lpp(cn|)=6.1,lph(cn|)=4.1,lpg(cn|)=17 
cn|=18,lm$(cn|)="2-Methyl-1-propanol",lpd(cn|)=15.1,lpp(cn|)=5.7,lph(cn|)=16,lpg(cn|)=22.7 
cn|=19,lm$(cn|)="Pentan",lpd(cn|)=14.5,lpp(cn|)=0,lph(cn|)=0,lpg(cn|)=14.5 
cn|=20,lm$(cn|)="1-Pentanol",lpd(cn|)=16,lpp(cn|)=4.5,lph(cn|)=13.9,lpg(cn|)=21.7 
cn|=21,lm$(cn|)="1-Propanol",lpd(cn|)=16,lpp(cn|)=6.8,lph(cn|)=17.4,lpg(cn|)=24.6 
cn|=22,lm$(cn|)="2-Propanol",lpd(cn|)=15.8,lpp(cn|)=6.1,lph(cn|)=16.4,lpg(cn|)=23.5 
cn|=23,lm$(cn|)="Propylacetat",lpd(cn|)=14.1,lpp(cn|)=8.1,lph(cn|)=7.8,lpg(cn|)=18.0 
cn|=24,lm$(cn|)="Tetrahydrofuran",lpd(cn|)=16.8,lpp(cn|)=5.7,lph(cn|)=8,lpg(cn|)=19.4 
cn|=25,lm$(cn|)="Chloroform", lpd(cn|)=17.8, lpp(cn|)=3.1, lph(cn|)=5.7, lpg(cn|)=19 
cn|=26,lm$(cn|)="Aceton", lpd(cn|)=15.5, lpp(cn|)=10.4 , lph(cn|)=7, lpg(cn|)=20.1 
cn|=27,lm$(cn|)="Acetonitril", lpd(cn|)=15.3, lpp(cn|)=18, lph(cn|)=6.1, lpg(cn|)=24.6 
cn|=28,lm$(cn|)="Ameisensäure",lpd(cn|)=14.3,lpp(cn|)=11.9,lph(cn|)=16.6,lpg(cn|)=25 
cn|=29,lm$(cn|)="Benzylalkohol", lpd(cn|)=18.4, lpp(cn|)=6.3, lph(cn|)=13.7, lpg(cn|)=23.7 
cn|=30,lm$(cn|)="1-Butanol", lpd(cn|)=16.0, lpp(cn|)=5.7, lph(cn|)=15.8, lpg(cn|)=23.1 
cn|=31,lm$(cn|)="Chloroform", lpd(cn|)=17.8, lpp(cn|)=3.1, lph(cn|)=5.7, lpg(cn|)=19 
cn|=32,lm$(cn|)="Dichlormethan", lpd(cn|)=18.2, lpp(cn|)=6.3, lph(cn|)=6.1, lpg(cn|)=20.3 
cn|=33,lm$(cn|)="Diethylether", lpd(cn|)=14.5, lpp(cn|)=2.9 , lph(cn|)=5.1, lpg(cn|)=15.8 
cn|=34,lm$(cn|)="Dimethylformamid", lpd(cn|)=17.4, lpp(cn|)=13.7, lph(cn|)=11.3, lpg(cn|)=24.8 
cn|=35,lm$(cn|)="Dimethylsulfoxid", lpd(cn|)=18.4, lpp(cn|)=16.4, lph(cn|)=10.2, lpg(cn|)=26.6 
cn|=36,lm$(cn|)="1,4-Dioxan",lpd(cn|)=19,lpp(cn|)=1.8,lph(cn|)=7.4,lpg(cn|)=20.5 
cn|=37,lm$(cn|)="Essigsäure", lpd(cn|)=14.5, lpp(cn|)=8, lph(cn|)=13.5, lpg(cn|)=21.3 
cn|=38,lm$(cn|)="Ethanol", lpd(cn|)=15.8, lpp(cn|)=8.8, lph(cn|)=19.4, lpg(cn|)=26.6 
cn|=39,lm$(cn|)="Ethylacetat", lpd(cn|)=15.8, lpp(cn|)=5.3, lph(cn|)=7.2, lpg(cn|)=18.2 
cn|=40,lm$(cn|)="Ethylformat",lpd(cn|)=15.5,lpp(cn|)=8.4,lph(cn|)=8.4,lpg(cn|)=19.6 
cn|=41,lm$(cn|)="n-Hexan", lpd(cn|)=14.9, lpp(cn|)=0, lph(cn|)=0, lpg(cn|)=14.9 
cn|=42,lm$(cn|)="Methanol",lpd(cn|)=15.1,lpp(cn|)=12.3,lph(cn|)=22.3,lpg(cn|)=29.7 
cn|=43,lm$(cn|)="Methylethylketon",lpd(cn|)=16,lpp(cn|)=9.0,lph(cn|)=5.1,lpg(cn|)=19 
cn|=44,lm$(cn|)="Methylsalicylat",lpd(cn|)=16,lpp(cn|)=8,lph(cn|)=12.3,lpg(cn|)=21.7 
cn|=45,lm$(cn|)="1-Pentanol",lpd(cn|)=16,lpp(cn|)=4.5,lph(cn|)=13.9,lpg(cn|)=21.7 
cn|=46,lm$(cn|)="2-Propanol",lpd(cn|)=15.8,lpp(cn|)=6.1,lph(cn|)=16.4,lpg(cn|)=23.5 
cn|=47,lm$(cn|)="Propylacetat",lpd(cn|)=14.1,lpp(cn|)=8.1,lph(cn|)=7.8,lpg(cn|)=18.0 
cn|=48,lm$(cn|)="Tetrahydrofuran",lpd(cn|)=16.8,lpp(cn|)=5.7,lph(cn|)=8,lpg(cn|)=19.4 
cn|=49,lm$(cn|)="Toluol",lpd(cn|)=18,lpp(cn|)=1.4,lph(cn|)=2,lpg(cn|)=18.2 
cn|=50,lm$(cn|)="Wasser",lpd(cn|)=15.5,lpp(cn|)=16.0,lph(cn|)=42.4,lpg(cn|)=47.9 
dstyle1%=WS_BORDER|WS_TABSTOP|ES_CENTER 
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DLGBASE UNIT 
DIALOG #1,1,1,345,140,"3D Hansen-Löslichkeitsparameter-Berechnung von LM-Mischungen  V3.2  (by Lerxst 2001)" 
  LTEXT "Gewünschte Löslichkeitsparameter : ",1002,10,11,140,10 
  LTEXT "disp.",1006,151,22,20,10 
  LTEXT "pol.",1007,184,22,20,10 
  LTEXT "hyd.",1008,213,22,20,10 
  EDITTEXT "",1003,150,10,20,10,dstyle1% 
  EDITTEXT "",1004,180,10,20,10,dstyle1% 
  EDITTEXT "",1005,210,10,20,10,dstyle1% 
  LTEXT "Lösungsmittelauswahl : ",1009,10,40,140,10 
  LTEXT "ICH Klasse 3",1010,160,40,100,10 
  LTEXT "Laborausstattung",1011,160,50,100,10 
  CHECKBOX "",1012,150,39,10,10,BS_AUTORADIOBUTTON 
  CHECKBOX "",1013,150,49,10,10,BS_AUTORADIOBUTTON 
  LTEXT "Abstandseingabe (maximal bzw. exakt) : ",1014,10,71,160,10 
  EDITTEXT "",1015,170,70,40,10,dstyle1% 
  PUSHBUTTON "LM-Mischung berechnen",1016,10,90,100,14,WS_TABSTOP 
  LTEXT "WEITERE MODULE :",1017,260,10,80,12 
  PUSHBUTTON "Abstand eines Lösungsmittels",1018,260,25,120,14,WS_TABSTOP 
  PUSHBUTTON "Abstand einer best. Mischung",1019,260,45,120,14,WS_TABSTOP 
  PUSHBUTTON "Mischung mit def. Abstand",1020,260,68,120,14,WS_TABSTOP 
  PUSHBUTTON "Schließen",1001,10,110,60,14,WS_TABSTOP 
  PUSHBUTTON "Pur",1025,80,110,30,14,WS_TABSTOP 
  LTEXT "Best :",1021,130,92,25,10 
  LTEXT "",1022,160,90,220,12,SS_CENTER|WS_BORDER 
  LTEXT "",1023,160,110,220,12,SS_CENTER|WS_BORDER 
  PUSHBUTTON "Auswahl anzeigen",1024,10,50,90,12 
  CHECKBOX "Polymernäherung",1040,10,24,100,10,BS_AUTOCHECKBOX 
ENDDIALOG 
DLG FILL 1,RGB(192,192,192) 
SHOWDIALOG #1 
~SendMessage(DLGITEM(1,1012), BM_SETCHECK, TRUE, 0) 
REPEAT 
  GETEVENT 
  IF MENU(11)=WM_COMMAND 
    SELECT MENU(12) 
    CASE 1001 
      ende!=TRUE 
    CASE 1012 
      lmwahl|=0 
    CASE 1013 
      lmwahl|=1 
    CASE 1016 
      GOSUB GetParameter 
      distmax=VAL(_WIN$(DLGITEM(1,1015))) 
      GOSUB Berechnung_equal 
      GOSUB Ergebnis_equal 
    CASE 1018 
      GOSUB LMdist 
    CASE 1019 
      GOSUB Mixdist 
    CASE 1020 
      GOSUB GetParameter 
      dist=VAL(_WIN$(DLGITEM(1,1015))) 
      IF dist <>0 
        GOSUB Abstand_misch 
      ELSE 
        _WIN$(DLGITEM(1,1022))="Bitte geben Sie einen Abstand > 0 ein !" 
        _WIN$(DLGITEM(1,1023))="" 
      ENDIF 
    CASE 1024 
      GOSUB LMAnzeige 
    CASE 1025 
      GOSUB GetParameter 
      GOSUB PURTest 
    CASE 1040 
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      IF polyn|=0 
        polyn|=1 
      ELSE 
        polyn|=0 
      ENDIF 
    ENDSELECT 
  ENDIF 
UNTIL ende! 
CLOSEDIALOG #1 
 
> PROCEDURE GetParameter 
  wlpd=VAL(_WIN$(DLGITEM(1,1003))) 
  wlpp=VAL(_WIN$(DLGITEM(1,1004))) 
  wlph=VAL(_WIN$(DLGITEM(1,1005))) 
RETURN 
> PROCEDURE LMAnzeige 
  OPENW #1,2,300,690,300,0 
  TITLEW #1,"Lösungsmittelauswahl" 
  zei|=0 
  FOR lmp|=1+(lmwahl|*25) TO 24+(lmwahl|*1)+(lmwahl|*25) STEP 2 
    INC zei| 
    TEXT 10,zei|*20,lmp|-(lmwahl|*25) 
    TEXT 40,zei|*20,lm$(lmp|) 
    TEXT 200,zei|*20,lpd(lmp|) 
    TEXT 240,zei|*20,lpp(lmp|) 
    TEXT 280,zei|*20,lph(lmp|) 
    IF lmp|<>50 
      TEXT 370,zei|*20,(lmp|+1)-(lmwahl|*25) 
      TEXT 400,zei|*20,lm$(lmp|+1) 
      TEXT 550,zei|*20,lpd(lmp|+1) 
      TEXT 590,zei|*20,lpp(lmp|+1) 
      TEXT 630,zei|*20,lph(lmp|+1) 
    ENDIF 
  NEXT lmp| 
  COLOR 249 
  PRINT  "   Zum Fortsetzen bitte Taste drücken" 
  KEYGET pause 
  CLOSEW #1 
RETURN 
 
> PROCEDURE LMdist 
  LOCAL subende!,res$ 
  DLGBASE UNIT 
  DIALOG #2,350,1,160,290,"Abstandsberechnung" 
    zei|=0 
    FOR lmp|=1+(lmwahl|*25) TO 24+(lmwahl|*1)+(lmwahl|*25) STEP 2 
      INC zei| 
      CHECKBOX lm$(lmp|),(2000+lmp|),5,((zei|-1)*20),90,20,BS_AUTORADIOBUTTON 
      IF lmp|<>50 
        CHECKBOX lm$(lmp|+1),(2000+lmp|+1),95,((zei|-1)*20),90,20,BS_AUTORADIOBUTTON 
      ENDIF 
    NEXT lmp| 
    PUSHBUTTON "Distanz berechnen",2051,5,260,80,14,WS_TABSTOP 
    PUSHBUTTON "Schließen",2052,95,260,60,14,WS_TABSTOP 
  ENDDIALOG 
  SHOWDIALOG #2 
  DLG FILL 2,RGB(192,192,192) 
  REPEAT 
    GETEVENT 
    IF MENU(11)=WM_COMMAND 
      IF 2000<MENU(12) AND MENU(12)<2051 THEN slm|=MENU(12)-2000 
      SELECT MENU(12) 
      CASE 2051 
        GOSUB GetParameter 
        tsumme=SQR((polyn|*3+1)*(wlpd-lpd(slm|))^2+(wlpp-lpp(slm|))^2+(wlph-lph(slm|))^2) 
        res$="Abstand zu "+lm$(slm|)+" :    "+STR$(ROUND(tsumme,1))+"     ("+STR$(ROUND((tsumme)^2,1))+")" 
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        _WIN$(DLGITEM(1,1022))="" 
        _WIN$(DLGITEM(1,1023))=res$ 
      CASE 2052 
        subende!=TRUE 
      CASE 1040 
        IF polyn|=0 
          polyn|=1 
        ELSE 
          polyn|=0 
        ENDIF 
      ENDSELECT 
    ENDIF 
  UNTIL subende! 
  CLOSEDIALOG #2 
RETURN 
> PROCEDURE Berechnung_equal 
  t1|=0,t2|=0 
  FOR t1|=1+(lmwahl|*25) TO 24+(lmwahl|*1)+(lmwahl|*25) 
    FOR t2|=t1| TO 24+(lmwahl|*1)+(lmwahl|*25) 
      IF t1|<>t2| 
        FOR t3=0 TO 1 STEP 0.01 
          tlpd(t1|,t2|)=t3*lpd(t1|)+(1-t3)*lpd(t2|) 
          tlpp(t1|,t2|)=t3*lpp(t1|)+(1-t3)*lpp(t2|) 
          tlph(t1|,t2|)=t3*lph(t1|)+(1-t3)*lph(t2|) 
          tsumme(t1|,t2|)=SQR((polyn|*3+1)*(wlpd-tlpd(t1|,t2|))^2+(wlpp-tlpp(t1|,t2|))^2+(wlph-tlph(t1|,t2|))^2) 
          IF t3=0 THEN 
            et3(t1|,t2|)=ROUND(t3,2) 
            esumme(t1|,t2|)=tsumme(t1|,t2|) 
          ENDIF 
          IF tsumme(t1|,t2|)<esumme(t1|,t2|) 
            et3(t1|,t2|)=ROUND(t3,2) 
            esumme(t1|,t2|)=tsumme(t1|,t2|) 
          ENDIF 
        NEXT t3 
      ENDIF 
    NEXT t2| 
  NEXT t1| 
RETURN 
 
> PROCEDURE Ergebnis_equal 
  OPENW #2,2,300,690,400,0 
  TITLEW #2,"Lösungsmittelaustausch" 
  LOCAL dcount|,res1$,res2$ 
  dcount|=0 
  t1|=0,t2|=0 
  COLOR 0 
  IF lmwahl|=0 THEN 
    best=esumme(1,2) 
  ELSE IF lmwahl|=1 
    best=esumme(26,27) 
  ENDIF 
  FOR t1|=1+(lmwahl|*25) TO 24+(lmwahl|*1)+(lmwahl|*25) 
    FOR t2|=t1| TO 24+(lmwahl|*1)+(lmwahl|*25) 
      IF t1|<>t2| THEN 
        elpd(t1|,t2|)=ROUND(et3(t1|,t2|)*lpd(t1|)+(1-et3(t1|,t2|))*lpd(t2|),1) 
        elpp(t1|,t2|)=ROUND(et3(t1|,t2|)*lpp(t1|)+(1-et3(t1|,t2|))*lpp(t2|),1) 
        elph(t1|,t2|)=ROUND(et3(t1|,t2|)*lph(t1|)+(1-et3(t1|,t2|))*lph(t2|),1) 
        IF esumme(t1|,t2|)<best THEN 
          best=esumme(t1|,t2|) 
          bestt1|=t1| 
          bestt2|=t2| 
        ENDIF 
        IF esumme(t1|,t2|)<=distmax AND ROUND(et3(t1|,t2|),2)<>0 AND ROUND(et3(t1|,t2|),2)<>1 THEN 
          INC dcount| 
          PRINT " Mix:  ";lm$(t1|);" und ";lm$(t2|);" - ratio: ";et3(t1|,t2|);" / ";ROUND(1-et3(t1|,t2|),2);" - value: ";elpd(t1|,t2|);"  ";elpp(t1|,t2|);"  
";elph(t1|,t2|);"  dist.: ";ROUND(esumme(t1|,t2|),1) 
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          IF INT(dcount|/20)=dcount|/20 
            PRINT 
            PRINT "Bitte Taste für weitere Ergebnisse drücken" 
            REPEAT 
            UNTIL INKEY$<>"" 
            CLS 
            dcount|=0 
          ENDIF 
        ENDIF 
      ENDIF 
    NEXT t2| 
  NEXT t1| 
  res1$=lm$(bestt1|)+"  und  "+lm$(bestt2|)+"  -  "+STR$(et3(bestt1|,bestt2|))+" zu "+STR$(ROUND(1-et3(bestt1|,bestt2|),2)) 
  res2$="Parameter:  "+STR$(ROUND(elpd(bestt1|,bestt2|),1))+"  "+STR$(ROUND(elpp(bestt1|,bestt2|),1))+"  
"+STR$(ROUND(elph(bestt1|,bestt2|),1))+"     Abstand: "+STR$(ROUND(esumme(bestt1|,bestt2|),1)) 
  _WIN$(DLGITEM(1,1022))=res1$ 
  _WIN$(DLGITEM(1,1023))=res2$ 
  PRINT 
  COLOR 249 
  PRINT " Ergebnisausgabe beendet - Bitte Taste drücken" 
  KEYGET pause 
  CLOSEW #2 
RETURN 
> PROCEDURE Abstand_misch 
  OPENW #3,2,300,690,400,0 
  TITLEW #3,"Lösungsmittel in definiertem Abstand" 
  LOCAL dcount|,res1$,res2$ 
  dcount|=0 
  best=dist*1000 
  bdist=dist*1000 
  brdist=dist*1000 
  t1|=0,t2|=0 
  FOR t1|=1+(lmwahl|*25) TO 24+(lmwahl|*1)+(lmwahl|*25) 
    FOR t2|=t1| TO 24+(lmwahl|*1)+(lmwahl|*25) 
      IF t1|<>t2| 
        tdist(t1|,t2|)=dist 
        FOR t3=0 TO 1 STEP 0.01 
          tlpd(t1|,t2|)=t3*lpd(t1|)+(1-t3)*lpd(t2|) 
          tlpp(t1|,t2|)=t3*lpp(t1|)+(1-t3)*lpp(t2|) 
          tlph(t1|,t2|)=t3*lph(t1|)+(1-t3)*lph(t2|) 
          tsumme(t1|,t2|)=SQR((polyn|*3+1)*(wlpd-tlpd(t1|,t2|))^2+(wlpp-tlpp(t1|,t2|))^2+(wlph-tlph(t1|,t2|))^2) 
          IF t3=0 
            et3(t1|,t2|)=ROUND(t3,2) 
            esumme(t1|,t2|)=tsumme(t1|,t2|) 
          ENDIF 
          IF ABS(tsumme(t1|,t2|)-dist)<tdist(t1|,t2|) 
            tdist(t1|,t2|)=ABS(tsumme(t1|,t2|)-dist) 
            edist(t1|,t2|)=tsumme(t1|,t2|) 
            et3(t1|,t2|)=ROUND(t3,2) 
            esumme(t1|,t2|)=tsumme(t1|,t2|) 
          ENDIF 
          IF ABS(tsumme(t1|,t2|)-dist)<brdist 
            brdist=ABS(tsumme(t1|,t2|)-dist) 
            bdist=tsumme(t1|,t2|) 
          ENDIF 
        NEXT t3 
      ENDIF 
    NEXT t2| 
  NEXT t1| 
  cabs=dist*1000 
  FOR t1|=1+(lmwahl|*25) TO 24+(lmwahl|*1)+(lmwahl|*25) 
    FOR t2|=t1| TO 24+(lmwahl|*1)+(lmwahl|*25) 
      IF t1|<>t2| THEN 
        elpd(t1|,t2|)=ROUND(et3(t1|,t2|)*lpd(t1|)+(1-et3(t1|,t2|))*lpd(t2|),1) 
        elpp(t1|,t2|)=ROUND(et3(t1|,t2|)*lpp(t1|)+(1-et3(t1|,t2|))*lpp(t2|),1) 
        elph(t1|,t2|)=ROUND(et3(t1|,t2|)*lph(t1|)+(1-et3(t1|,t2|))*lph(t2|),1) 
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      ENDIF 
      IF ABS(esumme(t1|,t2|)-dist)<cabs THEN 
        cabs=ABS(esumme(t1|,t2|)-dist) 
        cabst1|=t1| 
        cabst2|=t2| 
      ENDIF 
      IF ROUND(esumme(t1|,t2|))=dist THEN 
        INC dcount| 
        PRINT " Mix:  ";lm$(t1|);" und ";lm$(t2|);" - ratio: ";et3(t1|,t2|);" / ";ROUND(1-et3(t1|,t2|),2);" - value: ";elpd(t1|,t2|);"  ";elpp(t1|,t2|);"  
";elph(t1|,t2|);"  dist.: ";ROUND(esumme(t1|,t2|),1) 
        IF INT(dcount|/20)=dcount|/20 
          PRINT 
          PRINT " Bitte Taste für weitere Ergebnisse drücken" 
          REPEAT 
          UNTIL INKEY$<>"" 
          CLS 
          dcount|=0 
        ENDIF 
      ENDIF 
    NEXT t2| 
  NEXT t1| 
  IF cabst1|<>1 OR cabst2|<>1 AND cabst1|<>26 OR cabst2|<>26 AND ROUND(dist)=ROUND(esumme(cabst1|,cabst2|)) 
    res1$=lm$(cabst1|)+"  und  "+lm$(cabst2|)+"  -  "+STR$(et3(cabst1|,cabst2|))+" zu "+STR$(ROUND(1-et3(cabst1|,cabst2|),2)) 
    res2$="Parameter:  "+STR$(ROUND(elpd(cabst1|,cabst2|),1))+"  "+STR$(ROUND(elpp(cabst1|,cabst2|),1))+"  
"+STR$(ROUND(elph(cabst1|,cabst2|),1))+"     Abstand: "+STR$(ROUND(esumme(cabst1|,cabst2|),1)) 
    _WIN$(DLGITEM(1,1022))=res1$ 
    _WIN$(DLGITEM(1,1023))=res2$ 
  ELSE 
    res1$="" 
    res2$="" 
    _WIN$(DLGITEM(1,1022))=res1$ 
    _WIN$(DLGITEM(1,1023))=res2$ 
    COLOR 249 
    PRINT 
    PRINT " Nächster erreichbarer Abstand:    ";ROUND(bdist,1) 
  ENDIF 
  COLOR 249 
  PRINT 
  PRINT " Ergebnisausgabe beendet - Bitte Taste drücken" 
  KEYGET pause 
  CLOSEW #3 
RETURN 
> PROCEDURE PURTest 
  best=100000 
  t1|=0 
  FOR t1|=1+(lmwahl|*25) TO 24+(lmwahl|*1)+(lmwahl|*25) 
    tsumme=SQR((polyn|*3+1)*(wlpd-lpd(t1|))^2+(wlpp-lpp(t1|))^2+(wlph-lph(t1|))^2) 
    IF tsumme<best 
      best=tsumme 
      et1|=t1| 
      esumme=tsumme 
    ENDIF 
  NEXT t1| 
  res1$=lm$(et1|) 
  res2$="Parameter:  "+STR$(lpd(et1|))+"  "+STR$(lpp(et1|))+"  "+STR$(lph(et1|))+"     Abstand: "+STR$(ROUND(esumme,1))+"   
("+STR$(ROUND((esumme)^2,1))+")" 
  _WIN$(DLGITEM(1,1022))=res1$ 
  _WIN$(DLGITEM(1,1023))=res2$ 
RETURN 
> PROCEDURE Mixdist 
  LOCAL subende!,res1$,res2$,zei|,mlpd,mlpp,mlph 
  DLGBASE UNIT 
  DIALOG #3,350,1,160,310,"Abstandsberechnung einer definierten Mischung" 
    zei|=0 
    GROUPBOX "Lösungsmittel 1:",3000,2,1,89,260,BS_GROUPBOX|WS_GROUP 
    FOR lmp|=1+(lmwahl|*25) TO 24+(lmwahl|*1)+(lmwahl|*25) 
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      INC zei| 
      RADIOBUTTON lm$(lmp|),(3000+lmp|),3,zei|*10,87,10,BS_AUTORADIOBUTTON 
    NEXT lmp| 
    zei|=0 
    GROUPBOX "Lösungsmittel 2:",3060,94,1,89,260,BS_GROUPBOX|WS_GROUP 
    FOR lmp|=1+(lmwahl|*25) TO 24+(lmwahl|*1)+(lmwahl|*25) 
      INC zei| 
      RADIOBUTTON lm$(lmp|),(3060+lmp|),95,zei|*10,87,10,BS_AUTORADIOBUTTON 
    NEXT lmp| 
    PUSHBUTTON "Distanz berechnen",3051,5,280,80,14,WS_TABSTOP 
    PUSHBUTTON "Schließen",3052,95,280,60,14,WS_TABSTOP 
    LTEXT "Anteil von Lösungsmittel 1 in % : ",3200,7,266,130,10 
    EDITTEXT "",3201,135,265,15,10,WS_BORDER|WS_TABSTOP|SS_CENTER 
  ENDDIALOG 
  SHOWDIALOG #3 
  DLG FILL 3,RGB(192,192,192) 
  REPEAT 
    GETEVENT 
    IF MENU(11)=WM_COMMAND 
      IF 3000<MENU(12) AND MENU(12)<3051 THEN slm1|=MENU(12)-3000 
      IF 3060<MENU(12) AND MENU(12)<3111 THEN slm2|=MENU(12)-3060 
      SELECT MENU(12) 
      CASE 3051 
        GOSUB GetParameter 
        alm1=VAL(_WIN$(DLGITEM(3,3201)))/100 
        tsumme=SQR((polyn|*3+1)*(wlpd-(alm1*lpd(slm1|)+(1-alm1)*lpd(slm2|)))^2+(wlpp-(alm1*lpp(slm1|)+(1-alm1)*lpp(slm2|)))^2+(wlph-
(alm1*lph(slm1|)+(1-alm1)*lph(slm2|)))^2) 
        mlpd=ROUND(alm1*lpd(slm1|)+(1-alm1)*lpd(slm2|),1) 
        mlpp=ROUND(alm1*lpp(slm1|)+(1-alm1)*lpp(slm2|),1) 
        mlph=ROUND(alm1*lph(slm1|)+(1-alm1)*lph(slm2|),1) 
        res1$=lm$(slm1|)+" / "+lm$(slm2|)+"   "+STR$(alm1)+" zu "+STR$(1-alm1) 
        res2$="Parameter:  "+STR$(mlpd)+"  "+STR$(mlpp)+"  "+STR$(mlph)+"      Abstand:   "+STR$(ROUND(tsumme,1))+"  
("+STR$(ROUND((tsumme)^2,1))+")" 
        _WIN$(DLGITEM(1,1022))=res1$ 
        _WIN$(DLGITEM(1,1023))=res2$ 
      CASE 3052 
        subende!=TRUE 
      CASE 1040 
        IF polyn|=0 
          polyn|=1 
        ELSE 
          polyn|=0 
        ENDIF 
      ENDSELECT 
    ENDIF 
  UNTIL subende! 
  CLOSEDIALOG #3 
RETURN 
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